Spinal Muscular Atrophy (SMA) - Market Insight, Epidemiology and Market Forecast - 2027

Spinal Muscular Atrophy (SMA) - Market Insight, Epidemiology and Market Forecast - 2027

  • Pages: 137
  • Geography: Global
  • Delivery Timeline: 24 Hours
  • Publication: Aug, 2018
  • SKU: DIMI0219
  • Single User License
    (20% Off)
    $6,250.00
  • Site License
    (30% Off)
    $12,500.00
  • Global License
    (40% Off)
    $18,750.00
Request Sample

Name*  
Email ID*  
Mobile*  
Company*  
Country*  
Zip Code*  
Address*  
Message*  
X

Request Sample Pages

Request Before Buy
Name*  
Email ID*  
Mobile*  
Company*  
Message*  
X

Inquire Before Buy

Send Friend
Name*  
Email ID*  
Mobile*  
Company*  
Message*  
X

Send to Friend

DelveInsight’s ‘Spinal Muscular Atrophy (SMA) - Market Insights, Epidemiology and Market Forecast-2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Spinal Muscular Atrophy in the United States, EU5 (France, Germany, Italy, Spain and United Kingdom) and Japan.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of SMA from 2017 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to find best of the opportunities and assess underlying potential of the market.

Geography Covered: 
- The United States
- EU5 (France, Germany, Italy, Spain and the United Kingdom)
- Japan

Study Period: 2017-2027

SMA- Disease Understanding and Treatment Algorithm
The DelveInsight Spinal Muscular Atrophy market report gives the thorough understanding of SMA by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for SMA in the US, Europe and Japan.

SMA Epidemiology
The SMA epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. 
The disease epidemiology covered in the report is segmented by diagnosed prevalent population of SMA and Diagnosed Type-Specific cases of SMA (Type 1, 2, 3 & 4) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2027.
According to DelveInsight, the prevalent population of SMA was estimated to be 38,900 [7MM] in 2017.

SMA Drug Chapters
This segment of the SMA report encloses the detailed analysis of marketed drugs and late stage (Phase-III & Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Spinraza is the only approved drug for the treatment of SMA. The market of Spinraza has shown high revenue and patient acceptance in launch year, however high price of the drug and reimbursement issues are hampering the growth of Spinraza. Even after the approval of Spinraza there are numerous unmet needs of the market and to counter such demands many companies are working rigorously to bring better affordable therapy to the SMA market.
Detailed chapters for all the upcoming therapies i.e., AVXS-101 (Avexis), CK-2127107 (Cytokinetics Inc.), RG7916 (Hoffman-La Roche), Olesoxime (Hoffman-La Roche), LMI070 (Novartis Pharmaceuticals) etc., have been covered in the report.

SMA Market Outlook
The SMA market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology. 
This segment gives a through detail of market trend of off-label therapies, marketed therapies and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight. 
According to DelveInsight, the global market of Spinal Muscular Atrophy (SMA) was estimated to be USD 825 Million in 2017, and is expected to increase at a CAGR of XX% from 2017-2027.

SMA Drugs Uptake
This section focusses on the rate of uptake of the potential drugs that will get launched in the market during the study period from 2017-2027. The analysis covers market uptake by drugs and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

SMA Report Insights

• Patient Population

• Therapeutic Approaches

• Pipeline Analysis

• Market Size and Trends

• Market Opportunities

• Impact of upcoming Therapies

SMA Report Key Strengths

• 10 Year Forecast

• 7MM Coverage

• Epidemiology Segmentation

• Drugs Uptake 

• Highly Analysed Market

• Key Cross Competition

SMA Report Assessment

• Current Treatment Practices

• Unmet Needs

• Detailed Pipeline Product Profiles

• Market Attractiveness

• Market Drivers and Barriers

Key Benefits
- This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving the SMA market
- Organize sales and marketing efforts by identifying the best opportunities for SMA market
- To understand the future market competition in the SMA market.

1. Report Summary
2. Spinal Muscular Atrophy (SMA) Market Overview at a Glance
2.1. Total Market Share Distribution of SMA for 7 MM in 2017
2.2. Total Market Share Distribution of SMA for 7 MM in 2027
3. Spinal Muscular Atrophy: Background & Overview
3.1. Introduction
3.2. Classification
3.3. Causes
3.4. Pathophysiology
3.5. Symptoms
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Population and Forecast Parameters
4.2. Key Notes
4.3. Prevalent Population of SMA in 7MM
4.4. Diagnosed Prevalent SMA Cases in 2017
4.5. Diagnosed Prevalent SMA Cases in 2027
4.6. United States
4.6.1. Diagnosed Prevalent Cases of SMA in United States
4.7. EU5 (Germany, France, UK, Spain & Italy)
4.8. Germany
4.8.1. Diagnosed Prevalent Cases of SMA in Germany
4.9. France
4.9.1. Diagnosed Prevalent Cases of SMA in France
4.10. United Kingdom
4.10.1. Diagnosed Prevalent Cases of SMA in UK
4.11. Spain
4.11.1. Diagnosed Prevalent Cases of SMA in Spain
4.12. Italy
4.12.1. Diagnosed Prevalent Cases of SMA in Italy
4.13. Japan
4.14. Diagnosed Prevalent Cases of SMA in Japan
5. Treatment Algorithm
5.1. Therapeutic strategies
5.2. Experts Opinions for Off-Label (Supportive Therapies) drugs
5.3. US Association Current Recommendations for SMA (Guidelines)
5.4. Europe Association Current Recommendations for SMA
5.5. Japan Association Current Recommendations for SMA
6. Unmet needs
7. Marketed Drugs List
7.1. Marketed Drugs
7.2. Spinraza (nusinersen): Biogen, Inc.
7.2.1. Drug Description
7.2.2. Mechanism of Action
7.2.3. Regulatory Milestones
7.2.4. Advantages & Disadvantages
7.2.5. Safety and Efficacy
7.2.6. Product Profile
7.2.7. Drug Sales
8. Emerging Drugs
9. Key Cross Competition
9.1. AVXS-101: Avexis
9.1.1. Regulatory Milestones
9.1.2. Clinical Development
9.1.3. Ongoing Trials Information
9.1.4. Safety and Efficacy
9.1.5. Advantages and Disadvantages
9.1.6. Product Profile
9.1.7. AVXS-101 Market analysis
9.2. LMI070: Novartis Pharmaceuticals
9.2.1. Clinical Development
9.2.2. Ongoing Trials Information
9.2.3. Safety and Efficacy
9.2.4. Advantages and Disadvantages
9.2.5. Product Profile
9.2.6. LMI070 Market analysis
9.3. CK-2127107: Cytokinetics, Inc.
9.3.1. Regulatory Milestones
9.3.2. Other development activities
9.3.3. Clinical Development
9.3.4. Ongoing Trials Information
9.3.5. Safety and Efficacy
9.3.6. Advantages and Disadvantages
9.3.7. Product Profile
9.3.8. CK-2127107 Market analysis
9.4. RG7916: Hoffmann-La Roche
9.4.1. Regulatory Milestones
9.4.2. Other development activities
9.4.3. Clinical Development
9.4.4. Ongoing Trials Information
9.4.5. Safety and Efficacy
9.4.6. Advantages and Disadvantages
9.4.7. Product Profile
9.4.8. RG7916 Market analysis
9.5. Olesoxime (TRO19622): Hoffmann-La Roche
9.5.1. Regulatory Milestones
9.5.2. Other development activities
9.5.3. Clinical Development
9.5.4. Ongoing Trials Information
9.5.5. Safety and Efficacy
9.5.6. Advantages and Disadvantages
9.5.7. Product Profile
10. Other Emerging Therapies
11. Market Size
11.1. Key Findings
11.2. Global SMA Market Analysis
11.3. Overview of Global SMA Market (2017-2027)
11.4. Existing and Upcoming Therapies
11.5. Total Market Size of SMA for 7 MM in 2017-2027
11.6. Total Market Size of SMA in 7MM by Therapies
11.7. Total Patient Share of SMA in 7MM by Therapies
12. United States
12.1. Trends of Existing Therapy
12.2. Upcoming Therapies and Their Impact on Market
12.3. Forecasted Market Size of SMA
12.4. Total Market Size of SMA in the US by Therapies
12.5. Total Patient Share of SMA in the US by Therapies
13. Europe
13.1. Trends of Existing Therapy
13.2. Upcoming Therapies and Their Impact on Market
13.3. Forecasted Market Size of SMA in EU5
13.4. Total Market Size of SMA in EU5 by Therapies
13.5. Total Patient Share of SMA in EU5 by Therapies
13.6. Germany
13.6.1. Market Size of SMA in Germany
13.6.2. Total Market Size of SMA in Germany by Therapies
13.6.3. Total Patient Share of SMA in Germany by Therapies
13.7. France
13.7.1. Market Size of SMA in France
13.7.2. Total Market Size of SMA in France by Therapies
13.7.3. Total Patient Share of SMA in France by Therapies
13.8. United Kingdom
13.8.1. Market Size of SMA in UK
13.8.2. Total Market Size of SMA in the UK by Therapies
13.8.3. Total Patient Share of SMA in France by Therapies
13.9. Spain
13.9.1. Market Size of SMA in Spain
13.9.2. Total Market Size of SMA in Spain by Therapies
13.9.3. Total Patient Share of SMA in Spain by Therapies
13.10. Italy
13.10.1. Market Size of SMA in Italy
13.10.2. Total Market Size of SMA in Italy by Therapies
13.10.3. Total Patient Share of SMA in Italy by Therapies
13.11. Japan
13.11.1. Market Size of SMA in Japan
13.11.2. Total Market Size of SMA in Japan by Therapies
13.11.3. Total Patient Share of SMA in Japan by Therapies
14. Market Drivers and Barriers
15. Appendix
16. Report Methodology
16.1. Sources Used
17. Consulting Services
18. Disclaimer
19. About DelveInsight

 

Table 1 Types of SMA linked to Chromosome-5
Table 2 Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Table 3 Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Table 4 Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Table 5 Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Table 6 Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Table 7 Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Table 8 Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Table 9 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Table 10 Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Table 11 Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Table 12 Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Table 13 Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Table 14 Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Table 15 Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Table 16 Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Table 17 Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Table 18 Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Table 19 Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Table 20 Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Table 21 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Table 22 Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Table 23 Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Table 24 Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Table 25 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Table 26 Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Table 27 Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Table 28 Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Table 29  Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Table 30 United States Association Current Recommendations for SMA
Table 31 European Association Current Recommendations for SMA
Table 32 Japanese Association Current Recommendations for SMA
Table 33 List of Marketed Drugs for SMA
Table 34 Market Size of SMA in 7MM (USD Million) (2017-2027)
Table 35 7MM Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 36 7MM Drug-Specific Patient Share of SMA, (2017-2027)
Table 37 United States Market Size of SMA in USD Million, (2017-2027)
Table 38 United States Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 39 United States Drug-Specific Patient Share of SMA, (2017-2027)
Table 40 EU5 Market Size of SMA in USD Million, (2017-2027)
Table 41 EU5 Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 42 EU5 Drug-Specific Patient Share of SMA, (2017-2027)
Table 43 Germany Market Size of SMA in USD Million, (2017-2027)
Table 44 Germany Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 45 Germany Drug-Specific Patient Share of SMA, (2017-2027)
Table 46 France Market Size of SMA in USD Million, (2017-2027)
Table 47 France Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 48 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 49 UK Market Size of SMA in USD Million, (2017-2027)
Table 50 UK Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 51 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 52 Spain Market Size of SMA in USD Million, (2017-2027)
Table 53 Spain Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 54 Spain Drug-Specific Patient Share of SMA, (2017-2027)
Table 55 Italy Market Size of SMA in USD Million, (2017-2027)
Table 56 Italy Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 57 Italy Drug-Specific Patient Share of SMA, (2017-2027)
Table 58 Japan Market Size of SMA in USD Million, (2017-2027)
Table 59 Japan Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 60 Drug-Specific Patient Share of SMA, (2017-2027)

 

Figure 1: Inheritance of SMA in an autosomal recessive pattern
Figure 2: Classification of SMA
Figure 3: Schematic representation of a portion of chromosome 5 that contains two SMN genes
Figure 4: Targets for therapy in SMA
Figure 5: Diagnosis tests in SMA
Figure 6: Diagnostic Evaluation of SMA
Figure 7: Total SMA Cases in 7MM -2017
Figure 8: Total SMA Cases in 7MM - 2027
Figure 9: SMA Incidence and Prevalence Rates
Figure 10: Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Figure 11: Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Figure 12: Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Figure 13: Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Figure 14: Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Figure 15: Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Figure 16: Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Figure 17: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Figure 18: Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Figure 19: Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Figure 20: Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Figure 21: Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Figure 22: Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Figure 23: Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Figure 24: Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Figure 25: Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Figure 26: Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Figure 27: Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Figure 28: Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Figure 29: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Figure 30: Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Figure 31: Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Figure 32: Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Figure 33: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Figure 34: Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Figure 35: Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Figure 36: Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Figure 37: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Figure 38: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 39: 7MM Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 40: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 41: United States Market Size of SMA in USD Million, (2017-2027)
Figure 42: US Estimated revenue of Marketed and Pipeline Drugs in USD Million (2017-2027)
Figure 43: US Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 44: SMA market in EU5 countries in USD Million, (2017-2027)
Figure 45: EU5 Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 46: EU5 Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 47: Germany Market Size of SMA in USD Million, (2017-2027)
Figure 48: Germany Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 49: Germany Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 50: France Market Size of SMA in USD Million, (2017-2027)
Figure 51: France Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 52: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 53: UK Market Size of SMA in USD Million, (2017-2027)
Figure 54: UK Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 55: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 56: Spain Market Size of SMA in USD Million, (2017-2027)
Figure 57: Spain Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 58: Spain Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 59: Italy Market Size of SMA in USD Million, (2017-2027)
Figure 60: Italy Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 61: Italy Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 62: Japan Market Size of SMA in USD Million (2017-2027)
Figure 63: Japan Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 64: Japan Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)

 

Table 1 Types of SMA linked to Chromosome-5
Table 2 Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Table 3 Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Table 4 Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Table 5 Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Table 6 Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Table 7 Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Table 8 Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Table 9 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Table 10 Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Table 11 Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Table 12 Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Table 13 Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Table 14 Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Table 15 Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Table 16 Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Table 17 Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Table 18 Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Table 19 Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Table 20 Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Table 21 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Table 22 Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Table 23 Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Table 24 Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Table 25 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Table 26 Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Table 27 Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Table 28 Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Table 29  Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Table 30 United States Association Current Recommendations for SMA
Table 31 European Association Current Recommendations for SMA
Table 32 Japanese Association Current Recommendations for SMA
Table 33 List of Marketed Drugs for SMA
Table 34 Market Size of SMA in 7MM (USD Million) (2017-2027)
Table 35 7MM Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 36 7MM Drug-Specific Patient Share of SMA, (2017-2027)
Table 37 United States Market Size of SMA in USD Million, (2017-2027)
Table 38 United States Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 39 United States Drug-Specific Patient Share of SMA, (2017-2027)
Table 40 EU5 Market Size of SMA in USD Million, (2017-2027)
Table 41 EU5 Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 42 EU5 Drug-Specific Patient Share of SMA, (2017-2027)
Table 43 Germany Market Size of SMA in USD Million, (2017-2027)
Table 44 Germany Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 45 Germany Drug-Specific Patient Share of SMA, (2017-2027)
Table 46 France Market Size of SMA in USD Million, (2017-2027)
Table 47 France Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 48 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 49 UK Market Size of SMA in USD Million, (2017-2027)
Table 50 UK Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 51 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 52 Spain Market Size of SMA in USD Million, (2017-2027)
Table 53 Spain Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 54 Spain Drug-Specific Patient Share of SMA, (2017-2027)
Table 55 Italy Market Size of SMA in USD Million, (2017-2027)
Table 56 Italy Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 57 Italy Drug-Specific Patient Share of SMA, (2017-2027)
Table 58 Japan Market Size of SMA in USD Million, (2017-2027)
Table 59 Japan Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 60 Drug-Specific Patient Share of SMA, (2017-2027)

 

Figure 1: Inheritance of SMA in an autosomal recessive pattern
Figure 2: Classification of SMA
Figure 3: Schematic representation of a portion of chromosome 5 that contains two SMN genes
Figure 4: Targets for therapy in SMA
Figure 5: Diagnosis tests in SMA
Figure 6: Diagnostic Evaluation of SMA
Figure 7: Total SMA Cases in 7MM -2017
Figure 8: Total SMA Cases in 7MM - 2027
Figure 9: SMA Incidence and Prevalence Rates
Figure 10: Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Figure 11: Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Figure 12: Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Figure 13: Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Figure 14: Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Figure 15: Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Figure 16: Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Figure 17: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Figure 18: Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Figure 19: Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Figure 20: Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Figure 21: Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Figure 22: Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Figure 23: Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Figure 24: Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Figure 25: Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Figure 26: Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Figure 27: Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Figure 28: Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Figure 29: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Figure 30: Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Figure 31: Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Figure 32: Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Figure 33: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Figure 34: Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Figure 35: Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Figure 36: Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Figure 37: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Figure 38: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 39: 7MM Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 40: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 41: United States Market Size of SMA in USD Million, (2017-2027)
Figure 42: US Estimated revenue of Marketed and Pipeline Drugs in USD Million (2017-2027)
Figure 43: US Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 44: SMA market in EU5 countries in USD Million, (2017-2027)
Figure 45: EU5 Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 46: EU5 Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 47: Germany Market Size of SMA in USD Million, (2017-2027)
Figure 48: Germany Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 49: Germany Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 50: France Market Size of SMA in USD Million, (2017-2027)
Figure 51: France Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 52: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 53: UK Market Size of SMA in USD Million, (2017-2027)
Figure 54: UK Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 55: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 56: Spain Market Size of SMA in USD Million, (2017-2027)
Figure 57: Spain Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 58: Spain Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 59: Italy Market Size of SMA in USD Million, (2017-2027)
Figure 60: Italy Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 61: Italy Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 62: Japan Market Size of SMA in USD Million (2017-2027)
Figure 63: Japan Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 64: Japan Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)

 

Table 1 Types of SMA linked to Chromosome-5
Table 2 Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Table 3 Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Table 4 Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Table 5 Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Table 6 Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Table 7 Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Table 8 Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Table 9 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Table 10 Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Table 11 Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Table 12 Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Table 13 Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Table 14 Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Table 15 Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Table 16 Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Table 17 Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Table 18 Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Table 19 Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Table 20 Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Table 21 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Table 22 Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Table 23 Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Table 24 Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Table 25 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Table 26 Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Table 27 Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Table 28 Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Table 29  Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Table 30 United States Association Current Recommendations for SMA
Table 31 European Association Current Recommendations for SMA
Table 32 Japanese Association Current Recommendations for SMA
Table 33 List of Marketed Drugs for SMA
Table 34 Market Size of SMA in 7MM (USD Million) (2017-2027)
Table 35 7MM Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 36 7MM Drug-Specific Patient Share of SMA, (2017-2027)
Table 37 United States Market Size of SMA in USD Million, (2017-2027)
Table 38 United States Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 39 United States Drug-Specific Patient Share of SMA, (2017-2027)
Table 40 EU5 Market Size of SMA in USD Million, (2017-2027)
Table 41 EU5 Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 42 EU5 Drug-Specific Patient Share of SMA, (2017-2027)
Table 43 Germany Market Size of SMA in USD Million, (2017-2027)
Table 44 Germany Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 45 Germany Drug-Specific Patient Share of SMA, (2017-2027)
Table 46 France Market Size of SMA in USD Million, (2017-2027)
Table 47 France Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 48 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 49 UK Market Size of SMA in USD Million, (2017-2027)
Table 50 UK Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 51 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 52 Spain Market Size of SMA in USD Million, (2017-2027)
Table 53 Spain Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 54 Spain Drug-Specific Patient Share of SMA, (2017-2027)
Table 55 Italy Market Size of SMA in USD Million, (2017-2027)
Table 56 Italy Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 57 Italy Drug-Specific Patient Share of SMA, (2017-2027)
Table 58 Japan Market Size of SMA in USD Million, (2017-2027)
Table 59 Japan Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 60 Drug-Specific Patient Share of SMA, (2017-2027)

 

Figure 1: Inheritance of SMA in an autosomal recessive pattern
Figure 2: Classification of SMA
Figure 3: Schematic representation of a portion of chromosome 5 that contains two SMN genes
Figure 4: Targets for therapy in SMA
Figure 5: Diagnosis tests in SMA
Figure 6: Diagnostic Evaluation of SMA
Figure 7: Total SMA Cases in 7MM -2017
Figure 8: Total SMA Cases in 7MM - 2027
Figure 9: SMA Incidence and Prevalence Rates
Figure 10: Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Figure 11: Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Figure 12: Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Figure 13: Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Figure 14: Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Figure 15: Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Figure 16: Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Figure 17: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Figure 18: Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Figure 19: Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Figure 20: Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Figure 21: Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Figure 22: Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Figure 23: Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Figure 24: Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Figure 25: Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Figure 26: Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Figure 27: Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Figure 28: Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Figure 29: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Figure 30: Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Figure 31: Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Figure 32: Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Figure 33: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Figure 34: Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Figure 35: Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Figure 36: Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Figure 37: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Figure 38: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 39: 7MM Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 40: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 41: United States Market Size of SMA in USD Million, (2017-2027)
Figure 42: US Estimated revenue of Marketed and Pipeline Drugs in USD Million (2017-2027)
Figure 43: US Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 44: SMA market in EU5 countries in USD Million, (2017-2027)
Figure 45: EU5 Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 46: EU5 Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 47: Germany Market Size of SMA in USD Million, (2017-2027)
Figure 48: Germany Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 49: Germany Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 50: France Market Size of SMA in USD Million, (2017-2027)
Figure 51: France Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 52: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 53: UK Market Size of SMA in USD Million, (2017-2027)
Figure 54: UK Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 55: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 56: Spain Market Size of SMA in USD Million, (2017-2027)
Figure 57: Spain Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 58: Spain Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 59: Italy Market Size of SMA in USD Million, (2017-2027)
Figure 60: Italy Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 61: Italy Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 62: Japan Market Size of SMA in USD Million (2017-2027)
Figure 63: Japan Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 64: Japan Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)

 

Table 1 Types of SMA linked to Chromosome-5
Table 2 Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Table 3 Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Table 4 Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Table 5 Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Table 6 Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Table 7 Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Table 8 Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Table 9 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Table 10 Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Table 11 Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Table 12 Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Table 13 Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Table 14 Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Table 15 Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Table 16 Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Table 17 Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Table 18 Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Table 19 Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Table 20 Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Table 21 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Table 22 Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Table 23 Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Table 24 Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Table 25 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Table 26 Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Table 27 Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Table 28 Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Table 29  Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Table 30 United States Association Current Recommendations for SMA
Table 31 European Association Current Recommendations for SMA
Table 32 Japanese Association Current Recommendations for SMA
Table 33 List of Marketed Drugs for SMA
Table 34 Market Size of SMA in 7MM (USD Million) (2017-2027)
Table 35 7MM Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 36 7MM Drug-Specific Patient Share of SMA, (2017-2027)
Table 37 United States Market Size of SMA in USD Million, (2017-2027)
Table 38 United States Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 39 United States Drug-Specific Patient Share of SMA, (2017-2027)
Table 40 EU5 Market Size of SMA in USD Million, (2017-2027)
Table 41 EU5 Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 42 EU5 Drug-Specific Patient Share of SMA, (2017-2027)
Table 43 Germany Market Size of SMA in USD Million, (2017-2027)
Table 44 Germany Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 45 Germany Drug-Specific Patient Share of SMA, (2017-2027)
Table 46 France Market Size of SMA in USD Million, (2017-2027)
Table 47 France Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 48 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 49 UK Market Size of SMA in USD Million, (2017-2027)
Table 50 UK Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 51 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 52 Spain Market Size of SMA in USD Million, (2017-2027)
Table 53 Spain Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 54 Spain Drug-Specific Patient Share of SMA, (2017-2027)
Table 55 Italy Market Size of SMA in USD Million, (2017-2027)
Table 56 Italy Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 57 Italy Drug-Specific Patient Share of SMA, (2017-2027)
Table 58 Japan Market Size of SMA in USD Million, (2017-2027)
Table 59 Japan Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 60 Drug-Specific Patient Share of SMA, (2017-2027)

 

Figure 1: Inheritance of SMA in an autosomal recessive pattern
Figure 2: Classification of SMA
Figure 3: Schematic representation of a portion of chromosome 5 that contains two SMN genes
Figure 4: Targets for therapy in SMA
Figure 5: Diagnosis tests in SMA
Figure 6: Diagnostic Evaluation of SMA
Figure 7: Total SMA Cases in 7MM -2017
Figure 8: Total SMA Cases in 7MM - 2027
Figure 9: SMA Incidence and Prevalence Rates
Figure 10: Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Figure 11: Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Figure 12: Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Figure 13: Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Figure 14: Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Figure 15: Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Figure 16: Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Figure 17: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Figure 18: Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Figure 19: Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Figure 20: Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Figure 21: Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Figure 22: Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Figure 23: Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Figure 24: Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Figure 25: Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Figure 26: Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Figure 27: Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Figure 28: Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Figure 29: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Figure 30: Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Figure 31: Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Figure 32: Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Figure 33: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Figure 34: Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Figure 35: Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Figure 36: Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Figure 37: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Figure 38: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 39: 7MM Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 40: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 41: United States Market Size of SMA in USD Million, (2017-2027)
Figure 42: US Estimated revenue of Marketed and Pipeline Drugs in USD Million (2017-2027)
Figure 43: US Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 44: SMA market in EU5 countries in USD Million, (2017-2027)
Figure 45: EU5 Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 46: EU5 Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 47: Germany Market Size of SMA in USD Million, (2017-2027)
Figure 48: Germany Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 49: Germany Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 50: France Market Size of SMA in USD Million, (2017-2027)
Figure 51: France Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 52: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 53: UK Market Size of SMA in USD Million, (2017-2027)
Figure 54: UK Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 55: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 56: Spain Market Size of SMA in USD Million, (2017-2027)
Figure 57: Spain Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 58: Spain Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 59: Italy Market Size of SMA in USD Million, (2017-2027)
Figure 60: Italy Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 61: Italy Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 62: Japan Market Size of SMA in USD Million (2017-2027)
Figure 63: Japan Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 64: Japan Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)

 

Table 1 Types of SMA linked to Chromosome-5
Table 2 Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Table 3 Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Table 4 Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Table 5 Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Table 6 Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Table 7 Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Table 8 Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Table 9 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Table 10 Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Table 11 Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Table 12 Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Table 13 Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Table 14 Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Table 15 Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Table 16 Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Table 17 Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Table 18 Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Table 19 Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Table 20 Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Table 21 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Table 22 Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Table 23 Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Table 24 Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Table 25 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Table 26 Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Table 27 Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Table 28 Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Table 29  Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Table 30 United States Association Current Recommendations for SMA
Table 31 European Association Current Recommendations for SMA
Table 32 Japanese Association Current Recommendations for SMA
Table 33 List of Marketed Drugs for SMA
Table 34 Market Size of SMA in 7MM (USD Million) (2017-2027)
Table 35 7MM Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 36 7MM Drug-Specific Patient Share of SMA, (2017-2027)
Table 37 United States Market Size of SMA in USD Million, (2017-2027)
Table 38 United States Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 39 United States Drug-Specific Patient Share of SMA, (2017-2027)
Table 40 EU5 Market Size of SMA in USD Million, (2017-2027)
Table 41 EU5 Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 42 EU5 Drug-Specific Patient Share of SMA, (2017-2027)
Table 43 Germany Market Size of SMA in USD Million, (2017-2027)
Table 44 Germany Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 45 Germany Drug-Specific Patient Share of SMA, (2017-2027)
Table 46 France Market Size of SMA in USD Million, (2017-2027)
Table 47 France Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 48 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 49 UK Market Size of SMA in USD Million, (2017-2027)
Table 50 UK Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 51 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 52 Spain Market Size of SMA in USD Million, (2017-2027)
Table 53 Spain Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 54 Spain Drug-Specific Patient Share of SMA, (2017-2027)
Table 55 Italy Market Size of SMA in USD Million, (2017-2027)
Table 56 Italy Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 57 Italy Drug-Specific Patient Share of SMA, (2017-2027)
Table 58 Japan Market Size of SMA in USD Million, (2017-2027)
Table 59 Japan Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 60 Drug-Specific Patient Share of SMA, (2017-2027)

 

Figure 1: Inheritance of SMA in an autosomal recessive pattern
Figure 2: Classification of SMA
Figure 3: Schematic representation of a portion of chromosome 5 that contains two SMN genes
Figure 4: Targets for therapy in SMA
Figure 5: Diagnosis tests in SMA
Figure 6: Diagnostic Evaluation of SMA
Figure 7: Total SMA Cases in 7MM -2017
Figure 8: Total SMA Cases in 7MM - 2027
Figure 9: SMA Incidence and Prevalence Rates
Figure 10: Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Figure 11: Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Figure 12: Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Figure 13: Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Figure 14: Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Figure 15: Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Figure 16: Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Figure 17: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Figure 18: Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Figure 19: Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Figure 20: Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Figure 21: Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Figure 22: Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Figure 23: Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Figure 24: Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Figure 25: Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Figure 26: Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Figure 27: Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Figure 28: Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Figure 29: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Figure 30: Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Figure 31: Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Figure 32: Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Figure 33: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Figure 34: Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Figure 35: Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Figure 36: Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Figure 37: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Figure 38: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 39: 7MM Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 40: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 41: United States Market Size of SMA in USD Million, (2017-2027)
Figure 42: US Estimated revenue of Marketed and Pipeline Drugs in USD Million (2017-2027)
Figure 43: US Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 44: SMA market in EU5 countries in USD Million, (2017-2027)
Figure 45: EU5 Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 46: EU5 Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 47: Germany Market Size of SMA in USD Million, (2017-2027)
Figure 48: Germany Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 49: Germany Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 50: France Market Size of SMA in USD Million, (2017-2027)
Figure 51: France Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 52: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 53: UK Market Size of SMA in USD Million, (2017-2027)
Figure 54: UK Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 55: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 56: Spain Market Size of SMA in USD Million, (2017-2027)
Figure 57: Spain Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 58: Spain Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 59: Italy Market Size of SMA in USD Million, (2017-2027)
Figure 60: Italy Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 61: Italy Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 62: Japan Market Size of SMA in USD Million (2017-2027)
Figure 63: Japan Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 64: Japan Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)

 

Table 1 Types of SMA linked to Chromosome-5
Table 2 Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Table 3 Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Table 4 Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Table 5 Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Table 6 Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Table 7 Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Table 8 Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Table 9 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Table 10 Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Table 11 Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Table 12 Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Table 13 Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Table 14 Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Table 15 Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Table 16 Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Table 17 Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Table 18 Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Table 19 Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Table 20 Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Table 21 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Table 22 Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Table 23 Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Table 24 Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Table 25 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Table 26 Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Table 27 Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Table 28 Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Table 29  Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Table 30 United States Association Current Recommendations for SMA
Table 31 European Association Current Recommendations for SMA
Table 32 Japanese Association Current Recommendations for SMA
Table 33 List of Marketed Drugs for SMA
Table 34 Market Size of SMA in 7MM (USD Million) (2017-2027)
Table 35 7MM Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 36 7MM Drug-Specific Patient Share of SMA, (2017-2027)
Table 37 United States Market Size of SMA in USD Million, (2017-2027)
Table 38 United States Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 39 United States Drug-Specific Patient Share of SMA, (2017-2027)
Table 40 EU5 Market Size of SMA in USD Million, (2017-2027)
Table 41 EU5 Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 42 EU5 Drug-Specific Patient Share of SMA, (2017-2027)
Table 43 Germany Market Size of SMA in USD Million, (2017-2027)
Table 44 Germany Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 45 Germany Drug-Specific Patient Share of SMA, (2017-2027)
Table 46 France Market Size of SMA in USD Million, (2017-2027)
Table 47 France Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 48 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 49 UK Market Size of SMA in USD Million, (2017-2027)
Table 50 UK Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 51 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 52 Spain Market Size of SMA in USD Million, (2017-2027)
Table 53 Spain Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 54 Spain Drug-Specific Patient Share of SMA, (2017-2027)
Table 55 Italy Market Size of SMA in USD Million, (2017-2027)
Table 56 Italy Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 57 Italy Drug-Specific Patient Share of SMA, (2017-2027)
Table 58 Japan Market Size of SMA in USD Million, (2017-2027)
Table 59 Japan Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 60 Drug-Specific Patient Share of SMA, (2017-2027)

 

Figure 1: Inheritance of SMA in an autosomal recessive pattern
Figure 2: Classification of SMA
Figure 3: Schematic representation of a portion of chromosome 5 that contains two SMN genes
Figure 4: Targets for therapy in SMA
Figure 5: Diagnosis tests in SMA
Figure 6: Diagnostic Evaluation of SMA
Figure 7: Total SMA Cases in 7MM -2017
Figure 8: Total SMA Cases in 7MM - 2027
Figure 9: SMA Incidence and Prevalence Rates
Figure 10: Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Figure 11: Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Figure 12: Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Figure 13: Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Figure 14: Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Figure 15: Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Figure 16: Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Figure 17: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Figure 18: Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Figure 19: Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Figure 20: Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Figure 21: Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Figure 22: Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Figure 23: Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Figure 24: Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Figure 25: Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Figure 26: Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Figure 27: Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Figure 28: Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Figure 29: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Figure 30: Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Figure 31: Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Figure 32: Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Figure 33: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Figure 34: Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Figure 35: Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Figure 36: Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Figure 37: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Figure 38: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 39: 7MM Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 40: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 41: United States Market Size of SMA in USD Million, (2017-2027)
Figure 42: US Estimated revenue of Marketed and Pipeline Drugs in USD Million (2017-2027)
Figure 43: US Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 44: SMA market in EU5 countries in USD Million, (2017-2027)
Figure 45: EU5 Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 46: EU5 Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 47: Germany Market Size of SMA in USD Million, (2017-2027)
Figure 48: Germany Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 49: Germany Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 50: France Market Size of SMA in USD Million, (2017-2027)
Figure 51: France Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 52: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 53: UK Market Size of SMA in USD Million, (2017-2027)
Figure 54: UK Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 55: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 56: Spain Market Size of SMA in USD Million, (2017-2027)
Figure 57: Spain Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 58: Spain Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 59: Italy Market Size of SMA in USD Million, (2017-2027)
Figure 60: Italy Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 61: Italy Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 62: Japan Market Size of SMA in USD Million (2017-2027)
Figure 63: Japan Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 64: Japan Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)

 

Table 1 Types of SMA linked to Chromosome-5
Table 2 Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Table 3 Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Table 4 Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Table 5 Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Table 6 Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Table 7 Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Table 8 Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Table 9 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Table 10 Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Table 11 Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Table 12 Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Table 13 Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Table 14 Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Table 15 Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Table 16 Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Table 17 Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Table 18 Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Table 19 Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Table 20 Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Table 21 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Table 22 Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Table 23 Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Table 24 Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Table 25 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Table 26 Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Table 27 Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Table 28 Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Table 29  Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Table 30 United States Association Current Recommendations for SMA
Table 31 European Association Current Recommendations for SMA
Table 32 Japanese Association Current Recommendations for SMA
Table 33 List of Marketed Drugs for SMA
Table 34 Market Size of SMA in 7MM (USD Million) (2017-2027)
Table 35 7MM Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 36 7MM Drug-Specific Patient Share of SMA, (2017-2027)
Table 37 United States Market Size of SMA in USD Million, (2017-2027)
Table 38 United States Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 39 United States Drug-Specific Patient Share of SMA, (2017-2027)
Table 40 EU5 Market Size of SMA in USD Million, (2017-2027)
Table 41 EU5 Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 42 EU5 Drug-Specific Patient Share of SMA, (2017-2027)
Table 43 Germany Market Size of SMA in USD Million, (2017-2027)
Table 44 Germany Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 45 Germany Drug-Specific Patient Share of SMA, (2017-2027)
Table 46 France Market Size of SMA in USD Million, (2017-2027)
Table 47 France Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 48 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 49 UK Market Size of SMA in USD Million, (2017-2027)
Table 50 UK Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 51 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 52 Spain Market Size of SMA in USD Million, (2017-2027)
Table 53 Spain Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 54 Spain Drug-Specific Patient Share of SMA, (2017-2027)
Table 55 Italy Market Size of SMA in USD Million, (2017-2027)
Table 56 Italy Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 57 Italy Drug-Specific Patient Share of SMA, (2017-2027)
Table 58 Japan Market Size of SMA in USD Million, (2017-2027)
Table 59 Japan Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 60 Drug-Specific Patient Share of SMA, (2017-2027)

 

Figure 1: Inheritance of SMA in an autosomal recessive pattern
Figure 2: Classification of SMA
Figure 3: Schematic representation of a portion of chromosome 5 that contains two SMN genes
Figure 4: Targets for therapy in SMA
Figure 5: Diagnosis tests in SMA
Figure 6: Diagnostic Evaluation of SMA
Figure 7: Total SMA Cases in 7MM -2017
Figure 8: Total SMA Cases in 7MM - 2027
Figure 9: SMA Incidence and Prevalence Rates
Figure 10: Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Figure 11: Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Figure 12: Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Figure 13: Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Figure 14: Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Figure 15: Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Figure 16: Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Figure 17: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Figure 18: Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Figure 19: Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Figure 20: Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Figure 21: Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Figure 22: Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Figure 23: Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Figure 24: Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Figure 25: Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Figure 26: Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Figure 27: Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Figure 28: Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Figure 29: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Figure 30: Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Figure 31: Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Figure 32: Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Figure 33: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Figure 34: Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Figure 35: Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Figure 36: Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Figure 37: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Figure 38: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 39: 7MM Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 40: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 41: United States Market Size of SMA in USD Million, (2017-2027)
Figure 42: US Estimated revenue of Marketed and Pipeline Drugs in USD Million (2017-2027)
Figure 43: US Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 44: SMA market in EU5 countries in USD Million, (2017-2027)
Figure 45: EU5 Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 46: EU5 Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 47: Germany Market Size of SMA in USD Million, (2017-2027)
Figure 48: Germany Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 49: Germany Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 50: France Market Size of SMA in USD Million, (2017-2027)
Figure 51: France Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 52: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 53: UK Market Size of SMA in USD Million, (2017-2027)
Figure 54: UK Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 55: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 56: Spain Market Size of SMA in USD Million, (2017-2027)
Figure 57: Spain Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 58: Spain Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 59: Italy Market Size of SMA in USD Million, (2017-2027)
Figure 60: Italy Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 61: Italy Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 62: Japan Market Size of SMA in USD Million (2017-2027)
Figure 63: Japan Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 64: Japan Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)

 

Table 1 Types of SMA linked to Chromosome-5
Table 2 Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Table 3 Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Table 4 Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Table 5 Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Table 6 Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Table 7 Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Table 8 Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Table 9 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Table 10 Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Table 11 Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Table 12 Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Table 13 Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Table 14 Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Table 15 Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Table 16 Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Table 17 Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Table 18 Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Table 19 Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Table 20 Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Table 21 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Table 22 Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Table 23 Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Table 24 Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Table 25 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Table 26 Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Table 27 Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Table 28 Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Table 29  Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Table 30 United States Association Current Recommendations for SMA
Table 31 European Association Current Recommendations for SMA
Table 32 Japanese Association Current Recommendations for SMA
Table 33 List of Marketed Drugs for SMA
Table 34 Market Size of SMA in 7MM (USD Million) (2017-2027)
Table 35 7MM Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 36 7MM Drug-Specific Patient Share of SMA, (2017-2027)
Table 37 United States Market Size of SMA in USD Million, (2017-2027)
Table 38 United States Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 39 United States Drug-Specific Patient Share of SMA, (2017-2027)
Table 40 EU5 Market Size of SMA in USD Million, (2017-2027)
Table 41 EU5 Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 42 EU5 Drug-Specific Patient Share of SMA, (2017-2027)
Table 43 Germany Market Size of SMA in USD Million, (2017-2027)
Table 44 Germany Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 45 Germany Drug-Specific Patient Share of SMA, (2017-2027)
Table 46 France Market Size of SMA in USD Million, (2017-2027)
Table 47 France Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 48 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 49 UK Market Size of SMA in USD Million, (2017-2027)
Table 50 UK Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 51 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 52 Spain Market Size of SMA in USD Million, (2017-2027)
Table 53 Spain Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 54 Spain Drug-Specific Patient Share of SMA, (2017-2027)
Table 55 Italy Market Size of SMA in USD Million, (2017-2027)
Table 56 Italy Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 57 Italy Drug-Specific Patient Share of SMA, (2017-2027)
Table 58 Japan Market Size of SMA in USD Million, (2017-2027)
Table 59 Japan Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 60 Drug-Specific Patient Share of SMA, (2017-2027)

 

Figure 1: Inheritance of SMA in an autosomal recessive pattern
Figure 2: Classification of SMA
Figure 3: Schematic representation of a portion of chromosome 5 that contains two SMN genes
Figure 4: Targets for therapy in SMA
Figure 5: Diagnosis tests in SMA
Figure 6: Diagnostic Evaluation of SMA
Figure 7: Total SMA Cases in 7MM -2017
Figure 8: Total SMA Cases in 7MM - 2027
Figure 9: SMA Incidence and Prevalence Rates
Figure 10: Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Figure 11: Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Figure 12: Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Figure 13: Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Figure 14: Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Figure 15: Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Figure 16: Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Figure 17: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Figure 18: Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Figure 19: Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Figure 20: Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Figure 21: Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Figure 22: Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Figure 23: Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Figure 24: Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Figure 25: Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Figure 26: Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Figure 27: Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Figure 28: Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Figure 29: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Figure 30: Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Figure 31: Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Figure 32: Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Figure 33: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Figure 34: Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Figure 35: Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Figure 36: Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Figure 37: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Figure 38: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 39: 7MM Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 40: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 41: United States Market Size of SMA in USD Million, (2017-2027)
Figure 42: US Estimated revenue of Marketed and Pipeline Drugs in USD Million (2017-2027)
Figure 43: US Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 44: SMA market in EU5 countries in USD Million, (2017-2027)
Figure 45: EU5 Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 46: EU5 Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 47: Germany Market Size of SMA in USD Million, (2017-2027)
Figure 48: Germany Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 49: Germany Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 50: France Market Size of SMA in USD Million, (2017-2027)
Figure 51: France Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 52: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 53: UK Market Size of SMA in USD Million, (2017-2027)
Figure 54: UK Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 55: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 56: Spain Market Size of SMA in USD Million, (2017-2027)
Figure 57: Spain Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 58: Spain Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 59: Italy Market Size of SMA in USD Million, (2017-2027)
Figure 60: Italy Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 61: Italy Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 62: Japan Market Size of SMA in USD Million (2017-2027)
Figure 63: Japan Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 64: Japan Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)

 

Table 1 Types of SMA linked to Chromosome-5
Table 2 Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Table 3 Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Table 4 Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Table 5 Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Table 6 Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Table 7 Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Table 8 Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Table 9 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Table 10 Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Table 11 Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Table 12 Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Table 13 Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Table 14 Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Table 15 Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Table 16 Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Table 17 Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Table 18 Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Table 19 Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Table 20 Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Table 21 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Table 22 Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Table 23 Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Table 24 Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Table 25 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Table 26 Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Table 27 Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Table 28 Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Table 29  Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Table 30 United States Association Current Recommendations for SMA
Table 31 European Association Current Recommendations for SMA
Table 32 Japanese Association Current Recommendations for SMA
Table 33 List of Marketed Drugs for SMA
Table 34 Market Size of SMA in 7MM (USD Million) (2017-2027)
Table 35 7MM Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 36 7MM Drug-Specific Patient Share of SMA, (2017-2027)
Table 37 United States Market Size of SMA in USD Million, (2017-2027)
Table 38 United States Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 39 United States Drug-Specific Patient Share of SMA, (2017-2027)
Table 40 EU5 Market Size of SMA in USD Million, (2017-2027)
Table 41 EU5 Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 42 EU5 Drug-Specific Patient Share of SMA, (2017-2027)
Table 43 Germany Market Size of SMA in USD Million, (2017-2027)
Table 44 Germany Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 45 Germany Drug-Specific Patient Share of SMA, (2017-2027)
Table 46 France Market Size of SMA in USD Million, (2017-2027)
Table 47 France Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 48 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 49 UK Market Size of SMA in USD Million, (2017-2027)
Table 50 UK Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 51 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 52 Spain Market Size of SMA in USD Million, (2017-2027)
Table 53 Spain Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 54 Spain Drug-Specific Patient Share of SMA, (2017-2027)
Table 55 Italy Market Size of SMA in USD Million, (2017-2027)
Table 56 Italy Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 57 Italy Drug-Specific Patient Share of SMA, (2017-2027)
Table 58 Japan Market Size of SMA in USD Million, (2017-2027)
Table 59 Japan Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 60 Drug-Specific Patient Share of SMA, (2017-2027)

 

Figure 1: Inheritance of SMA in an autosomal recessive pattern
Figure 2: Classification of SMA
Figure 3: Schematic representation of a portion of chromosome 5 that contains two SMN genes
Figure 4: Targets for therapy in SMA
Figure 5: Diagnosis tests in SMA
Figure 6: Diagnostic Evaluation of SMA
Figure 7: Total SMA Cases in 7MM -2017
Figure 8: Total SMA Cases in 7MM - 2027
Figure 9: SMA Incidence and Prevalence Rates
Figure 10: Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Figure 11: Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Figure 12: Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Figure 13: Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Figure 14: Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Figure 15: Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Figure 16: Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Figure 17: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Figure 18: Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Figure 19: Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Figure 20: Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Figure 21: Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Figure 22: Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Figure 23: Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Figure 24: Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Figure 25: Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Figure 26: Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Figure 27: Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Figure 28: Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Figure 29: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Figure 30: Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Figure 31: Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Figure 32: Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Figure 33: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Figure 34: Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Figure 35: Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Figure 36: Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Figure 37: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Figure 38: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 39: 7MM Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 40: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 41: United States Market Size of SMA in USD Million, (2017-2027)
Figure 42: US Estimated revenue of Marketed and Pipeline Drugs in USD Million (2017-2027)
Figure 43: US Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 44: SMA market in EU5 countries in USD Million, (2017-2027)
Figure 45: EU5 Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 46: EU5 Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 47: Germany Market Size of SMA in USD Million, (2017-2027)
Figure 48: Germany Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 49: Germany Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 50: France Market Size of SMA in USD Million, (2017-2027)
Figure 51: France Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 52: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 53: UK Market Size of SMA in USD Million, (2017-2027)
Figure 54: UK Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 55: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 56: Spain Market Size of SMA in USD Million, (2017-2027)
Figure 57: Spain Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 58: Spain Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 59: Italy Market Size of SMA in USD Million, (2017-2027)
Figure 60: Italy Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 61: Italy Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 62: Japan Market Size of SMA in USD Million (2017-2027)
Figure 63: Japan Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 64: Japan Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)

 

Table 1 Types of SMA linked to Chromosome-5
Table 2 Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Table 3 Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Table 4 Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Table 5 Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Table 6 Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Table 7 Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Table 8 Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Table 9 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Table 10 Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Table 11 Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Table 12 Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Table 13 Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Table 14 Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Table 15 Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Table 16 Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Table 17 Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Table 18 Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Table 19 Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Table 20 Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Table 21 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Table 22 Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Table 23 Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Table 24 Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Table 25 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Table 26 Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Table 27 Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Table 28 Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Table 29  Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Table 30 United States Association Current Recommendations for SMA
Table 31 European Association Current Recommendations for SMA
Table 32 Japanese Association Current Recommendations for SMA
Table 33 List of Marketed Drugs for SMA
Table 34 Market Size of SMA in 7MM (USD Million) (2017-2027)
Table 35 7MM Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 36 7MM Drug-Specific Patient Share of SMA, (2017-2027)
Table 37 United States Market Size of SMA in USD Million, (2017-2027)
Table 38 United States Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 39 United States Drug-Specific Patient Share of SMA, (2017-2027)
Table 40 EU5 Market Size of SMA in USD Million, (2017-2027)
Table 41 EU5 Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 42 EU5 Drug-Specific Patient Share of SMA, (2017-2027)
Table 43 Germany Market Size of SMA in USD Million, (2017-2027)
Table 44 Germany Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 45 Germany Drug-Specific Patient Share of SMA, (2017-2027)
Table 46 France Market Size of SMA in USD Million, (2017-2027)
Table 47 France Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 48 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 49 UK Market Size of SMA in USD Million, (2017-2027)
Table 50 UK Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 51 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 52 Spain Market Size of SMA in USD Million, (2017-2027)
Table 53 Spain Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 54 Spain Drug-Specific Patient Share of SMA, (2017-2027)
Table 55 Italy Market Size of SMA in USD Million, (2017-2027)
Table 56 Italy Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 57 Italy Drug-Specific Patient Share of SMA, (2017-2027)
Table 58 Japan Market Size of SMA in USD Million, (2017-2027)
Table 59 Japan Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 60 Drug-Specific Patient Share of SMA, (2017-2027)

 

Figure 1: Inheritance of SMA in an autosomal recessive pattern
Figure 2: Classification of SMA
Figure 3: Schematic representation of a portion of chromosome 5 that contains two SMN genes
Figure 4: Targets for therapy in SMA
Figure 5: Diagnosis tests in SMA
Figure 6: Diagnostic Evaluation of SMA
Figure 7: Total SMA Cases in 7MM -2017
Figure 8: Total SMA Cases in 7MM - 2027
Figure 9: SMA Incidence and Prevalence Rates
Figure 10: Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Figure 11: Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Figure 12: Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Figure 13: Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Figure 14: Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Figure 15: Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Figure 16: Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Figure 17: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Figure 18: Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Figure 19: Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Figure 20: Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Figure 21: Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Figure 22: Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Figure 23: Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Figure 24: Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Figure 25: Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Figure 26: Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Figure 27: Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Figure 28: Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Figure 29: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Figure 30: Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Figure 31: Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Figure 32: Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Figure 33: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Figure 34: Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Figure 35: Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Figure 36: Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Figure 37: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Figure 38: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 39: 7MM Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 40: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 41: United States Market Size of SMA in USD Million, (2017-2027)
Figure 42: US Estimated revenue of Marketed and Pipeline Drugs in USD Million (2017-2027)
Figure 43: US Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 44: SMA market in EU5 countries in USD Million, (2017-2027)
Figure 45: EU5 Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 46: EU5 Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 47: Germany Market Size of SMA in USD Million, (2017-2027)
Figure 48: Germany Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 49: Germany Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 50: France Market Size of SMA in USD Million, (2017-2027)
Figure 51: France Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 52: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 53: UK Market Size of SMA in USD Million, (2017-2027)
Figure 54: UK Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 55: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 56: Spain Market Size of SMA in USD Million, (2017-2027)
Figure 57: Spain Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 58: Spain Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 59: Italy Market Size of SMA in USD Million, (2017-2027)
Figure 60: Italy Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 61: Italy Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 62: Japan Market Size of SMA in USD Million (2017-2027)
Figure 63: Japan Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 64: Japan Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)

 

Table 1 Types of SMA linked to Chromosome-5
Table 2 Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Table 3 Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Table 4 Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Table 5 Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Table 6 Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Table 7 Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Table 8 Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Table 9 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Table 10 Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Table 11 Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Table 12 Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Table 13 Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Table 14 Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Table 15 Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Table 16 Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Table 17 Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Table 18 Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Table 19 Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Table 20 Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Table 21 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Table 22 Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Table 23 Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Table 24 Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Table 25 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Table 26 Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Table 27 Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Table 28 Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Table 29  Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Table 30 United States Association Current Recommendations for SMA
Table 31 European Association Current Recommendations for SMA
Table 32 Japanese Association Current Recommendations for SMA
Table 33 List of Marketed Drugs for SMA
Table 34 Market Size of SMA in 7MM (USD Million) (2017-2027)
Table 35 7MM Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 36 7MM Drug-Specific Patient Share of SMA, (2017-2027)
Table 37 United States Market Size of SMA in USD Million, (2017-2027)
Table 38 United States Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 39 United States Drug-Specific Patient Share of SMA, (2017-2027)
Table 40 EU5 Market Size of SMA in USD Million, (2017-2027)
Table 41 EU5 Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 42 EU5 Drug-Specific Patient Share of SMA, (2017-2027)
Table 43 Germany Market Size of SMA in USD Million, (2017-2027)
Table 44 Germany Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 45 Germany Drug-Specific Patient Share of SMA, (2017-2027)
Table 46 France Market Size of SMA in USD Million, (2017-2027)
Table 47 France Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 48 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 49 UK Market Size of SMA in USD Million, (2017-2027)
Table 50 UK Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 51 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 52 Spain Market Size of SMA in USD Million, (2017-2027)
Table 53 Spain Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 54 Spain Drug-Specific Patient Share of SMA, (2017-2027)
Table 55 Italy Market Size of SMA in USD Million, (2017-2027)
Table 56 Italy Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 57 Italy Drug-Specific Patient Share of SMA, (2017-2027)
Table 58 Japan Market Size of SMA in USD Million, (2017-2027)
Table 59 Japan Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 60 Drug-Specific Patient Share of SMA, (2017-2027)

 

Figure 1: Inheritance of SMA in an autosomal recessive pattern
Figure 2: Classification of SMA
Figure 3: Schematic representation of a portion of chromosome 5 that contains two SMN genes
Figure 4: Targets for therapy in SMA
Figure 5: Diagnosis tests in SMA
Figure 6: Diagnostic Evaluation of SMA
Figure 7: Total SMA Cases in 7MM -2017
Figure 8: Total SMA Cases in 7MM - 2027
Figure 9: SMA Incidence and Prevalence Rates
Figure 10: Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Figure 11: Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Figure 12: Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Figure 13: Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Figure 14: Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Figure 15: Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Figure 16: Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Figure 17: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Figure 18: Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Figure 19: Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Figure 20: Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Figure 21: Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Figure 22: Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Figure 23: Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Figure 24: Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Figure 25: Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Figure 26: Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Figure 27: Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Figure 28: Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Figure 29: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Figure 30: Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Figure 31: Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Figure 32: Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Figure 33: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Figure 34: Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Figure 35: Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Figure 36: Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Figure 37: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Figure 38: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 39: 7MM Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 40: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 41: United States Market Size of SMA in USD Million, (2017-2027)
Figure 42: US Estimated revenue of Marketed and Pipeline Drugs in USD Million (2017-2027)
Figure 43: US Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 44: SMA market in EU5 countries in USD Million, (2017-2027)
Figure 45: EU5 Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 46: EU5 Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 47: Germany Market Size of SMA in USD Million, (2017-2027)
Figure 48: Germany Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 49: Germany Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 50: France Market Size of SMA in USD Million, (2017-2027)
Figure 51: France Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 52: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 53: UK Market Size of SMA in USD Million, (2017-2027)
Figure 54: UK Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 55: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 56: Spain Market Size of SMA in USD Million, (2017-2027)
Figure 57: Spain Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 58: Spain Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 59: Italy Market Size of SMA in USD Million, (2017-2027)
Figure 60: Italy Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 61: Italy Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 62: Japan Market Size of SMA in USD Million (2017-2027)
Figure 63: Japan Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 64: Japan Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)

 

Table 1 Types of SMA linked to Chromosome-5
Table 2 Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Table 3 Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Table 4 Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Table 5 Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Table 6 Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Table 7 Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Table 8 Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Table 9 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Table 10 Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Table 11 Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Table 12 Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Table 13 Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Table 14 Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Table 15 Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Table 16 Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Table 17 Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Table 18 Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Table 19 Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Table 20 Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Table 21 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Table 22 Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Table 23 Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Table 24 Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Table 25 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Table 26 Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Table 27 Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Table 28 Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Table 29  Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Table 30 United States Association Current Recommendations for SMA
Table 31 European Association Current Recommendations for SMA
Table 32 Japanese Association Current Recommendations for SMA
Table 33 List of Marketed Drugs for SMA
Table 34 Market Size of SMA in 7MM (USD Million) (2017-2027)
Table 35 7MM Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 36 7MM Drug-Specific Patient Share of SMA, (2017-2027)
Table 37 United States Market Size of SMA in USD Million, (2017-2027)
Table 38 United States Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 39 United States Drug-Specific Patient Share of SMA, (2017-2027)
Table 40 EU5 Market Size of SMA in USD Million, (2017-2027)
Table 41 EU5 Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 42 EU5 Drug-Specific Patient Share of SMA, (2017-2027)
Table 43 Germany Market Size of SMA in USD Million, (2017-2027)
Table 44 Germany Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 45 Germany Drug-Specific Patient Share of SMA, (2017-2027)
Table 46 France Market Size of SMA in USD Million, (2017-2027)
Table 47 France Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 48 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 49 UK Market Size of SMA in USD Million, (2017-2027)
Table 50 UK Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 51 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 52 Spain Market Size of SMA in USD Million, (2017-2027)
Table 53 Spain Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 54 Spain Drug-Specific Patient Share of SMA, (2017-2027)
Table 55 Italy Market Size of SMA in USD Million, (2017-2027)
Table 56 Italy Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 57 Italy Drug-Specific Patient Share of SMA, (2017-2027)
Table 58 Japan Market Size of SMA in USD Million, (2017-2027)
Table 59 Japan Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 60 Drug-Specific Patient Share of SMA, (2017-2027)

 

Figure 1: Inheritance of SMA in an autosomal recessive pattern
Figure 2: Classification of SMA
Figure 3: Schematic representation of a portion of chromosome 5 that contains two SMN genes
Figure 4: Targets for therapy in SMA
Figure 5: Diagnosis tests in SMA
Figure 6: Diagnostic Evaluation of SMA
Figure 7: Total SMA Cases in 7MM -2017
Figure 8: Total SMA Cases in 7MM - 2027
Figure 9: SMA Incidence and Prevalence Rates
Figure 10: Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Figure 11: Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Figure 12: Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Figure 13: Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Figure 14: Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Figure 15: Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Figure 16: Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Figure 17: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Figure 18: Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Figure 19: Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Figure 20: Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Figure 21: Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Figure 22: Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Figure 23: Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Figure 24: Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Figure 25: Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Figure 26: Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Figure 27: Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Figure 28: Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Figure 29: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Figure 30: Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Figure 31: Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Figure 32: Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Figure 33: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Figure 34: Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Figure 35: Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Figure 36: Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Figure 37: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Figure 38: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 39: 7MM Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 40: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 41: United States Market Size of SMA in USD Million, (2017-2027)
Figure 42: US Estimated revenue of Marketed and Pipeline Drugs in USD Million (2017-2027)
Figure 43: US Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 44: SMA market in EU5 countries in USD Million, (2017-2027)
Figure 45: EU5 Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 46: EU5 Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 47: Germany Market Size of SMA in USD Million, (2017-2027)
Figure 48: Germany Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 49: Germany Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 50: France Market Size of SMA in USD Million, (2017-2027)
Figure 51: France Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 52: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 53: UK Market Size of SMA in USD Million, (2017-2027)
Figure 54: UK Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 55: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 56: Spain Market Size of SMA in USD Million, (2017-2027)
Figure 57: Spain Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 58: Spain Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 59: Italy Market Size of SMA in USD Million, (2017-2027)
Figure 60: Italy Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 61: Italy Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 62: Japan Market Size of SMA in USD Million (2017-2027)
Figure 63: Japan Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 64: Japan Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)

 

Table 1 Types of SMA linked to Chromosome-5
Table 2 Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Table 3 Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Table 4 Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Table 5 Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Table 6 Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Table 7 Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Table 8 Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Table 9 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Table 10 Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Table 11 Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Table 12 Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Table 13 Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Table 14 Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Table 15 Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Table 16 Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Table 17 Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Table 18 Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Table 19 Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Table 20 Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Table 21 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Table 22 Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Table 23 Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Table 24 Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Table 25 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Table 26 Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Table 27 Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Table 28 Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Table 29  Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Table 30 United States Association Current Recommendations for SMA
Table 31 European Association Current Recommendations for SMA
Table 32 Japanese Association Current Recommendations for SMA
Table 33 List of Marketed Drugs for SMA
Table 34 Market Size of SMA in 7MM (USD Million) (2017-2027)
Table 35 7MM Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 36 7MM Drug-Specific Patient Share of SMA, (2017-2027)
Table 37 United States Market Size of SMA in USD Million, (2017-2027)
Table 38 United States Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 39 United States Drug-Specific Patient Share of SMA, (2017-2027)
Table 40 EU5 Market Size of SMA in USD Million, (2017-2027)
Table 41 EU5 Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 42 EU5 Drug-Specific Patient Share of SMA, (2017-2027)
Table 43 Germany Market Size of SMA in USD Million, (2017-2027)
Table 44 Germany Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 45 Germany Drug-Specific Patient Share of SMA, (2017-2027)
Table 46 France Market Size of SMA in USD Million, (2017-2027)
Table 47 France Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 48 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 49 UK Market Size of SMA in USD Million, (2017-2027)
Table 50 UK Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 51 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 52 Spain Market Size of SMA in USD Million, (2017-2027)
Table 53 Spain Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 54 Spain Drug-Specific Patient Share of SMA, (2017-2027)
Table 55 Italy Market Size of SMA in USD Million, (2017-2027)
Table 56 Italy Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 57 Italy Drug-Specific Patient Share of SMA, (2017-2027)
Table 58 Japan Market Size of SMA in USD Million, (2017-2027)
Table 59 Japan Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 60 Drug-Specific Patient Share of SMA, (2017-2027)

 

Figure 1: Inheritance of SMA in an autosomal recessive pattern
Figure 2: Classification of SMA
Figure 3: Schematic representation of a portion of chromosome 5 that contains two SMN genes
Figure 4: Targets for therapy in SMA
Figure 5: Diagnosis tests in SMA
Figure 6: Diagnostic Evaluation of SMA
Figure 7: Total SMA Cases in 7MM -2017
Figure 8: Total SMA Cases in 7MM - 2027
Figure 9: SMA Incidence and Prevalence Rates
Figure 10: Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Figure 11: Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Figure 12: Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Figure 13: Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Figure 14: Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Figure 15: Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Figure 16: Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Figure 17: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Figure 18: Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Figure 19: Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Figure 20: Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Figure 21: Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Figure 22: Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Figure 23: Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Figure 24: Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Figure 25: Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Figure 26: Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Figure 27: Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Figure 28: Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Figure 29: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Figure 30: Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Figure 31: Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Figure 32: Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Figure 33: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Figure 34: Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Figure 35: Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Figure 36: Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Figure 37: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Figure 38: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 39: 7MM Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 40: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 41: United States Market Size of SMA in USD Million, (2017-2027)
Figure 42: US Estimated revenue of Marketed and Pipeline Drugs in USD Million (2017-2027)
Figure 43: US Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 44: SMA market in EU5 countries in USD Million, (2017-2027)
Figure 45: EU5 Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 46: EU5 Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 47: Germany Market Size of SMA in USD Million, (2017-2027)
Figure 48: Germany Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 49: Germany Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 50: France Market Size of SMA in USD Million, (2017-2027)
Figure 51: France Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 52: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 53: UK Market Size of SMA in USD Million, (2017-2027)
Figure 54: UK Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 55: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 56: Spain Market Size of SMA in USD Million, (2017-2027)
Figure 57: Spain Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 58: Spain Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 59: Italy Market Size of SMA in USD Million, (2017-2027)
Figure 60: Italy Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 61: Italy Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 62: Japan Market Size of SMA in USD Million (2017-2027)
Figure 63: Japan Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 64: Japan Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)

 

Table 1 Types of SMA linked to Chromosome-5
Table 2 Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Table 3 Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Table 4 Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Table 5 Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Table 6 Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Table 7 Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Table 8 Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Table 9 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Table 10 Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Table 11 Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Table 12 Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Table 13 Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Table 14 Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Table 15 Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Table 16 Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Table 17 Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Table 18 Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Table 19 Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Table 20 Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Table 21 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Table 22 Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Table 23 Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Table 24 Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Table 25 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Table 26 Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Table 27 Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Table 28 Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Table 29  Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Table 30 United States Association Current Recommendations for SMA
Table 31 European Association Current Recommendations for SMA
Table 32 Japanese Association Current Recommendations for SMA
Table 33 List of Marketed Drugs for SMA
Table 34 Market Size of SMA in 7MM (USD Million) (2017-2027)
Table 35 7MM Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 36 7MM Drug-Specific Patient Share of SMA, (2017-2027)
Table 37 United States Market Size of SMA in USD Million, (2017-2027)
Table 38 United States Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 39 United States Drug-Specific Patient Share of SMA, (2017-2027)
Table 40 EU5 Market Size of SMA in USD Million, (2017-2027)
Table 41 EU5 Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 42 EU5 Drug-Specific Patient Share of SMA, (2017-2027)
Table 43 Germany Market Size of SMA in USD Million, (2017-2027)
Table 44 Germany Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 45 Germany Drug-Specific Patient Share of SMA, (2017-2027)
Table 46 France Market Size of SMA in USD Million, (2017-2027)
Table 47 France Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 48 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 49 UK Market Size of SMA in USD Million, (2017-2027)
Table 50 UK Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 51 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 52 Spain Market Size of SMA in USD Million, (2017-2027)
Table 53 Spain Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 54 Spain Drug-Specific Patient Share of SMA, (2017-2027)
Table 55 Italy Market Size of SMA in USD Million, (2017-2027)
Table 56 Italy Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 57 Italy Drug-Specific Patient Share of SMA, (2017-2027)
Table 58 Japan Market Size of SMA in USD Million, (2017-2027)
Table 59 Japan Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 60 Drug-Specific Patient Share of SMA, (2017-2027)

 

Figure 1: Inheritance of SMA in an autosomal recessive pattern
Figure 2: Classification of SMA
Figure 3: Schematic representation of a portion of chromosome 5 that contains two SMN genes
Figure 4: Targets for therapy in SMA
Figure 5: Diagnosis tests in SMA
Figure 6: Diagnostic Evaluation of SMA
Figure 7: Total SMA Cases in 7MM -2017
Figure 8: Total SMA Cases in 7MM - 2027
Figure 9: SMA Incidence and Prevalence Rates
Figure 10: Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Figure 11: Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Figure 12: Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Figure 13: Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Figure 14: Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Figure 15: Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Figure 16: Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Figure 17: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Figure 18: Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Figure 19: Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Figure 20: Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Figure 21: Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Figure 22: Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Figure 23: Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Figure 24: Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Figure 25: Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Figure 26: Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Figure 27: Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Figure 28: Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Figure 29: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Figure 30: Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Figure 31: Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Figure 32: Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Figure 33: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Figure 34: Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Figure 35: Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Figure 36: Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Figure 37: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Figure 38: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 39: 7MM Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 40: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 41: United States Market Size of SMA in USD Million, (2017-2027)
Figure 42: US Estimated revenue of Marketed and Pipeline Drugs in USD Million (2017-2027)
Figure 43: US Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 44: SMA market in EU5 countries in USD Million, (2017-2027)
Figure 45: EU5 Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 46: EU5 Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 47: Germany Market Size of SMA in USD Million, (2017-2027)
Figure 48: Germany Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 49: Germany Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 50: France Market Size of SMA in USD Million, (2017-2027)
Figure 51: France Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 52: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 53: UK Market Size of SMA in USD Million, (2017-2027)
Figure 54: UK Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 55: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 56: Spain Market Size of SMA in USD Million, (2017-2027)
Figure 57: Spain Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 58: Spain Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 59: Italy Market Size of SMA in USD Million, (2017-2027)
Figure 60: Italy Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 61: Italy Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 62: Japan Market Size of SMA in USD Million (2017-2027)
Figure 63: Japan Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 64: Japan Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)

 

Table 1 Types of SMA linked to Chromosome-5
Table 2 Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Table 3 Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Table 4 Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Table 5 Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Table 6 Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Table 7 Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Table 8 Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Table 9 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Table 10 Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Table 11 Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Table 12 Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Table 13 Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Table 14 Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Table 15 Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Table 16 Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Table 17 Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Table 18 Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Table 19 Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Table 20 Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Table 21 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Table 22 Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Table 23 Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Table 24 Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Table 25 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Table 26 Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Table 27 Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Table 28 Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Table 29  Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Table 30 United States Association Current Recommendations for SMA
Table 31 European Association Current Recommendations for SMA
Table 32 Japanese Association Current Recommendations for SMA
Table 33 List of Marketed Drugs for SMA
Table 34 Market Size of SMA in 7MM (USD Million) (2017-2027)
Table 35 7MM Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 36 7MM Drug-Specific Patient Share of SMA, (2017-2027)
Table 37 United States Market Size of SMA in USD Million, (2017-2027)
Table 38 United States Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 39 United States Drug-Specific Patient Share of SMA, (2017-2027)
Table 40 EU5 Market Size of SMA in USD Million, (2017-2027)
Table 41 EU5 Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 42 EU5 Drug-Specific Patient Share of SMA, (2017-2027)
Table 43 Germany Market Size of SMA in USD Million, (2017-2027)
Table 44 Germany Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 45 Germany Drug-Specific Patient Share of SMA, (2017-2027)
Table 46 France Market Size of SMA in USD Million, (2017-2027)
Table 47 France Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 48 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 49 UK Market Size of SMA in USD Million, (2017-2027)
Table 50 UK Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 51 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 52 Spain Market Size of SMA in USD Million, (2017-2027)
Table 53 Spain Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 54 Spain Drug-Specific Patient Share of SMA, (2017-2027)
Table 55 Italy Market Size of SMA in USD Million, (2017-2027)
Table 56 Italy Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 57 Italy Drug-Specific Patient Share of SMA, (2017-2027)
Table 58 Japan Market Size of SMA in USD Million, (2017-2027)
Table 59 Japan Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 60 Drug-Specific Patient Share of SMA, (2017-2027)

 

Figure 1: Inheritance of SMA in an autosomal recessive pattern
Figure 2: Classification of SMA
Figure 3: Schematic representation of a portion of chromosome 5 that contains two SMN genes
Figure 4: Targets for therapy in SMA
Figure 5: Diagnosis tests in SMA
Figure 6: Diagnostic Evaluation of SMA
Figure 7: Total SMA Cases in 7MM -2017
Figure 8: Total SMA Cases in 7MM - 2027
Figure 9: SMA Incidence and Prevalence Rates
Figure 10: Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Figure 11: Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Figure 12: Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Figure 13: Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Figure 14: Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Figure 15: Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Figure 16: Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Figure 17: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Figure 18: Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Figure 19: Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Figure 20: Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Figure 21: Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Figure 22: Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Figure 23: Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Figure 24: Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Figure 25: Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Figure 26: Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Figure 27: Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Figure 28: Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Figure 29: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Figure 30: Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Figure 31: Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Figure 32: Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Figure 33: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Figure 34: Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Figure 35: Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Figure 36: Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Figure 37: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Figure 38: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 39: 7MM Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 40: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 41: United States Market Size of SMA in USD Million, (2017-2027)
Figure 42: US Estimated revenue of Marketed and Pipeline Drugs in USD Million (2017-2027)
Figure 43: US Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 44: SMA market in EU5 countries in USD Million, (2017-2027)
Figure 45: EU5 Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 46: EU5 Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 47: Germany Market Size of SMA in USD Million, (2017-2027)
Figure 48: Germany Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 49: Germany Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 50: France Market Size of SMA in USD Million, (2017-2027)
Figure 51: France Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 52: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 53: UK Market Size of SMA in USD Million, (2017-2027)
Figure 54: UK Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 55: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 56: Spain Market Size of SMA in USD Million, (2017-2027)
Figure 57: Spain Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 58: Spain Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 59: Italy Market Size of SMA in USD Million, (2017-2027)
Figure 60: Italy Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 61: Italy Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 62: Japan Market Size of SMA in USD Million (2017-2027)
Figure 63: Japan Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 64: Japan Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)

 

Table 1 Types of SMA linked to Chromosome-5
Table 2 Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Table 3 Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Table 4 Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Table 5 Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Table 6 Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Table 7 Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Table 8 Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Table 9 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Table 10 Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Table 11 Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Table 12 Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Table 13 Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Table 14 Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Table 15 Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Table 16 Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Table 17 Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Table 18 Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Table 19 Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Table 20 Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Table 21 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Table 22 Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Table 23 Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Table 24 Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Table 25 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Table 26 Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Table 27 Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Table 28 Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Table 29  Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Table 30 United States Association Current Recommendations for SMA
Table 31 European Association Current Recommendations for SMA
Table 32 Japanese Association Current Recommendations for SMA
Table 33 List of Marketed Drugs for SMA
Table 34 Market Size of SMA in 7MM (USD Million) (2017-2027)
Table 35 7MM Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 36 7MM Drug-Specific Patient Share of SMA, (2017-2027)
Table 37 United States Market Size of SMA in USD Million, (2017-2027)
Table 38 United States Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 39 United States Drug-Specific Patient Share of SMA, (2017-2027)
Table 40 EU5 Market Size of SMA in USD Million, (2017-2027)
Table 41 EU5 Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 42 EU5 Drug-Specific Patient Share of SMA, (2017-2027)
Table 43 Germany Market Size of SMA in USD Million, (2017-2027)
Table 44 Germany Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 45 Germany Drug-Specific Patient Share of SMA, (2017-2027)
Table 46 France Market Size of SMA in USD Million, (2017-2027)
Table 47 France Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 48 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 49 UK Market Size of SMA in USD Million, (2017-2027)
Table 50 UK Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 51 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 52 Spain Market Size of SMA in USD Million, (2017-2027)
Table 53 Spain Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 54 Spain Drug-Specific Patient Share of SMA, (2017-2027)
Table 55 Italy Market Size of SMA in USD Million, (2017-2027)
Table 56 Italy Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 57 Italy Drug-Specific Patient Share of SMA, (2017-2027)
Table 58 Japan Market Size of SMA in USD Million, (2017-2027)
Table 59 Japan Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 60 Drug-Specific Patient Share of SMA, (2017-2027)

 

Figure 1: Inheritance of SMA in an autosomal recessive pattern
Figure 2: Classification of SMA
Figure 3: Schematic representation of a portion of chromosome 5 that contains two SMN genes
Figure 4: Targets for therapy in SMA
Figure 5: Diagnosis tests in SMA
Figure 6: Diagnostic Evaluation of SMA
Figure 7: Total SMA Cases in 7MM -2017
Figure 8: Total SMA Cases in 7MM - 2027
Figure 9: SMA Incidence and Prevalence Rates
Figure 10: Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Figure 11: Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Figure 12: Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Figure 13: Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Figure 14: Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Figure 15: Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Figure 16: Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Figure 17: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Figure 18: Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Figure 19: Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Figure 20: Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Figure 21: Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Figure 22: Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Figure 23: Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Figure 24: Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Figure 25: Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Figure 26: Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Figure 27: Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Figure 28: Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Figure 29: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Figure 30: Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Figure 31: Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Figure 32: Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Figure 33: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Figure 34: Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Figure 35: Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Figure 36: Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Figure 37: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Figure 38: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 39: 7MM Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 40: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 41: United States Market Size of SMA in USD Million, (2017-2027)
Figure 42: US Estimated revenue of Marketed and Pipeline Drugs in USD Million (2017-2027)
Figure 43: US Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 44: SMA market in EU5 countries in USD Million, (2017-2027)
Figure 45: EU5 Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 46: EU5 Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 47: Germany Market Size of SMA in USD Million, (2017-2027)
Figure 48: Germany Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 49: Germany Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 50: France Market Size of SMA in USD Million, (2017-2027)
Figure 51: France Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 52: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 53: UK Market Size of SMA in USD Million, (2017-2027)
Figure 54: UK Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 55: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 56: Spain Market Size of SMA in USD Million, (2017-2027)
Figure 57: Spain Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 58: Spain Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 59: Italy Market Size of SMA in USD Million, (2017-2027)
Figure 60: Italy Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 61: Italy Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 62: Japan Market Size of SMA in USD Million (2017-2027)
Figure 63: Japan Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 64: Japan Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)

 

Table 1 Types of SMA linked to Chromosome-5
Table 2 Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Table 3 Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Table 4 Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Table 5 Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Table 6 Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Table 7 Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Table 8 Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Table 9 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Table 10 Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Table 11 Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Table 12 Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Table 13 Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Table 14 Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Table 15 Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Table 16 Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Table 17 Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Table 18 Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Table 19 Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Table 20 Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Table 21 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Table 22 Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Table 23 Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Table 24 Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Table 25 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Table 26 Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Table 27 Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Table 28 Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Table 29  Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Table 30 United States Association Current Recommendations for SMA
Table 31 European Association Current Recommendations for SMA
Table 32 Japanese Association Current Recommendations for SMA
Table 33 List of Marketed Drugs for SMA
Table 34 Market Size of SMA in 7MM (USD Million) (2017-2027)
Table 35 7MM Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 36 7MM Drug-Specific Patient Share of SMA, (2017-2027)
Table 37 United States Market Size of SMA in USD Million, (2017-2027)
Table 38 United States Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 39 United States Drug-Specific Patient Share of SMA, (2017-2027)
Table 40 EU5 Market Size of SMA in USD Million, (2017-2027)
Table 41 EU5 Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 42 EU5 Drug-Specific Patient Share of SMA, (2017-2027)
Table 43 Germany Market Size of SMA in USD Million, (2017-2027)
Table 44 Germany Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 45 Germany Drug-Specific Patient Share of SMA, (2017-2027)
Table 46 France Market Size of SMA in USD Million, (2017-2027)
Table 47 France Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 48 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 49 UK Market Size of SMA in USD Million, (2017-2027)
Table 50 UK Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 51 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 52 Spain Market Size of SMA in USD Million, (2017-2027)
Table 53 Spain Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 54 Spain Drug-Specific Patient Share of SMA, (2017-2027)
Table 55 Italy Market Size of SMA in USD Million, (2017-2027)
Table 56 Italy Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 57 Italy Drug-Specific Patient Share of SMA, (2017-2027)
Table 58 Japan Market Size of SMA in USD Million, (2017-2027)
Table 59 Japan Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 60 Drug-Specific Patient Share of SMA, (2017-2027)

 

Figure 1: Inheritance of SMA in an autosomal recessive pattern
Figure 2: Classification of SMA
Figure 3: Schematic representation of a portion of chromosome 5 that contains two SMN genes
Figure 4: Targets for therapy in SMA
Figure 5: Diagnosis tests in SMA
Figure 6: Diagnostic Evaluation of SMA
Figure 7: Total SMA Cases in 7MM -2017
Figure 8: Total SMA Cases in 7MM - 2027
Figure 9: SMA Incidence and Prevalence Rates
Figure 10: Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Figure 11: Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Figure 12: Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Figure 13: Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Figure 14: Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Figure 15: Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Figure 16: Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Figure 17: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Figure 18: Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Figure 19: Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Figure 20: Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Figure 21: Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Figure 22: Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Figure 23: Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Figure 24: Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Figure 25: Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Figure 26: Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Figure 27: Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Figure 28: Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Figure 29: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Figure 30: Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Figure 31: Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Figure 32: Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Figure 33: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Figure 34: Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Figure 35: Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Figure 36: Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Figure 37: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Figure 38: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 39: 7MM Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 40: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 41: United States Market Size of SMA in USD Million, (2017-2027)
Figure 42: US Estimated revenue of Marketed and Pipeline Drugs in USD Million (2017-2027)
Figure 43: US Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 44: SMA market in EU5 countries in USD Million, (2017-2027)
Figure 45: EU5 Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 46: EU5 Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 47: Germany Market Size of SMA in USD Million, (2017-2027)
Figure 48: Germany Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 49: Germany Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 50: France Market Size of SMA in USD Million, (2017-2027)
Figure 51: France Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 52: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 53: UK Market Size of SMA in USD Million, (2017-2027)
Figure 54: UK Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 55: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 56: Spain Market Size of SMA in USD Million, (2017-2027)
Figure 57: Spain Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 58: Spain Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 59: Italy Market Size of SMA in USD Million, (2017-2027)
Figure 60: Italy Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 61: Italy Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 62: Japan Market Size of SMA in USD Million (2017-2027)
Figure 63: Japan Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 64: Japan Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)

 

Table 1 Types of SMA linked to Chromosome-5
Table 2 Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Table 3 Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Table 4 Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Table 5 Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Table 6 Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Table 7 Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Table 8 Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Table 9 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Table 10 Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Table 11 Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Table 12 Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Table 13 Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Table 14 Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Table 15 Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Table 16 Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Table 17 Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Table 18 Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Table 19 Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Table 20 Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Table 21 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Table 22 Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Table 23 Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Table 24 Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Table 25 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Table 26 Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Table 27 Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Table 28 Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Table 29  Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Table 30 United States Association Current Recommendations for SMA
Table 31 European Association Current Recommendations for SMA
Table 32 Japanese Association Current Recommendations for SMA
Table 33 List of Marketed Drugs for SMA
Table 34 Market Size of SMA in 7MM (USD Million) (2017-2027)
Table 35 7MM Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 36 7MM Drug-Specific Patient Share of SMA, (2017-2027)
Table 37 United States Market Size of SMA in USD Million, (2017-2027)
Table 38 United States Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 39 United States Drug-Specific Patient Share of SMA, (2017-2027)
Table 40 EU5 Market Size of SMA in USD Million, (2017-2027)
Table 41 EU5 Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 42 EU5 Drug-Specific Patient Share of SMA, (2017-2027)
Table 43 Germany Market Size of SMA in USD Million, (2017-2027)
Table 44 Germany Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 45 Germany Drug-Specific Patient Share of SMA, (2017-2027)
Table 46 France Market Size of SMA in USD Million, (2017-2027)
Table 47 France Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 48 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 49 UK Market Size of SMA in USD Million, (2017-2027)
Table 50 UK Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 51 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 52 Spain Market Size of SMA in USD Million, (2017-2027)
Table 53 Spain Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 54 Spain Drug-Specific Patient Share of SMA, (2017-2027)
Table 55 Italy Market Size of SMA in USD Million, (2017-2027)
Table 56 Italy Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 57 Italy Drug-Specific Patient Share of SMA, (2017-2027)
Table 58 Japan Market Size of SMA in USD Million, (2017-2027)
Table 59 Japan Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 60 Drug-Specific Patient Share of SMA, (2017-2027)

 

Figure 1: Inheritance of SMA in an autosomal recessive pattern
Figure 2: Classification of SMA
Figure 3: Schematic representation of a portion of chromosome 5 that contains two SMN genes
Figure 4: Targets for therapy in SMA
Figure 5: Diagnosis tests in SMA
Figure 6: Diagnostic Evaluation of SMA
Figure 7: Total SMA Cases in 7MM -2017
Figure 8: Total SMA Cases in 7MM - 2027
Figure 9: SMA Incidence and Prevalence Rates
Figure 10: Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Figure 11: Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Figure 12: Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Figure 13: Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Figure 14: Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Figure 15: Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Figure 16: Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Figure 17: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Figure 18: Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Figure 19: Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Figure 20: Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Figure 21: Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Figure 22: Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Figure 23: Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Figure 24: Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Figure 25: Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Figure 26: Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Figure 27: Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Figure 28: Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Figure 29: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Figure 30: Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Figure 31: Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Figure 32: Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Figure 33: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Figure 34: Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Figure 35: Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Figure 36: Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Figure 37: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Figure 38: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 39: 7MM Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 40: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 41: United States Market Size of SMA in USD Million, (2017-2027)
Figure 42: US Estimated revenue of Marketed and Pipeline Drugs in USD Million (2017-2027)
Figure 43: US Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 44: SMA market in EU5 countries in USD Million, (2017-2027)
Figure 45: EU5 Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 46: EU5 Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 47: Germany Market Size of SMA in USD Million, (2017-2027)
Figure 48: Germany Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 49: Germany Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 50: France Market Size of SMA in USD Million, (2017-2027)
Figure 51: France Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 52: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 53: UK Market Size of SMA in USD Million, (2017-2027)
Figure 54: UK Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 55: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 56: Spain Market Size of SMA in USD Million, (2017-2027)
Figure 57: Spain Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 58: Spain Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 59: Italy Market Size of SMA in USD Million, (2017-2027)
Figure 60: Italy Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 61: Italy Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 62: Japan Market Size of SMA in USD Million (2017-2027)
Figure 63: Japan Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 64: Japan Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)

 

Table 1 Types of SMA linked to Chromosome-5
Table 2 Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Table 3 Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Table 4 Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Table 5 Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Table 6 Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Table 7 Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Table 8 Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Table 9 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Table 10 Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Table 11 Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Table 12 Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Table 13 Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Table 14 Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Table 15 Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Table 16 Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Table 17 Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Table 18 Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Table 19 Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Table 20 Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Table 21 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Table 22 Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Table 23 Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Table 24 Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Table 25 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Table 26 Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Table 27 Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Table 28 Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Table 29  Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Table 30 United States Association Current Recommendations for SMA
Table 31 European Association Current Recommendations for SMA
Table 32 Japanese Association Current Recommendations for SMA
Table 33 List of Marketed Drugs for SMA
Table 34 Market Size of SMA in 7MM (USD Million) (2017-2027)
Table 35 7MM Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 36 7MM Drug-Specific Patient Share of SMA, (2017-2027)
Table 37 United States Market Size of SMA in USD Million, (2017-2027)
Table 38 United States Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 39 United States Drug-Specific Patient Share of SMA, (2017-2027)
Table 40 EU5 Market Size of SMA in USD Million, (2017-2027)
Table 41 EU5 Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 42 EU5 Drug-Specific Patient Share of SMA, (2017-2027)
Table 43 Germany Market Size of SMA in USD Million, (2017-2027)
Table 44 Germany Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 45 Germany Drug-Specific Patient Share of SMA, (2017-2027)
Table 46 France Market Size of SMA in USD Million, (2017-2027)
Table 47 France Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 48 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 49 UK Market Size of SMA in USD Million, (2017-2027)
Table 50 UK Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 51 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 52 Spain Market Size of SMA in USD Million, (2017-2027)
Table 53 Spain Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 54 Spain Drug-Specific Patient Share of SMA, (2017-2027)
Table 55 Italy Market Size of SMA in USD Million, (2017-2027)
Table 56 Italy Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 57 Italy Drug-Specific Patient Share of SMA, (2017-2027)
Table 58 Japan Market Size of SMA in USD Million, (2017-2027)
Table 59 Japan Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 60 Drug-Specific Patient Share of SMA, (2017-2027)

 

Figure 1: Inheritance of SMA in an autosomal recessive pattern
Figure 2: Classification of SMA
Figure 3: Schematic representation of a portion of chromosome 5 that contains two SMN genes
Figure 4: Targets for therapy in SMA
Figure 5: Diagnosis tests in SMA
Figure 6: Diagnostic Evaluation of SMA
Figure 7: Total SMA Cases in 7MM -2017
Figure 8: Total SMA Cases in 7MM - 2027
Figure 9: SMA Incidence and Prevalence Rates
Figure 10: Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Figure 11: Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Figure 12: Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Figure 13: Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Figure 14: Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Figure 15: Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Figure 16: Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Figure 17: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Figure 18: Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Figure 19: Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Figure 20: Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Figure 21: Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Figure 22: Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Figure 23: Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Figure 24: Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Figure 25: Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Figure 26: Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Figure 27: Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Figure 28: Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Figure 29: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Figure 30: Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Figure 31: Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Figure 32: Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Figure 33: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Figure 34: Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Figure 35: Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Figure 36: Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Figure 37: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Figure 38: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 39: 7MM Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 40: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 41: United States Market Size of SMA in USD Million, (2017-2027)
Figure 42: US Estimated revenue of Marketed and Pipeline Drugs in USD Million (2017-2027)
Figure 43: US Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 44: SMA market in EU5 countries in USD Million, (2017-2027)
Figure 45: EU5 Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 46: EU5 Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 47: Germany Market Size of SMA in USD Million, (2017-2027)
Figure 48: Germany Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 49: Germany Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 50: France Market Size of SMA in USD Million, (2017-2027)
Figure 51: France Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 52: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 53: UK Market Size of SMA in USD Million, (2017-2027)
Figure 54: UK Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 55: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 56: Spain Market Size of SMA in USD Million, (2017-2027)
Figure 57: Spain Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 58: Spain Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 59: Italy Market Size of SMA in USD Million, (2017-2027)
Figure 60: Italy Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 61: Italy Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 62: Japan Market Size of SMA in USD Million (2017-2027)
Figure 63: Japan Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 64: Japan Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)

 

Table 1 Types of SMA linked to Chromosome-5
Table 2 Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Table 3 Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Table 4 Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Table 5 Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Table 6 Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Table 7 Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Table 8 Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Table 9 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Table 10 Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Table 11 Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Table 12 Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Table 13 Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Table 14 Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Table 15 Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Table 16 Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Table 17 Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Table 18 Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Table 19 Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Table 20 Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Table 21 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Table 22 Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Table 23 Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Table 24 Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Table 25 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Table 26 Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Table 27 Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Table 28 Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Table 29  Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Table 30 United States Association Current Recommendations for SMA
Table 31 European Association Current Recommendations for SMA
Table 32 Japanese Association Current Recommendations for SMA
Table 33 List of Marketed Drugs for SMA
Table 34 Market Size of SMA in 7MM (USD Million) (2017-2027)
Table 35 7MM Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 36 7MM Drug-Specific Patient Share of SMA, (2017-2027)
Table 37 United States Market Size of SMA in USD Million, (2017-2027)
Table 38 United States Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 39 United States Drug-Specific Patient Share of SMA, (2017-2027)
Table 40 EU5 Market Size of SMA in USD Million, (2017-2027)
Table 41 EU5 Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 42 EU5 Drug-Specific Patient Share of SMA, (2017-2027)
Table 43 Germany Market Size of SMA in USD Million, (2017-2027)
Table 44 Germany Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 45 Germany Drug-Specific Patient Share of SMA, (2017-2027)
Table 46 France Market Size of SMA in USD Million, (2017-2027)
Table 47 France Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 48 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 49 UK Market Size of SMA in USD Million, (2017-2027)
Table 50 UK Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 51 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 52 Spain Market Size of SMA in USD Million, (2017-2027)
Table 53 Spain Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 54 Spain Drug-Specific Patient Share of SMA, (2017-2027)
Table 55 Italy Market Size of SMA in USD Million, (2017-2027)
Table 56 Italy Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 57 Italy Drug-Specific Patient Share of SMA, (2017-2027)
Table 58 Japan Market Size of SMA in USD Million, (2017-2027)
Table 59 Japan Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 60 Drug-Specific Patient Share of SMA, (2017-2027)

 

Figure 1: Inheritance of SMA in an autosomal recessive pattern
Figure 2: Classification of SMA
Figure 3: Schematic representation of a portion of chromosome 5 that contains two SMN genes
Figure 4: Targets for therapy in SMA
Figure 5: Diagnosis tests in SMA
Figure 6: Diagnostic Evaluation of SMA
Figure 7: Total SMA Cases in 7MM -2017
Figure 8: Total SMA Cases in 7MM - 2027
Figure 9: SMA Incidence and Prevalence Rates
Figure 10: Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Figure 11: Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Figure 12: Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Figure 13: Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Figure 14: Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Figure 15: Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Figure 16: Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Figure 17: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Figure 18: Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Figure 19: Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Figure 20: Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Figure 21: Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Figure 22: Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Figure 23: Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Figure 24: Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Figure 25: Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Figure 26: Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Figure 27: Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Figure 28: Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Figure 29: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Figure 30: Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Figure 31: Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Figure 32: Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Figure 33: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Figure 34: Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Figure 35: Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Figure 36: Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Figure 37: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Figure 38: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 39: 7MM Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 40: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 41: United States Market Size of SMA in USD Million, (2017-2027)
Figure 42: US Estimated revenue of Marketed and Pipeline Drugs in USD Million (2017-2027)
Figure 43: US Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 44: SMA market in EU5 countries in USD Million, (2017-2027)
Figure 45: EU5 Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 46: EU5 Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 47: Germany Market Size of SMA in USD Million, (2017-2027)
Figure 48: Germany Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 49: Germany Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 50: France Market Size of SMA in USD Million, (2017-2027)
Figure 51: France Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 52: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 53: UK Market Size of SMA in USD Million, (2017-2027)
Figure 54: UK Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 55: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 56: Spain Market Size of SMA in USD Million, (2017-2027)
Figure 57: Spain Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 58: Spain Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 59: Italy Market Size of SMA in USD Million, (2017-2027)
Figure 60: Italy Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 61: Italy Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 62: Japan Market Size of SMA in USD Million (2017-2027)
Figure 63: Japan Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 64: Japan Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)

 

Table 1 Types of SMA linked to Chromosome-5
Table 2 Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Table 3 Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Table 4 Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Table 5 Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Table 6 Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Table 7 Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Table 8 Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Table 9 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Table 10 Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Table 11 Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Table 12 Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Table 13 Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Table 14 Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Table 15 Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Table 16 Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Table 17 Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Table 18 Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Table 19 Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Table 20 Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Table 21 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Table 22 Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Table 23 Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Table 24 Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Table 25 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Table 26 Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Table 27 Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Table 28 Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Table 29  Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Table 30 United States Association Current Recommendations for SMA
Table 31 European Association Current Recommendations for SMA
Table 32 Japanese Association Current Recommendations for SMA
Table 33 List of Marketed Drugs for SMA
Table 34 Market Size of SMA in 7MM (USD Million) (2017-2027)
Table 35 7MM Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 36 7MM Drug-Specific Patient Share of SMA, (2017-2027)
Table 37 United States Market Size of SMA in USD Million, (2017-2027)
Table 38 United States Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 39 United States Drug-Specific Patient Share of SMA, (2017-2027)
Table 40 EU5 Market Size of SMA in USD Million, (2017-2027)
Table 41 EU5 Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 42 EU5 Drug-Specific Patient Share of SMA, (2017-2027)
Table 43 Germany Market Size of SMA in USD Million, (2017-2027)
Table 44 Germany Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 45 Germany Drug-Specific Patient Share of SMA, (2017-2027)
Table 46 France Market Size of SMA in USD Million, (2017-2027)
Table 47 France Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 48 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 49 UK Market Size of SMA in USD Million, (2017-2027)
Table 50 UK Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 51 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 52 Spain Market Size of SMA in USD Million, (2017-2027)
Table 53 Spain Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 54 Spain Drug-Specific Patient Share of SMA, (2017-2027)
Table 55 Italy Market Size of SMA in USD Million, (2017-2027)
Table 56 Italy Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 57 Italy Drug-Specific Patient Share of SMA, (2017-2027)
Table 58 Japan Market Size of SMA in USD Million, (2017-2027)
Table 59 Japan Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 60 Drug-Specific Patient Share of SMA, (2017-2027)

 

Figure 1: Inheritance of SMA in an autosomal recessive pattern
Figure 2: Classification of SMA
Figure 3: Schematic representation of a portion of chromosome 5 that contains two SMN genes
Figure 4: Targets for therapy in SMA
Figure 5: Diagnosis tests in SMA
Figure 6: Diagnostic Evaluation of SMA
Figure 7: Total SMA Cases in 7MM -2017
Figure 8: Total SMA Cases in 7MM - 2027
Figure 9: SMA Incidence and Prevalence Rates
Figure 10: Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Figure 11: Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Figure 12: Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Figure 13: Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Figure 14: Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Figure 15: Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Figure 16: Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Figure 17: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Figure 18: Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Figure 19: Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Figure 20: Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Figure 21: Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Figure 22: Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Figure 23: Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Figure 24: Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Figure 25: Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Figure 26: Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Figure 27: Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Figure 28: Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Figure 29: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Figure 30: Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Figure 31: Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Figure 32: Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Figure 33: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Figure 34: Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Figure 35: Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Figure 36: Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Figure 37: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Figure 38: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 39: 7MM Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 40: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 41: United States Market Size of SMA in USD Million, (2017-2027)
Figure 42: US Estimated revenue of Marketed and Pipeline Drugs in USD Million (2017-2027)
Figure 43: US Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 44: SMA market in EU5 countries in USD Million, (2017-2027)
Figure 45: EU5 Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 46: EU5 Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 47: Germany Market Size of SMA in USD Million, (2017-2027)
Figure 48: Germany Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 49: Germany Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 50: France Market Size of SMA in USD Million, (2017-2027)
Figure 51: France Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 52: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 53: UK Market Size of SMA in USD Million, (2017-2027)
Figure 54: UK Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 55: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 56: Spain Market Size of SMA in USD Million, (2017-2027)
Figure 57: Spain Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 58: Spain Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 59: Italy Market Size of SMA in USD Million, (2017-2027)
Figure 60: Italy Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 61: Italy Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 62: Japan Market Size of SMA in USD Million (2017-2027)
Figure 63: Japan Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 64: Japan Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)

 

Table 1 Types of SMA linked to Chromosome-5
Table 2 Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Table 3 Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Table 4 Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Table 5 Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Table 6 Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Table 7 Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Table 8 Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Table 9 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Table 10 Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Table 11 Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Table 12 Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Table 13 Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Table 14 Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Table 15 Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Table 16 Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Table 17 Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Table 18 Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Table 19 Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Table 20 Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Table 21 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Table 22 Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Table 23 Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Table 24 Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Table 25 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Table 26 Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Table 27 Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Table 28 Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Table 29  Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Table 30 United States Association Current Recommendations for SMA
Table 31 European Association Current Recommendations for SMA
Table 32 Japanese Association Current Recommendations for SMA
Table 33 List of Marketed Drugs for SMA
Table 34 Market Size of SMA in 7MM (USD Million) (2017-2027)
Table 35 7MM Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 36 7MM Drug-Specific Patient Share of SMA, (2017-2027)
Table 37 United States Market Size of SMA in USD Million, (2017-2027)
Table 38 United States Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 39 United States Drug-Specific Patient Share of SMA, (2017-2027)
Table 40 EU5 Market Size of SMA in USD Million, (2017-2027)
Table 41 EU5 Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 42 EU5 Drug-Specific Patient Share of SMA, (2017-2027)
Table 43 Germany Market Size of SMA in USD Million, (2017-2027)
Table 44 Germany Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 45 Germany Drug-Specific Patient Share of SMA, (2017-2027)
Table 46 France Market Size of SMA in USD Million, (2017-2027)
Table 47 France Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 48 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 49 UK Market Size of SMA in USD Million, (2017-2027)
Table 50 UK Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 51 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 52 Spain Market Size of SMA in USD Million, (2017-2027)
Table 53 Spain Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 54 Spain Drug-Specific Patient Share of SMA, (2017-2027)
Table 55 Italy Market Size of SMA in USD Million, (2017-2027)
Table 56 Italy Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 57 Italy Drug-Specific Patient Share of SMA, (2017-2027)
Table 58 Japan Market Size of SMA in USD Million, (2017-2027)
Table 59 Japan Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 60 Drug-Specific Patient Share of SMA, (2017-2027)

 

Figure 1: Inheritance of SMA in an autosomal recessive pattern
Figure 2: Classification of SMA
Figure 3: Schematic representation of a portion of chromosome 5 that contains two SMN genes
Figure 4: Targets for therapy in SMA
Figure 5: Diagnosis tests in SMA
Figure 6: Diagnostic Evaluation of SMA
Figure 7: Total SMA Cases in 7MM -2017
Figure 8: Total SMA Cases in 7MM - 2027
Figure 9: SMA Incidence and Prevalence Rates
Figure 10: Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Figure 11: Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Figure 12: Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Figure 13: Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Figure 14: Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Figure 15: Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Figure 16: Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Figure 17: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Figure 18: Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Figure 19: Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Figure 20: Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Figure 21: Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Figure 22: Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Figure 23: Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Figure 24: Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Figure 25: Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Figure 26: Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Figure 27: Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Figure 28: Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Figure 29: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Figure 30: Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Figure 31: Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Figure 32: Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Figure 33: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Figure 34: Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Figure 35: Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Figure 36: Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Figure 37: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Figure 38: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 39: 7MM Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 40: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 41: United States Market Size of SMA in USD Million, (2017-2027)
Figure 42: US Estimated revenue of Marketed and Pipeline Drugs in USD Million (2017-2027)
Figure 43: US Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 44: SMA market in EU5 countries in USD Million, (2017-2027)
Figure 45: EU5 Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 46: EU5 Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 47: Germany Market Size of SMA in USD Million, (2017-2027)
Figure 48: Germany Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 49: Germany Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 50: France Market Size of SMA in USD Million, (2017-2027)
Figure 51: France Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 52: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 53: UK Market Size of SMA in USD Million, (2017-2027)
Figure 54: UK Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 55: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 56: Spain Market Size of SMA in USD Million, (2017-2027)
Figure 57: Spain Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 58: Spain Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 59: Italy Market Size of SMA in USD Million, (2017-2027)
Figure 60: Italy Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 61: Italy Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 62: Japan Market Size of SMA in USD Million (2017-2027)
Figure 63: Japan Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 64: Japan Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)

 

Table 1 Types of SMA linked to Chromosome-5
Table 2 Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Table 3 Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Table 4 Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Table 5 Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Table 6 Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Table 7 Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Table 8 Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Table 9 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Table 10 Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Table 11 Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Table 12 Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Table 13 Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Table 14 Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Table 15 Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Table 16 Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Table 17 Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Table 18 Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Table 19 Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Table 20 Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Table 21 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Table 22 Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Table 23 Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Table 24 Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Table 25 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Table 26 Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Table 27 Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Table 28 Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Table 29  Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Table 30 United States Association Current Recommendations for SMA
Table 31 European Association Current Recommendations for SMA
Table 32 Japanese Association Current Recommendations for SMA
Table 33 List of Marketed Drugs for SMA
Table 34 Market Size of SMA in 7MM (USD Million) (2017-2027)
Table 35 7MM Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 36 7MM Drug-Specific Patient Share of SMA, (2017-2027)
Table 37 United States Market Size of SMA in USD Million, (2017-2027)
Table 38 United States Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 39 United States Drug-Specific Patient Share of SMA, (2017-2027)
Table 40 EU5 Market Size of SMA in USD Million, (2017-2027)
Table 41 EU5 Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 42 EU5 Drug-Specific Patient Share of SMA, (2017-2027)
Table 43 Germany Market Size of SMA in USD Million, (2017-2027)
Table 44 Germany Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 45 Germany Drug-Specific Patient Share of SMA, (2017-2027)
Table 46 France Market Size of SMA in USD Million, (2017-2027)
Table 47 France Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 48 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 49 UK Market Size of SMA in USD Million, (2017-2027)
Table 50 UK Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 51 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 52 Spain Market Size of SMA in USD Million, (2017-2027)
Table 53 Spain Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 54 Spain Drug-Specific Patient Share of SMA, (2017-2027)
Table 55 Italy Market Size of SMA in USD Million, (2017-2027)
Table 56 Italy Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 57 Italy Drug-Specific Patient Share of SMA, (2017-2027)
Table 58 Japan Market Size of SMA in USD Million, (2017-2027)
Table 59 Japan Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 60 Drug-Specific Patient Share of SMA, (2017-2027)

 

Figure 1: Inheritance of SMA in an autosomal recessive pattern
Figure 2: Classification of SMA
Figure 3: Schematic representation of a portion of chromosome 5 that contains two SMN genes
Figure 4: Targets for therapy in SMA
Figure 5: Diagnosis tests in SMA
Figure 6: Diagnostic Evaluation of SMA
Figure 7: Total SMA Cases in 7MM -2017
Figure 8: Total SMA Cases in 7MM - 2027
Figure 9: SMA Incidence and Prevalence Rates
Figure 10: Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Figure 11: Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Figure 12: Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Figure 13: Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Figure 14: Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Figure 15: Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Figure 16: Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Figure 17: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Figure 18: Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Figure 19: Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Figure 20: Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Figure 21: Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Figure 22: Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Figure 23: Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Figure 24: Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Figure 25: Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Figure 26: Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Figure 27: Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Figure 28: Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Figure 29: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Figure 30: Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Figure 31: Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Figure 32: Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Figure 33: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Figure 34: Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Figure 35: Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Figure 36: Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Figure 37: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Figure 38: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 39: 7MM Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 40: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 41: United States Market Size of SMA in USD Million, (2017-2027)
Figure 42: US Estimated revenue of Marketed and Pipeline Drugs in USD Million (2017-2027)
Figure 43: US Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 44: SMA market in EU5 countries in USD Million, (2017-2027)
Figure 45: EU5 Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 46: EU5 Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 47: Germany Market Size of SMA in USD Million, (2017-2027)
Figure 48: Germany Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 49: Germany Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 50: France Market Size of SMA in USD Million, (2017-2027)
Figure 51: France Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 52: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 53: UK Market Size of SMA in USD Million, (2017-2027)
Figure 54: UK Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 55: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 56: Spain Market Size of SMA in USD Million, (2017-2027)
Figure 57: Spain Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 58: Spain Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 59: Italy Market Size of SMA in USD Million, (2017-2027)
Figure 60: Italy Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 61: Italy Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 62: Japan Market Size of SMA in USD Million (2017-2027)
Figure 63: Japan Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 64: Japan Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)

 

Table 1 Types of SMA linked to Chromosome-5
Table 2 Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Table 3 Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Table 4 Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Table 5 Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Table 6 Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Table 7 Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Table 8 Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Table 9 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Table 10 Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Table 11 Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Table 12 Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Table 13 Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Table 14 Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Table 15 Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Table 16 Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Table 17 Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Table 18 Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Table 19 Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Table 20 Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Table 21 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Table 22 Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Table 23 Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Table 24 Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Table 25 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Table 26 Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Table 27 Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Table 28 Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Table 29  Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Table 30 United States Association Current Recommendations for SMA
Table 31 European Association Current Recommendations for SMA
Table 32 Japanese Association Current Recommendations for SMA
Table 33 List of Marketed Drugs for SMA
Table 34 Market Size of SMA in 7MM (USD Million) (2017-2027)
Table 35 7MM Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 36 7MM Drug-Specific Patient Share of SMA, (2017-2027)
Table 37 United States Market Size of SMA in USD Million, (2017-2027)
Table 38 United States Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 39 United States Drug-Specific Patient Share of SMA, (2017-2027)
Table 40 EU5 Market Size of SMA in USD Million, (2017-2027)
Table 41 EU5 Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 42 EU5 Drug-Specific Patient Share of SMA, (2017-2027)
Table 43 Germany Market Size of SMA in USD Million, (2017-2027)
Table 44 Germany Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 45 Germany Drug-Specific Patient Share of SMA, (2017-2027)
Table 46 France Market Size of SMA in USD Million, (2017-2027)
Table 47 France Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 48 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 49 UK Market Size of SMA in USD Million, (2017-2027)
Table 50 UK Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 51 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 52 Spain Market Size of SMA in USD Million, (2017-2027)
Table 53 Spain Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 54 Spain Drug-Specific Patient Share of SMA, (2017-2027)
Table 55 Italy Market Size of SMA in USD Million, (2017-2027)
Table 56 Italy Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 57 Italy Drug-Specific Patient Share of SMA, (2017-2027)
Table 58 Japan Market Size of SMA in USD Million, (2017-2027)
Table 59 Japan Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 60 Drug-Specific Patient Share of SMA, (2017-2027)

 

Figure 1: Inheritance of SMA in an autosomal recessive pattern
Figure 2: Classification of SMA
Figure 3: Schematic representation of a portion of chromosome 5 that contains two SMN genes
Figure 4: Targets for therapy in SMA
Figure 5: Diagnosis tests in SMA
Figure 6: Diagnostic Evaluation of SMA
Figure 7: Total SMA Cases in 7MM -2017
Figure 8: Total SMA Cases in 7MM - 2027
Figure 9: SMA Incidence and Prevalence Rates
Figure 10: Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Figure 11: Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Figure 12: Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Figure 13: Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Figure 14: Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Figure 15: Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Figure 16: Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Figure 17: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Figure 18: Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Figure 19: Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Figure 20: Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Figure 21: Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Figure 22: Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Figure 23: Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Figure 24: Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Figure 25: Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Figure 26: Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Figure 27: Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Figure 28: Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Figure 29: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Figure 30: Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Figure 31: Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Figure 32: Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Figure 33: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Figure 34: Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Figure 35: Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Figure 36: Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Figure 37: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Figure 38: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 39: 7MM Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 40: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 41: United States Market Size of SMA in USD Million, (2017-2027)
Figure 42: US Estimated revenue of Marketed and Pipeline Drugs in USD Million (2017-2027)
Figure 43: US Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 44: SMA market in EU5 countries in USD Million, (2017-2027)
Figure 45: EU5 Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 46: EU5 Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 47: Germany Market Size of SMA in USD Million, (2017-2027)
Figure 48: Germany Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 49: Germany Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 50: France Market Size of SMA in USD Million, (2017-2027)
Figure 51: France Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 52: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 53: UK Market Size of SMA in USD Million, (2017-2027)
Figure 54: UK Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 55: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 56: Spain Market Size of SMA in USD Million, (2017-2027)
Figure 57: Spain Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 58: Spain Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 59: Italy Market Size of SMA in USD Million, (2017-2027)
Figure 60: Italy Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 61: Italy Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 62: Japan Market Size of SMA in USD Million (2017-2027)
Figure 63: Japan Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 64: Japan Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)

 

Table 1 Types of SMA linked to Chromosome-5
Table 2 Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Table 3 Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Table 4 Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Table 5 Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Table 6 Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Table 7 Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Table 8 Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Table 9 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Table 10 Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Table 11 Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Table 12 Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Table 13 Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Table 14 Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Table 15 Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Table 16 Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Table 17 Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Table 18 Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Table 19 Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Table 20 Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Table 21 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Table 22 Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Table 23 Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Table 24 Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Table 25 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Table 26 Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Table 27 Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Table 28 Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Table 29  Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Table 30 United States Association Current Recommendations for SMA
Table 31 European Association Current Recommendations for SMA
Table 32 Japanese Association Current Recommendations for SMA
Table 33 List of Marketed Drugs for SMA
Table 34 Market Size of SMA in 7MM (USD Million) (2017-2027)
Table 35 7MM Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 36 7MM Drug-Specific Patient Share of SMA, (2017-2027)
Table 37 United States Market Size of SMA in USD Million, (2017-2027)
Table 38 United States Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 39 United States Drug-Specific Patient Share of SMA, (2017-2027)
Table 40 EU5 Market Size of SMA in USD Million, (2017-2027)
Table 41 EU5 Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 42 EU5 Drug-Specific Patient Share of SMA, (2017-2027)
Table 43 Germany Market Size of SMA in USD Million, (2017-2027)
Table 44 Germany Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 45 Germany Drug-Specific Patient Share of SMA, (2017-2027)
Table 46 France Market Size of SMA in USD Million, (2017-2027)
Table 47 France Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 48 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 49 UK Market Size of SMA in USD Million, (2017-2027)
Table 50 UK Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 51 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 52 Spain Market Size of SMA in USD Million, (2017-2027)
Table 53 Spain Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 54 Spain Drug-Specific Patient Share of SMA, (2017-2027)
Table 55 Italy Market Size of SMA in USD Million, (2017-2027)
Table 56 Italy Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 57 Italy Drug-Specific Patient Share of SMA, (2017-2027)
Table 58 Japan Market Size of SMA in USD Million, (2017-2027)
Table 59 Japan Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 60 Drug-Specific Patient Share of SMA, (2017-2027)

 

Figure 1: Inheritance of SMA in an autosomal recessive pattern
Figure 2: Classification of SMA
Figure 3: Schematic representation of a portion of chromosome 5 that contains two SMN genes
Figure 4: Targets for therapy in SMA
Figure 5: Diagnosis tests in SMA
Figure 6: Diagnostic Evaluation of SMA
Figure 7: Total SMA Cases in 7MM -2017
Figure 8: Total SMA Cases in 7MM - 2027
Figure 9: SMA Incidence and Prevalence Rates
Figure 10: Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Figure 11: Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Figure 12: Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Figure 13: Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Figure 14: Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Figure 15: Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Figure 16: Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Figure 17: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Figure 18: Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Figure 19: Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Figure 20: Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Figure 21: Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Figure 22: Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Figure 23: Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Figure 24: Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Figure 25: Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Figure 26: Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Figure 27: Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Figure 28: Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Figure 29: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Figure 30: Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Figure 31: Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Figure 32: Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Figure 33: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Figure 34: Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Figure 35: Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Figure 36: Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Figure 37: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Figure 38: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 39: 7MM Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 40: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 41: United States Market Size of SMA in USD Million, (2017-2027)
Figure 42: US Estimated revenue of Marketed and Pipeline Drugs in USD Million (2017-2027)
Figure 43: US Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 44: SMA market in EU5 countries in USD Million, (2017-2027)
Figure 45: EU5 Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 46: EU5 Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 47: Germany Market Size of SMA in USD Million, (2017-2027)
Figure 48: Germany Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 49: Germany Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 50: France Market Size of SMA in USD Million, (2017-2027)
Figure 51: France Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 52: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 53: UK Market Size of SMA in USD Million, (2017-2027)
Figure 54: UK Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 55: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 56: Spain Market Size of SMA in USD Million, (2017-2027)
Figure 57: Spain Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 58: Spain Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 59: Italy Market Size of SMA in USD Million, (2017-2027)
Figure 60: Italy Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 61: Italy Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 62: Japan Market Size of SMA in USD Million (2017-2027)
Figure 63: Japan Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 64: Japan Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)

 

Table 1 Types of SMA linked to Chromosome-5
Table 2 Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Table 3 Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Table 4 Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Table 5 Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Table 6 Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Table 7 Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Table 8 Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Table 9 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Table 10 Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Table 11 Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Table 12 Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Table 13 Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Table 14 Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Table 15 Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Table 16 Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Table 17 Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Table 18 Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Table 19 Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Table 20 Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Table 21 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Table 22 Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Table 23 Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Table 24 Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Table 25 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Table 26 Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Table 27 Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Table 28 Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Table 29  Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Table 30 United States Association Current Recommendations for SMA
Table 31 European Association Current Recommendations for SMA
Table 32 Japanese Association Current Recommendations for SMA
Table 33 List of Marketed Drugs for SMA
Table 34 Market Size of SMA in 7MM (USD Million) (2017-2027)
Table 35 7MM Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 36 7MM Drug-Specific Patient Share of SMA, (2017-2027)
Table 37 United States Market Size of SMA in USD Million, (2017-2027)
Table 38 United States Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 39 United States Drug-Specific Patient Share of SMA, (2017-2027)
Table 40 EU5 Market Size of SMA in USD Million, (2017-2027)
Table 41 EU5 Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 42 EU5 Drug-Specific Patient Share of SMA, (2017-2027)
Table 43 Germany Market Size of SMA in USD Million, (2017-2027)
Table 44 Germany Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 45 Germany Drug-Specific Patient Share of SMA, (2017-2027)
Table 46 France Market Size of SMA in USD Million, (2017-2027)
Table 47 France Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 48 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 49 UK Market Size of SMA in USD Million, (2017-2027)
Table 50 UK Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 51 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 52 Spain Market Size of SMA in USD Million, (2017-2027)
Table 53 Spain Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 54 Spain Drug-Specific Patient Share of SMA, (2017-2027)
Table 55 Italy Market Size of SMA in USD Million, (2017-2027)
Table 56 Italy Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 57 Italy Drug-Specific Patient Share of SMA, (2017-2027)
Table 58 Japan Market Size of SMA in USD Million, (2017-2027)
Table 59 Japan Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 60 Drug-Specific Patient Share of SMA, (2017-2027)

 

Figure 1: Inheritance of SMA in an autosomal recessive pattern
Figure 2: Classification of SMA
Figure 3: Schematic representation of a portion of chromosome 5 that contains two SMN genes
Figure 4: Targets for therapy in SMA
Figure 5: Diagnosis tests in SMA
Figure 6: Diagnostic Evaluation of SMA
Figure 7: Total SMA Cases in 7MM -2017
Figure 8: Total SMA Cases in 7MM - 2027
Figure 9: SMA Incidence and Prevalence Rates
Figure 10: Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Figure 11: Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Figure 12: Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Figure 13: Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Figure 14: Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Figure 15: Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Figure 16: Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Figure 17: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Figure 18: Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Figure 19: Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Figure 20: Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Figure 21: Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Figure 22: Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Figure 23: Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Figure 24: Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Figure 25: Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Figure 26: Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Figure 27: Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Figure 28: Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Figure 29: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Figure 30: Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Figure 31: Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Figure 32: Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Figure 33: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Figure 34: Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Figure 35: Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Figure 36: Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Figure 37: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Figure 38: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 39: 7MM Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 40: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 41: United States Market Size of SMA in USD Million, (2017-2027)
Figure 42: US Estimated revenue of Marketed and Pipeline Drugs in USD Million (2017-2027)
Figure 43: US Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 44: SMA market in EU5 countries in USD Million, (2017-2027)
Figure 45: EU5 Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 46: EU5 Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 47: Germany Market Size of SMA in USD Million, (2017-2027)
Figure 48: Germany Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 49: Germany Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 50: France Market Size of SMA in USD Million, (2017-2027)
Figure 51: France Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 52: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 53: UK Market Size of SMA in USD Million, (2017-2027)
Figure 54: UK Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 55: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 56: Spain Market Size of SMA in USD Million, (2017-2027)
Figure 57: Spain Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 58: Spain Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 59: Italy Market Size of SMA in USD Million, (2017-2027)
Figure 60: Italy Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 61: Italy Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 62: Japan Market Size of SMA in USD Million (2017-2027)
Figure 63: Japan Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 64: Japan Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)

 

Table 1 Types of SMA linked to Chromosome-5
Table 2 Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Table 3 Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Table 4 Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Table 5 Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Table 6 Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Table 7 Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Table 8 Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Table 9 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Table 10 Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Table 11 Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Table 12 Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Table 13 Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Table 14 Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Table 15 Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Table 16 Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Table 17 Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Table 18 Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Table 19 Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Table 20 Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Table 21 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Table 22 Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Table 23 Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Table 24 Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Table 25 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Table 26 Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Table 27 Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Table 28 Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Table 29  Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Table 30 United States Association Current Recommendations for SMA
Table 31 European Association Current Recommendations for SMA
Table 32 Japanese Association Current Recommendations for SMA
Table 33 List of Marketed Drugs for SMA
Table 34 Market Size of SMA in 7MM (USD Million) (2017-2027)
Table 35 7MM Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 36 7MM Drug-Specific Patient Share of SMA, (2017-2027)
Table 37 United States Market Size of SMA in USD Million, (2017-2027)
Table 38 United States Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 39 United States Drug-Specific Patient Share of SMA, (2017-2027)
Table 40 EU5 Market Size of SMA in USD Million, (2017-2027)
Table 41 EU5 Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 42 EU5 Drug-Specific Patient Share of SMA, (2017-2027)
Table 43 Germany Market Size of SMA in USD Million, (2017-2027)
Table 44 Germany Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 45 Germany Drug-Specific Patient Share of SMA, (2017-2027)
Table 46 France Market Size of SMA in USD Million, (2017-2027)
Table 47 France Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 48 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 49 UK Market Size of SMA in USD Million, (2017-2027)
Table 50 UK Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 51 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 52 Spain Market Size of SMA in USD Million, (2017-2027)
Table 53 Spain Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 54 Spain Drug-Specific Patient Share of SMA, (2017-2027)
Table 55 Italy Market Size of SMA in USD Million, (2017-2027)
Table 56 Italy Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 57 Italy Drug-Specific Patient Share of SMA, (2017-2027)
Table 58 Japan Market Size of SMA in USD Million, (2017-2027)
Table 59 Japan Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 60 Drug-Specific Patient Share of SMA, (2017-2027)

 

Figure 1: Inheritance of SMA in an autosomal recessive pattern
Figure 2: Classification of SMA
Figure 3: Schematic representation of a portion of chromosome 5 that contains two SMN genes
Figure 4: Targets for therapy in SMA
Figure 5: Diagnosis tests in SMA
Figure 6: Diagnostic Evaluation of SMA
Figure 7: Total SMA Cases in 7MM -2017
Figure 8: Total SMA Cases in 7MM - 2027
Figure 9: SMA Incidence and Prevalence Rates
Figure 10: Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Figure 11: Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Figure 12: Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Figure 13: Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Figure 14: Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Figure 15: Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Figure 16: Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Figure 17: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Figure 18: Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Figure 19: Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Figure 20: Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Figure 21: Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Figure 22: Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Figure 23: Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Figure 24: Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Figure 25: Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Figure 26: Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Figure 27: Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Figure 28: Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Figure 29: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Figure 30: Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Figure 31: Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Figure 32: Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Figure 33: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Figure 34: Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Figure 35: Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Figure 36: Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Figure 37: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Figure 38: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 39: 7MM Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 40: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 41: United States Market Size of SMA in USD Million, (2017-2027)
Figure 42: US Estimated revenue of Marketed and Pipeline Drugs in USD Million (2017-2027)
Figure 43: US Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 44: SMA market in EU5 countries in USD Million, (2017-2027)
Figure 45: EU5 Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 46: EU5 Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 47: Germany Market Size of SMA in USD Million, (2017-2027)
Figure 48: Germany Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 49: Germany Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 50: France Market Size of SMA in USD Million, (2017-2027)
Figure 51: France Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 52: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 53: UK Market Size of SMA in USD Million, (2017-2027)
Figure 54: UK Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 55: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 56: Spain Market Size of SMA in USD Million, (2017-2027)
Figure 57: Spain Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 58: Spain Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 59: Italy Market Size of SMA in USD Million, (2017-2027)
Figure 60: Italy Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 61: Italy Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 62: Japan Market Size of SMA in USD Million (2017-2027)
Figure 63: Japan Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 64: Japan Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)

 

Table 1 Types of SMA linked to Chromosome-5
Table 2 Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Table 3 Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Table 4 Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Table 5 Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Table 6 Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Table 7 Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Table 8 Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Table 9 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Table 10 Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Table 11 Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Table 12 Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Table 13 Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Table 14 Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Table 15 Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Table 16 Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Table 17 Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Table 18 Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Table 19 Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Table 20 Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Table 21 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Table 22 Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Table 23 Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Table 24 Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Table 25 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Table 26 Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Table 27 Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Table 28 Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Table 29  Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Table 30 United States Association Current Recommendations for SMA
Table 31 European Association Current Recommendations for SMA
Table 32 Japanese Association Current Recommendations for SMA
Table 33 List of Marketed Drugs for SMA
Table 34 Market Size of SMA in 7MM (USD Million) (2017-2027)
Table 35 7MM Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 36 7MM Drug-Specific Patient Share of SMA, (2017-2027)
Table 37 United States Market Size of SMA in USD Million, (2017-2027)
Table 38 United States Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 39 United States Drug-Specific Patient Share of SMA, (2017-2027)
Table 40 EU5 Market Size of SMA in USD Million, (2017-2027)
Table 41 EU5 Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 42 EU5 Drug-Specific Patient Share of SMA, (2017-2027)
Table 43 Germany Market Size of SMA in USD Million, (2017-2027)
Table 44 Germany Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 45 Germany Drug-Specific Patient Share of SMA, (2017-2027)
Table 46 France Market Size of SMA in USD Million, (2017-2027)
Table 47 France Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 48 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 49 UK Market Size of SMA in USD Million, (2017-2027)
Table 50 UK Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 51 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 52 Spain Market Size of SMA in USD Million, (2017-2027)
Table 53 Spain Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 54 Spain Drug-Specific Patient Share of SMA, (2017-2027)
Table 55 Italy Market Size of SMA in USD Million, (2017-2027)
Table 56 Italy Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 57 Italy Drug-Specific Patient Share of SMA, (2017-2027)
Table 58 Japan Market Size of SMA in USD Million, (2017-2027)
Table 59 Japan Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 60 Drug-Specific Patient Share of SMA, (2017-2027)

 

Figure 1: Inheritance of SMA in an autosomal recessive pattern
Figure 2: Classification of SMA
Figure 3: Schematic representation of a portion of chromosome 5 that contains two SMN genes
Figure 4: Targets for therapy in SMA
Figure 5: Diagnosis tests in SMA
Figure 6: Diagnostic Evaluation of SMA
Figure 7: Total SMA Cases in 7MM -2017
Figure 8: Total SMA Cases in 7MM - 2027
Figure 9: SMA Incidence and Prevalence Rates
Figure 10: Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Figure 11: Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Figure 12: Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Figure 13: Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Figure 14: Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Figure 15: Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Figure 16: Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Figure 17: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Figure 18: Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Figure 19: Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Figure 20: Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Figure 21: Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Figure 22: Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Figure 23: Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Figure 24: Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Figure 25: Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Figure 26: Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Figure 27: Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Figure 28: Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Figure 29: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Figure 30: Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Figure 31: Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Figure 32: Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Figure 33: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Figure 34: Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Figure 35: Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Figure 36: Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Figure 37: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Figure 38: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 39: 7MM Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 40: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 41: United States Market Size of SMA in USD Million, (2017-2027)
Figure 42: US Estimated revenue of Marketed and Pipeline Drugs in USD Million (2017-2027)
Figure 43: US Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 44: SMA market in EU5 countries in USD Million, (2017-2027)
Figure 45: EU5 Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 46: EU5 Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 47: Germany Market Size of SMA in USD Million, (2017-2027)
Figure 48: Germany Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 49: Germany Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 50: France Market Size of SMA in USD Million, (2017-2027)
Figure 51: France Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 52: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 53: UK Market Size of SMA in USD Million, (2017-2027)
Figure 54: UK Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 55: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 56: Spain Market Size of SMA in USD Million, (2017-2027)
Figure 57: Spain Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 58: Spain Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 59: Italy Market Size of SMA in USD Million, (2017-2027)
Figure 60: Italy Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 61: Italy Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 62: Japan Market Size of SMA in USD Million (2017-2027)
Figure 63: Japan Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 64: Japan Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)

 

Table 1 Types of SMA linked to Chromosome-5
Table 2 Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Table 3 Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Table 4 Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Table 5 Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Table 6 Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Table 7 Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Table 8 Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Table 9 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Table 10 Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Table 11 Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Table 12 Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Table 13 Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Table 14 Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Table 15 Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Table 16 Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Table 17 Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Table 18 Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Table 19 Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Table 20 Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Table 21 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Table 22 Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Table 23 Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Table 24 Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Table 25 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Table 26 Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Table 27 Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Table 28 Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Table 29  Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Table 30 United States Association Current Recommendations for SMA
Table 31 European Association Current Recommendations for SMA
Table 32 Japanese Association Current Recommendations for SMA
Table 33 List of Marketed Drugs for SMA
Table 34 Market Size of SMA in 7MM (USD Million) (2017-2027)
Table 35 7MM Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 36 7MM Drug-Specific Patient Share of SMA, (2017-2027)
Table 37 United States Market Size of SMA in USD Million, (2017-2027)
Table 38 United States Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 39 United States Drug-Specific Patient Share of SMA, (2017-2027)
Table 40 EU5 Market Size of SMA in USD Million, (2017-2027)
Table 41 EU5 Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 42 EU5 Drug-Specific Patient Share of SMA, (2017-2027)
Table 43 Germany Market Size of SMA in USD Million, (2017-2027)
Table 44 Germany Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 45 Germany Drug-Specific Patient Share of SMA, (2017-2027)
Table 46 France Market Size of SMA in USD Million, (2017-2027)
Table 47 France Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 48 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 49 UK Market Size of SMA in USD Million, (2017-2027)
Table 50 UK Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 51 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 52 Spain Market Size of SMA in USD Million, (2017-2027)
Table 53 Spain Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 54 Spain Drug-Specific Patient Share of SMA, (2017-2027)
Table 55 Italy Market Size of SMA in USD Million, (2017-2027)
Table 56 Italy Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 57 Italy Drug-Specific Patient Share of SMA, (2017-2027)
Table 58 Japan Market Size of SMA in USD Million, (2017-2027)
Table 59 Japan Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 60 Drug-Specific Patient Share of SMA, (2017-2027)

 

Figure 1: Inheritance of SMA in an autosomal recessive pattern
Figure 2: Classification of SMA
Figure 3: Schematic representation of a portion of chromosome 5 that contains two SMN genes
Figure 4: Targets for therapy in SMA
Figure 5: Diagnosis tests in SMA
Figure 6: Diagnostic Evaluation of SMA
Figure 7: Total SMA Cases in 7MM -2017
Figure 8: Total SMA Cases in 7MM - 2027
Figure 9: SMA Incidence and Prevalence Rates
Figure 10: Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Figure 11: Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Figure 12: Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Figure 13: Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Figure 14: Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Figure 15: Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Figure 16: Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Figure 17: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Figure 18: Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Figure 19: Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Figure 20: Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Figure 21: Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Figure 22: Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Figure 23: Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Figure 24: Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Figure 25: Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Figure 26: Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Figure 27: Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Figure 28: Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Figure 29: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Figure 30: Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Figure 31: Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Figure 32: Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Figure 33: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Figure 34: Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Figure 35: Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Figure 36: Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Figure 37: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Figure 38: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 39: 7MM Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 40: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 41: United States Market Size of SMA in USD Million, (2017-2027)
Figure 42: US Estimated revenue of Marketed and Pipeline Drugs in USD Million (2017-2027)
Figure 43: US Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 44: SMA market in EU5 countries in USD Million, (2017-2027)
Figure 45: EU5 Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 46: EU5 Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 47: Germany Market Size of SMA in USD Million, (2017-2027)
Figure 48: Germany Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 49: Germany Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 50: France Market Size of SMA in USD Million, (2017-2027)
Figure 51: France Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 52: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 53: UK Market Size of SMA in USD Million, (2017-2027)
Figure 54: UK Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 55: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 56: Spain Market Size of SMA in USD Million, (2017-2027)
Figure 57: Spain Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 58: Spain Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 59: Italy Market Size of SMA in USD Million, (2017-2027)
Figure 60: Italy Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 61: Italy Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 62: Japan Market Size of SMA in USD Million (2017-2027)
Figure 63: Japan Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 64: Japan Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)

 

Table 1 Types of SMA linked to Chromosome-5
Table 2 Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Table 3 Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Table 4 Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Table 5 Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Table 6 Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Table 7 Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Table 8 Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Table 9 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Table 10 Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Table 11 Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Table 12 Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Table 13 Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Table 14 Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Table 15 Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Table 16 Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Table 17 Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Table 18 Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Table 19 Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Table 20 Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Table 21 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Table 22 Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Table 23 Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Table 24 Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Table 25 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Table 26 Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Table 27 Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Table 28 Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Table 29  Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Table 30 United States Association Current Recommendations for SMA
Table 31 European Association Current Recommendations for SMA
Table 32 Japanese Association Current Recommendations for SMA
Table 33 List of Marketed Drugs for SMA
Table 34 Market Size of SMA in 7MM (USD Million) (2017-2027)
Table 35 7MM Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 36 7MM Drug-Specific Patient Share of SMA, (2017-2027)
Table 37 United States Market Size of SMA in USD Million, (2017-2027)
Table 38 United States Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 39 United States Drug-Specific Patient Share of SMA, (2017-2027)
Table 40 EU5 Market Size of SMA in USD Million, (2017-2027)
Table 41 EU5 Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 42 EU5 Drug-Specific Patient Share of SMA, (2017-2027)
Table 43 Germany Market Size of SMA in USD Million, (2017-2027)
Table 44 Germany Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 45 Germany Drug-Specific Patient Share of SMA, (2017-2027)
Table 46 France Market Size of SMA in USD Million, (2017-2027)
Table 47 France Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 48 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 49 UK Market Size of SMA in USD Million, (2017-2027)
Table 50 UK Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 51 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 52 Spain Market Size of SMA in USD Million, (2017-2027)
Table 53 Spain Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 54 Spain Drug-Specific Patient Share of SMA, (2017-2027)
Table 55 Italy Market Size of SMA in USD Million, (2017-2027)
Table 56 Italy Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 57 Italy Drug-Specific Patient Share of SMA, (2017-2027)
Table 58 Japan Market Size of SMA in USD Million, (2017-2027)
Table 59 Japan Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 60 Drug-Specific Patient Share of SMA, (2017-2027)

 

Figure 1: Inheritance of SMA in an autosomal recessive pattern
Figure 2: Classification of SMA
Figure 3: Schematic representation of a portion of chromosome 5 that contains two SMN genes
Figure 4: Targets for therapy in SMA
Figure 5: Diagnosis tests in SMA
Figure 6: Diagnostic Evaluation of SMA
Figure 7: Total SMA Cases in 7MM -2017
Figure 8: Total SMA Cases in 7MM - 2027
Figure 9: SMA Incidence and Prevalence Rates
Figure 10: Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Figure 11: Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Figure 12: Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Figure 13: Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Figure 14: Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Figure 15: Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Figure 16: Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Figure 17: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Figure 18: Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Figure 19: Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Figure 20: Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Figure 21: Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Figure 22: Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Figure 23: Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Figure 24: Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Figure 25: Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Figure 26: Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Figure 27: Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Figure 28: Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Figure 29: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Figure 30: Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Figure 31: Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Figure 32: Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Figure 33: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Figure 34: Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Figure 35: Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Figure 36: Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Figure 37: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Figure 38: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 39: 7MM Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 40: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 41: United States Market Size of SMA in USD Million, (2017-2027)
Figure 42: US Estimated revenue of Marketed and Pipeline Drugs in USD Million (2017-2027)
Figure 43: US Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 44: SMA market in EU5 countries in USD Million, (2017-2027)
Figure 45: EU5 Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 46: EU5 Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 47: Germany Market Size of SMA in USD Million, (2017-2027)
Figure 48: Germany Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 49: Germany Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 50: France Market Size of SMA in USD Million, (2017-2027)
Figure 51: France Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 52: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 53: UK Market Size of SMA in USD Million, (2017-2027)
Figure 54: UK Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 55: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 56: Spain Market Size of SMA in USD Million, (2017-2027)
Figure 57: Spain Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 58: Spain Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 59: Italy Market Size of SMA in USD Million, (2017-2027)
Figure 60: Italy Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 61: Italy Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 62: Japan Market Size of SMA in USD Million (2017-2027)
Figure 63: Japan Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 64: Japan Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)

 

Table 1 Types of SMA linked to Chromosome-5
Table 2 Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Table 3 Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Table 4 Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Table 5 Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Table 6 Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Table 7 Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Table 8 Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Table 9 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Table 10 Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Table 11 Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Table 12 Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Table 13 Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Table 14 Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Table 15 Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Table 16 Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Table 17 Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Table 18 Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Table 19 Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Table 20 Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Table 21 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Table 22 Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Table 23 Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Table 24 Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Table 25 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Table 26 Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Table 27 Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Table 28 Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Table 29  Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Table 30 United States Association Current Recommendations for SMA
Table 31 European Association Current Recommendations for SMA
Table 32 Japanese Association Current Recommendations for SMA
Table 33 List of Marketed Drugs for SMA
Table 34 Market Size of SMA in 7MM (USD Million) (2017-2027)
Table 35 7MM Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 36 7MM Drug-Specific Patient Share of SMA, (2017-2027)
Table 37 United States Market Size of SMA in USD Million, (2017-2027)
Table 38 United States Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 39 United States Drug-Specific Patient Share of SMA, (2017-2027)
Table 40 EU5 Market Size of SMA in USD Million, (2017-2027)
Table 41 EU5 Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 42 EU5 Drug-Specific Patient Share of SMA, (2017-2027)
Table 43 Germany Market Size of SMA in USD Million, (2017-2027)
Table 44 Germany Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 45 Germany Drug-Specific Patient Share of SMA, (2017-2027)
Table 46 France Market Size of SMA in USD Million, (2017-2027)
Table 47 France Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 48 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 49 UK Market Size of SMA in USD Million, (2017-2027)
Table 50 UK Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 51 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 52 Spain Market Size of SMA in USD Million, (2017-2027)
Table 53 Spain Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 54 Spain Drug-Specific Patient Share of SMA, (2017-2027)
Table 55 Italy Market Size of SMA in USD Million, (2017-2027)
Table 56 Italy Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 57 Italy Drug-Specific Patient Share of SMA, (2017-2027)
Table 58 Japan Market Size of SMA in USD Million, (2017-2027)
Table 59 Japan Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 60 Drug-Specific Patient Share of SMA, (2017-2027)

 

Figure 1: Inheritance of SMA in an autosomal recessive pattern
Figure 2: Classification of SMA
Figure 3: Schematic representation of a portion of chromosome 5 that contains two SMN genes
Figure 4: Targets for therapy in SMA
Figure 5: Diagnosis tests in SMA
Figure 6: Diagnostic Evaluation of SMA
Figure 7: Total SMA Cases in 7MM -2017
Figure 8: Total SMA Cases in 7MM - 2027
Figure 9: SMA Incidence and Prevalence Rates
Figure 10: Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Figure 11: Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Figure 12: Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Figure 13: Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Figure 14: Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Figure 15: Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Figure 16: Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Figure 17: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Figure 18: Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Figure 19: Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Figure 20: Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Figure 21: Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Figure 22: Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Figure 23: Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Figure 24: Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Figure 25: Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Figure 26: Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Figure 27: Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Figure 28: Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Figure 29: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Figure 30: Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Figure 31: Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Figure 32: Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Figure 33: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Figure 34: Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Figure 35: Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Figure 36: Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Figure 37: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Figure 38: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 39: 7MM Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 40: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 41: United States Market Size of SMA in USD Million, (2017-2027)
Figure 42: US Estimated revenue of Marketed and Pipeline Drugs in USD Million (2017-2027)
Figure 43: US Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 44: SMA market in EU5 countries in USD Million, (2017-2027)
Figure 45: EU5 Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 46: EU5 Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 47: Germany Market Size of SMA in USD Million, (2017-2027)
Figure 48: Germany Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 49: Germany Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 50: France Market Size of SMA in USD Million, (2017-2027)
Figure 51: France Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 52: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 53: UK Market Size of SMA in USD Million, (2017-2027)
Figure 54: UK Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 55: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 56: Spain Market Size of SMA in USD Million, (2017-2027)
Figure 57: Spain Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 58: Spain Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 59: Italy Market Size of SMA in USD Million, (2017-2027)
Figure 60: Italy Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 61: Italy Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 62: Japan Market Size of SMA in USD Million (2017-2027)
Figure 63: Japan Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 64: Japan Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)

 

Table 1 Types of SMA linked to Chromosome-5
Table 2 Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Table 3 Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Table 4 Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Table 5 Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Table 6 Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Table 7 Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Table 8 Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Table 9 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Table 10 Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Table 11 Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Table 12 Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Table 13 Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Table 14 Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Table 15 Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Table 16 Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Table 17 Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Table 18 Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Table 19 Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Table 20 Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Table 21 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Table 22 Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Table 23 Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Table 24 Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Table 25 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Table 26 Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Table 27 Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Table 28 Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Table 29  Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Table 30 United States Association Current Recommendations for SMA
Table 31 European Association Current Recommendations for SMA
Table 32 Japanese Association Current Recommendations for SMA
Table 33 List of Marketed Drugs for SMA
Table 34 Market Size of SMA in 7MM (USD Million) (2017-2027)
Table 35 7MM Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 36 7MM Drug-Specific Patient Share of SMA, (2017-2027)
Table 37 United States Market Size of SMA in USD Million, (2017-2027)
Table 38 United States Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 39 United States Drug-Specific Patient Share of SMA, (2017-2027)
Table 40 EU5 Market Size of SMA in USD Million, (2017-2027)
Table 41 EU5 Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 42 EU5 Drug-Specific Patient Share of SMA, (2017-2027)
Table 43 Germany Market Size of SMA in USD Million, (2017-2027)
Table 44 Germany Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 45 Germany Drug-Specific Patient Share of SMA, (2017-2027)
Table 46 France Market Size of SMA in USD Million, (2017-2027)
Table 47 France Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 48 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 49 UK Market Size of SMA in USD Million, (2017-2027)
Table 50 UK Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 51 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 52 Spain Market Size of SMA in USD Million, (2017-2027)
Table 53 Spain Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 54 Spain Drug-Specific Patient Share of SMA, (2017-2027)
Table 55 Italy Market Size of SMA in USD Million, (2017-2027)
Table 56 Italy Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 57 Italy Drug-Specific Patient Share of SMA, (2017-2027)
Table 58 Japan Market Size of SMA in USD Million, (2017-2027)
Table 59 Japan Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 60 Drug-Specific Patient Share of SMA, (2017-2027)

 

Figure 1: Inheritance of SMA in an autosomal recessive pattern
Figure 2: Classification of SMA
Figure 3: Schematic representation of a portion of chromosome 5 that contains two SMN genes
Figure 4: Targets for therapy in SMA
Figure 5: Diagnosis tests in SMA
Figure 6: Diagnostic Evaluation of SMA
Figure 7: Total SMA Cases in 7MM -2017
Figure 8: Total SMA Cases in 7MM - 2027
Figure 9: SMA Incidence and Prevalence Rates
Figure 10: Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Figure 11: Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Figure 12: Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Figure 13: Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Figure 14: Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Figure 15: Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Figure 16: Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Figure 17: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Figure 18: Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Figure 19: Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Figure 20: Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Figure 21: Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Figure 22: Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Figure 23: Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Figure 24: Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Figure 25: Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Figure 26: Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Figure 27: Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Figure 28: Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Figure 29: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Figure 30: Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Figure 31: Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Figure 32: Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Figure 33: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Figure 34: Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Figure 35: Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Figure 36: Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Figure 37: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Figure 38: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 39: 7MM Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 40: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 41: United States Market Size of SMA in USD Million, (2017-2027)
Figure 42: US Estimated revenue of Marketed and Pipeline Drugs in USD Million (2017-2027)
Figure 43: US Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 44: SMA market in EU5 countries in USD Million, (2017-2027)
Figure 45: EU5 Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 46: EU5 Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 47: Germany Market Size of SMA in USD Million, (2017-2027)
Figure 48: Germany Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 49: Germany Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 50: France Market Size of SMA in USD Million, (2017-2027)
Figure 51: France Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 52: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 53: UK Market Size of SMA in USD Million, (2017-2027)
Figure 54: UK Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 55: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 56: Spain Market Size of SMA in USD Million, (2017-2027)
Figure 57: Spain Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 58: Spain Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 59: Italy Market Size of SMA in USD Million, (2017-2027)
Figure 60: Italy Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 61: Italy Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 62: Japan Market Size of SMA in USD Million (2017-2027)
Figure 63: Japan Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 64: Japan Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)

 

Table 1 Types of SMA linked to Chromosome-5
Table 2 Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Table 3 Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Table 4 Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Table 5 Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Table 6 Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Table 7 Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Table 8 Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Table 9 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Table 10 Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Table 11 Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Table 12 Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Table 13 Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Table 14 Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Table 15 Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Table 16 Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Table 17 Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Table 18 Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Table 19 Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Table 20 Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Table 21 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Table 22 Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Table 23 Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Table 24 Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Table 25 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Table 26 Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Table 27 Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Table 28 Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Table 29  Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Table 30 United States Association Current Recommendations for SMA
Table 31 European Association Current Recommendations for SMA
Table 32 Japanese Association Current Recommendations for SMA
Table 33 List of Marketed Drugs for SMA
Table 34 Market Size of SMA in 7MM (USD Million) (2017-2027)
Table 35 7MM Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 36 7MM Drug-Specific Patient Share of SMA, (2017-2027)
Table 37 United States Market Size of SMA in USD Million, (2017-2027)
Table 38 United States Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 39 United States Drug-Specific Patient Share of SMA, (2017-2027)
Table 40 EU5 Market Size of SMA in USD Million, (2017-2027)
Table 41 EU5 Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 42 EU5 Drug-Specific Patient Share of SMA, (2017-2027)
Table 43 Germany Market Size of SMA in USD Million, (2017-2027)
Table 44 Germany Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 45 Germany Drug-Specific Patient Share of SMA, (2017-2027)
Table 46 France Market Size of SMA in USD Million, (2017-2027)
Table 47 France Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 48 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 49 UK Market Size of SMA in USD Million, (2017-2027)
Table 50 UK Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 51 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 52 Spain Market Size of SMA in USD Million, (2017-2027)
Table 53 Spain Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 54 Spain Drug-Specific Patient Share of SMA, (2017-2027)
Table 55 Italy Market Size of SMA in USD Million, (2017-2027)
Table 56 Italy Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 57 Italy Drug-Specific Patient Share of SMA, (2017-2027)
Table 58 Japan Market Size of SMA in USD Million, (2017-2027)
Table 59 Japan Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 60 Drug-Specific Patient Share of SMA, (2017-2027)

 

Figure 1: Inheritance of SMA in an autosomal recessive pattern
Figure 2: Classification of SMA
Figure 3: Schematic representation of a portion of chromosome 5 that contains two SMN genes
Figure 4: Targets for therapy in SMA
Figure 5: Diagnosis tests in SMA
Figure 6: Diagnostic Evaluation of SMA
Figure 7: Total SMA Cases in 7MM -2017
Figure 8: Total SMA Cases in 7MM - 2027
Figure 9: SMA Incidence and Prevalence Rates
Figure 10: Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Figure 11: Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Figure 12: Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Figure 13: Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Figure 14: Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Figure 15: Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Figure 16: Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Figure 17: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Figure 18: Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Figure 19: Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Figure 20: Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Figure 21: Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Figure 22: Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Figure 23: Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Figure 24: Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Figure 25: Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Figure 26: Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Figure 27: Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Figure 28: Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Figure 29: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Figure 30: Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Figure 31: Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Figure 32: Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Figure 33: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Figure 34: Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Figure 35: Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Figure 36: Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Figure 37: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Figure 38: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 39: 7MM Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 40: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 41: United States Market Size of SMA in USD Million, (2017-2027)
Figure 42: US Estimated revenue of Marketed and Pipeline Drugs in USD Million (2017-2027)
Figure 43: US Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 44: SMA market in EU5 countries in USD Million, (2017-2027)
Figure 45: EU5 Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 46: EU5 Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 47: Germany Market Size of SMA in USD Million, (2017-2027)
Figure 48: Germany Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 49: Germany Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 50: France Market Size of SMA in USD Million, (2017-2027)
Figure 51: France Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 52: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 53: UK Market Size of SMA in USD Million, (2017-2027)
Figure 54: UK Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 55: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 56: Spain Market Size of SMA in USD Million, (2017-2027)
Figure 57: Spain Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 58: Spain Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 59: Italy Market Size of SMA in USD Million, (2017-2027)
Figure 60: Italy Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 61: Italy Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 62: Japan Market Size of SMA in USD Million (2017-2027)
Figure 63: Japan Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 64: Japan Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)

 

Table 1 Types of SMA linked to Chromosome-5
Table 2 Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Table 3 Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Table 4 Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Table 5 Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Table 6 Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Table 7 Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Table 8 Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Table 9 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Table 10 Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Table 11 Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Table 12 Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Table 13 Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Table 14 Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Table 15 Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Table 16 Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Table 17 Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Table 18 Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Table 19 Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Table 20 Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Table 21 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Table 22 Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Table 23 Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Table 24 Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Table 25 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Table 26 Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Table 27 Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Table 28 Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Table 29  Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Table 30 United States Association Current Recommendations for SMA
Table 31 European Association Current Recommendations for SMA
Table 32 Japanese Association Current Recommendations for SMA
Table 33 List of Marketed Drugs for SMA
Table 34 Market Size of SMA in 7MM (USD Million) (2017-2027)
Table 35 7MM Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 36 7MM Drug-Specific Patient Share of SMA, (2017-2027)
Table 37 United States Market Size of SMA in USD Million, (2017-2027)
Table 38 United States Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 39 United States Drug-Specific Patient Share of SMA, (2017-2027)
Table 40 EU5 Market Size of SMA in USD Million, (2017-2027)
Table 41 EU5 Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 42 EU5 Drug-Specific Patient Share of SMA, (2017-2027)
Table 43 Germany Market Size of SMA in USD Million, (2017-2027)
Table 44 Germany Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 45 Germany Drug-Specific Patient Share of SMA, (2017-2027)
Table 46 France Market Size of SMA in USD Million, (2017-2027)
Table 47 France Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 48 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 49 UK Market Size of SMA in USD Million, (2017-2027)
Table 50 UK Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 51 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 52 Spain Market Size of SMA in USD Million, (2017-2027)
Table 53 Spain Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 54 Spain Drug-Specific Patient Share of SMA, (2017-2027)
Table 55 Italy Market Size of SMA in USD Million, (2017-2027)
Table 56 Italy Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 57 Italy Drug-Specific Patient Share of SMA, (2017-2027)
Table 58 Japan Market Size of SMA in USD Million, (2017-2027)
Table 59 Japan Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 60 Drug-Specific Patient Share of SMA, (2017-2027)

 

Figure 1: Inheritance of SMA in an autosomal recessive pattern
Figure 2: Classification of SMA
Figure 3: Schematic representation of a portion of chromosome 5 that contains two SMN genes
Figure 4: Targets for therapy in SMA
Figure 5: Diagnosis tests in SMA
Figure 6: Diagnostic Evaluation of SMA
Figure 7: Total SMA Cases in 7MM -2017
Figure 8: Total SMA Cases in 7MM - 2027
Figure 9: SMA Incidence and Prevalence Rates
Figure 10: Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Figure 11: Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Figure 12: Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Figure 13: Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Figure 14: Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Figure 15: Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Figure 16: Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Figure 17: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Figure 18: Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Figure 19: Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Figure 20: Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Figure 21: Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Figure 22: Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Figure 23: Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Figure 24: Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Figure 25: Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Figure 26: Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Figure 27: Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Figure 28: Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Figure 29: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Figure 30: Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Figure 31: Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Figure 32: Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Figure 33: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Figure 34: Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Figure 35: Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Figure 36: Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Figure 37: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Figure 38: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 39: 7MM Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 40: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 41: United States Market Size of SMA in USD Million, (2017-2027)
Figure 42: US Estimated revenue of Marketed and Pipeline Drugs in USD Million (2017-2027)
Figure 43: US Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 44: SMA market in EU5 countries in USD Million, (2017-2027)
Figure 45: EU5 Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 46: EU5 Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 47: Germany Market Size of SMA in USD Million, (2017-2027)
Figure 48: Germany Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 49: Germany Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 50: France Market Size of SMA in USD Million, (2017-2027)
Figure 51: France Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 52: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 53: UK Market Size of SMA in USD Million, (2017-2027)
Figure 54: UK Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 55: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 56: Spain Market Size of SMA in USD Million, (2017-2027)
Figure 57: Spain Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 58: Spain Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 59: Italy Market Size of SMA in USD Million, (2017-2027)
Figure 60: Italy Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 61: Italy Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 62: Japan Market Size of SMA in USD Million (2017-2027)
Figure 63: Japan Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 64: Japan Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)

 

Table 1 Types of SMA linked to Chromosome-5
Table 2 Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Table 3 Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Table 4 Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Table 5 Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Table 6 Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Table 7 Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Table 8 Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Table 9 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Table 10 Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Table 11 Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Table 12 Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Table 13 Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Table 14 Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Table 15 Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Table 16 Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Table 17 Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Table 18 Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Table 19 Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Table 20 Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Table 21 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Table 22 Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Table 23 Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Table 24 Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Table 25 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Table 26 Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Table 27 Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Table 28 Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Table 29  Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Table 30 United States Association Current Recommendations for SMA
Table 31 European Association Current Recommendations for SMA
Table 32 Japanese Association Current Recommendations for SMA
Table 33 List of Marketed Drugs for SMA
Table 34 Market Size of SMA in 7MM (USD Million) (2017-2027)
Table 35 7MM Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 36 7MM Drug-Specific Patient Share of SMA, (2017-2027)
Table 37 United States Market Size of SMA in USD Million, (2017-2027)
Table 38 United States Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 39 United States Drug-Specific Patient Share of SMA, (2017-2027)
Table 40 EU5 Market Size of SMA in USD Million, (2017-2027)
Table 41 EU5 Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 42 EU5 Drug-Specific Patient Share of SMA, (2017-2027)
Table 43 Germany Market Size of SMA in USD Million, (2017-2027)
Table 44 Germany Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 45 Germany Drug-Specific Patient Share of SMA, (2017-2027)
Table 46 France Market Size of SMA in USD Million, (2017-2027)
Table 47 France Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 48 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 49 UK Market Size of SMA in USD Million, (2017-2027)
Table 50 UK Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 51 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 52 Spain Market Size of SMA in USD Million, (2017-2027)
Table 53 Spain Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 54 Spain Drug-Specific Patient Share of SMA, (2017-2027)
Table 55 Italy Market Size of SMA in USD Million, (2017-2027)
Table 56 Italy Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 57 Italy Drug-Specific Patient Share of SMA, (2017-2027)
Table 58 Japan Market Size of SMA in USD Million, (2017-2027)
Table 59 Japan Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 60 Drug-Specific Patient Share of SMA, (2017-2027)

 

Figure 1: Inheritance of SMA in an autosomal recessive pattern
Figure 2: Classification of SMA
Figure 3: Schematic representation of a portion of chromosome 5 that contains two SMN genes
Figure 4: Targets for therapy in SMA
Figure 5: Diagnosis tests in SMA
Figure 6: Diagnostic Evaluation of SMA
Figure 7: Total SMA Cases in 7MM -2017
Figure 8: Total SMA Cases in 7MM - 2027
Figure 9: SMA Incidence and Prevalence Rates
Figure 10: Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Figure 11: Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Figure 12: Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Figure 13: Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Figure 14: Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Figure 15: Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Figure 16: Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Figure 17: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Figure 18: Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Figure 19: Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Figure 20: Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Figure 21: Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Figure 22: Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Figure 23: Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Figure 24: Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Figure 25: Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Figure 26: Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Figure 27: Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Figure 28: Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Figure 29: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Figure 30: Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Figure 31: Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Figure 32: Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Figure 33: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Figure 34: Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Figure 35: Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Figure 36: Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Figure 37: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Figure 38: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 39: 7MM Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 40: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 41: United States Market Size of SMA in USD Million, (2017-2027)
Figure 42: US Estimated revenue of Marketed and Pipeline Drugs in USD Million (2017-2027)
Figure 43: US Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 44: SMA market in EU5 countries in USD Million, (2017-2027)
Figure 45: EU5 Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 46: EU5 Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 47: Germany Market Size of SMA in USD Million, (2017-2027)
Figure 48: Germany Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 49: Germany Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 50: France Market Size of SMA in USD Million, (2017-2027)
Figure 51: France Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 52: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 53: UK Market Size of SMA in USD Million, (2017-2027)
Figure 54: UK Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 55: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 56: Spain Market Size of SMA in USD Million, (2017-2027)
Figure 57: Spain Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 58: Spain Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 59: Italy Market Size of SMA in USD Million, (2017-2027)
Figure 60: Italy Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 61: Italy Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 62: Japan Market Size of SMA in USD Million (2017-2027)
Figure 63: Japan Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 64: Japan Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)

 

Table 1 Types of SMA linked to Chromosome-5
Table 2 Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Table 3 Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Table 4 Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Table 5 Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Table 6 Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Table 7 Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Table 8 Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Table 9 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Table 10 Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Table 11 Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Table 12 Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Table 13 Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Table 14 Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Table 15 Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Table 16 Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Table 17 Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Table 18 Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Table 19 Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Table 20 Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Table 21 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Table 22 Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Table 23 Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Table 24 Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Table 25 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Table 26 Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Table 27 Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Table 28 Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Table 29  Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Table 30 United States Association Current Recommendations for SMA
Table 31 European Association Current Recommendations for SMA
Table 32 Japanese Association Current Recommendations for SMA
Table 33 List of Marketed Drugs for SMA
Table 34 Market Size of SMA in 7MM (USD Million) (2017-2027)
Table 35 7MM Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 36 7MM Drug-Specific Patient Share of SMA, (2017-2027)
Table 37 United States Market Size of SMA in USD Million, (2017-2027)
Table 38 United States Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 39 United States Drug-Specific Patient Share of SMA, (2017-2027)
Table 40 EU5 Market Size of SMA in USD Million, (2017-2027)
Table 41 EU5 Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 42 EU5 Drug-Specific Patient Share of SMA, (2017-2027)
Table 43 Germany Market Size of SMA in USD Million, (2017-2027)
Table 44 Germany Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 45 Germany Drug-Specific Patient Share of SMA, (2017-2027)
Table 46 France Market Size of SMA in USD Million, (2017-2027)
Table 47 France Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 48 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 49 UK Market Size of SMA in USD Million, (2017-2027)
Table 50 UK Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 51 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 52 Spain Market Size of SMA in USD Million, (2017-2027)
Table 53 Spain Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 54 Spain Drug-Specific Patient Share of SMA, (2017-2027)
Table 55 Italy Market Size of SMA in USD Million, (2017-2027)
Table 56 Italy Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 57 Italy Drug-Specific Patient Share of SMA, (2017-2027)
Table 58 Japan Market Size of SMA in USD Million, (2017-2027)
Table 59 Japan Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 60 Drug-Specific Patient Share of SMA, (2017-2027)

 

Figure 1: Inheritance of SMA in an autosomal recessive pattern
Figure 2: Classification of SMA
Figure 3: Schematic representation of a portion of chromosome 5 that contains two SMN genes
Figure 4: Targets for therapy in SMA
Figure 5: Diagnosis tests in SMA
Figure 6: Diagnostic Evaluation of SMA
Figure 7: Total SMA Cases in 7MM -2017
Figure 8: Total SMA Cases in 7MM - 2027
Figure 9: SMA Incidence and Prevalence Rates
Figure 10: Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Figure 11: Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Figure 12: Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Figure 13: Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Figure 14: Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Figure 15: Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Figure 16: Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Figure 17: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Figure 18: Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Figure 19: Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Figure 20: Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Figure 21: Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Figure 22: Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Figure 23: Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Figure 24: Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Figure 25: Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Figure 26: Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Figure 27: Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Figure 28: Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Figure 29: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Figure 30: Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Figure 31: Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Figure 32: Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Figure 33: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Figure 34: Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Figure 35: Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Figure 36: Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Figure 37: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Figure 38: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 39: 7MM Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 40: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 41: United States Market Size of SMA in USD Million, (2017-2027)
Figure 42: US Estimated revenue of Marketed and Pipeline Drugs in USD Million (2017-2027)
Figure 43: US Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 44: SMA market in EU5 countries in USD Million, (2017-2027)
Figure 45: EU5 Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 46: EU5 Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 47: Germany Market Size of SMA in USD Million, (2017-2027)
Figure 48: Germany Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 49: Germany Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 50: France Market Size of SMA in USD Million, (2017-2027)
Figure 51: France Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 52: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 53: UK Market Size of SMA in USD Million, (2017-2027)
Figure 54: UK Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 55: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 56: Spain Market Size of SMA in USD Million, (2017-2027)
Figure 57: Spain Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 58: Spain Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 59: Italy Market Size of SMA in USD Million, (2017-2027)
Figure 60: Italy Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 61: Italy Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 62: Japan Market Size of SMA in USD Million (2017-2027)
Figure 63: Japan Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 64: Japan Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)

 

Table 1 Types of SMA linked to Chromosome-5
Table 2 Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Table 3 Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Table 4 Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Table 5 Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Table 6 Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Table 7 Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Table 8 Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Table 9 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Table 10 Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Table 11 Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Table 12 Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Table 13 Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Table 14 Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Table 15 Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Table 16 Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Table 17 Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Table 18 Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Table 19 Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Table 20 Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Table 21 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Table 22 Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Table 23 Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Table 24 Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Table 25 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Table 26 Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Table 27 Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Table 28 Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Table 29  Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Table 30 United States Association Current Recommendations for SMA
Table 31 European Association Current Recommendations for SMA
Table 32 Japanese Association Current Recommendations for SMA
Table 33 List of Marketed Drugs for SMA
Table 34 Market Size of SMA in 7MM (USD Million) (2017-2027)
Table 35 7MM Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 36 7MM Drug-Specific Patient Share of SMA, (2017-2027)
Table 37 United States Market Size of SMA in USD Million, (2017-2027)
Table 38 United States Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 39 United States Drug-Specific Patient Share of SMA, (2017-2027)
Table 40 EU5 Market Size of SMA in USD Million, (2017-2027)
Table 41 EU5 Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 42 EU5 Drug-Specific Patient Share of SMA, (2017-2027)
Table 43 Germany Market Size of SMA in USD Million, (2017-2027)
Table 44 Germany Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 45 Germany Drug-Specific Patient Share of SMA, (2017-2027)
Table 46 France Market Size of SMA in USD Million, (2017-2027)
Table 47 France Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 48 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 49 UK Market Size of SMA in USD Million, (2017-2027)
Table 50 UK Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 51 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 52 Spain Market Size of SMA in USD Million, (2017-2027)
Table 53 Spain Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 54 Spain Drug-Specific Patient Share of SMA, (2017-2027)
Table 55 Italy Market Size of SMA in USD Million, (2017-2027)
Table 56 Italy Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 57 Italy Drug-Specific Patient Share of SMA, (2017-2027)
Table 58 Japan Market Size of SMA in USD Million, (2017-2027)
Table 59 Japan Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 60 Drug-Specific Patient Share of SMA, (2017-2027)

 

Figure 1: Inheritance of SMA in an autosomal recessive pattern
Figure 2: Classification of SMA
Figure 3: Schematic representation of a portion of chromosome 5 that contains two SMN genes
Figure 4: Targets for therapy in SMA
Figure 5: Diagnosis tests in SMA
Figure 6: Diagnostic Evaluation of SMA
Figure 7: Total SMA Cases in 7MM -2017
Figure 8: Total SMA Cases in 7MM - 2027
Figure 9: SMA Incidence and Prevalence Rates
Figure 10: Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Figure 11: Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Figure 12: Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Figure 13: Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Figure 14: Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Figure 15: Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Figure 16: Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Figure 17: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Figure 18: Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Figure 19: Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Figure 20: Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Figure 21: Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Figure 22: Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Figure 23: Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Figure 24: Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Figure 25: Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Figure 26: Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Figure 27: Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Figure 28: Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Figure 29: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Figure 30: Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Figure 31: Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Figure 32: Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Figure 33: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Figure 34: Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Figure 35: Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Figure 36: Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Figure 37: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Figure 38: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 39: 7MM Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 40: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 41: United States Market Size of SMA in USD Million, (2017-2027)
Figure 42: US Estimated revenue of Marketed and Pipeline Drugs in USD Million (2017-2027)
Figure 43: US Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 44: SMA market in EU5 countries in USD Million, (2017-2027)
Figure 45: EU5 Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 46: EU5 Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 47: Germany Market Size of SMA in USD Million, (2017-2027)
Figure 48: Germany Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 49: Germany Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 50: France Market Size of SMA in USD Million, (2017-2027)
Figure 51: France Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 52: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 53: UK Market Size of SMA in USD Million, (2017-2027)
Figure 54: UK Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 55: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 56: Spain Market Size of SMA in USD Million, (2017-2027)
Figure 57: Spain Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 58: Spain Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 59: Italy Market Size of SMA in USD Million, (2017-2027)
Figure 60: Italy Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 61: Italy Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 62: Japan Market Size of SMA in USD Million (2017-2027)
Figure 63: Japan Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 64: Japan Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)

 

Table 1 Types of SMA linked to Chromosome-5
Table 2 Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Table 3 Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Table 4 Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Table 5 Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Table 6 Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Table 7 Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Table 8 Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Table 9 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Table 10 Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Table 11 Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Table 12 Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Table 13 Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Table 14 Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Table 15 Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Table 16 Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Table 17 Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Table 18 Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Table 19 Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Table 20 Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Table 21 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Table 22 Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Table 23 Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Table 24 Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Table 25 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Table 26 Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Table 27 Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Table 28 Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Table 29  Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Table 30 United States Association Current Recommendations for SMA
Table 31 European Association Current Recommendations for SMA
Table 32 Japanese Association Current Recommendations for SMA
Table 33 List of Marketed Drugs for SMA
Table 34 Market Size of SMA in 7MM (USD Million) (2017-2027)
Table 35 7MM Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 36 7MM Drug-Specific Patient Share of SMA, (2017-2027)
Table 37 United States Market Size of SMA in USD Million, (2017-2027)
Table 38 United States Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 39 United States Drug-Specific Patient Share of SMA, (2017-2027)
Table 40 EU5 Market Size of SMA in USD Million, (2017-2027)
Table 41 EU5 Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 42 EU5 Drug-Specific Patient Share of SMA, (2017-2027)
Table 43 Germany Market Size of SMA in USD Million, (2017-2027)
Table 44 Germany Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 45 Germany Drug-Specific Patient Share of SMA, (2017-2027)
Table 46 France Market Size of SMA in USD Million, (2017-2027)
Table 47 France Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 48 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 49 UK Market Size of SMA in USD Million, (2017-2027)
Table 50 UK Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 51 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 52 Spain Market Size of SMA in USD Million, (2017-2027)
Table 53 Spain Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 54 Spain Drug-Specific Patient Share of SMA, (2017-2027)
Table 55 Italy Market Size of SMA in USD Million, (2017-2027)
Table 56 Italy Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 57 Italy Drug-Specific Patient Share of SMA, (2017-2027)
Table 58 Japan Market Size of SMA in USD Million, (2017-2027)
Table 59 Japan Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 60 Drug-Specific Patient Share of SMA, (2017-2027)

 

Figure 1: Inheritance of SMA in an autosomal recessive pattern
Figure 2: Classification of SMA
Figure 3: Schematic representation of a portion of chromosome 5 that contains two SMN genes
Figure 4: Targets for therapy in SMA
Figure 5: Diagnosis tests in SMA
Figure 6: Diagnostic Evaluation of SMA
Figure 7: Total SMA Cases in 7MM -2017
Figure 8: Total SMA Cases in 7MM - 2027
Figure 9: SMA Incidence and Prevalence Rates
Figure 10: Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Figure 11: Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Figure 12: Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Figure 13: Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Figure 14: Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Figure 15: Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Figure 16: Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Figure 17: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Figure 18: Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Figure 19: Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Figure 20: Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Figure 21: Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Figure 22: Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Figure 23: Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Figure 24: Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Figure 25: Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Figure 26: Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Figure 27: Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Figure 28: Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Figure 29: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Figure 30: Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Figure 31: Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Figure 32: Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Figure 33: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Figure 34: Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Figure 35: Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Figure 36: Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Figure 37: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Figure 38: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 39: 7MM Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 40: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 41: United States Market Size of SMA in USD Million, (2017-2027)
Figure 42: US Estimated revenue of Marketed and Pipeline Drugs in USD Million (2017-2027)
Figure 43: US Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 44: SMA market in EU5 countries in USD Million, (2017-2027)
Figure 45: EU5 Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 46: EU5 Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 47: Germany Market Size of SMA in USD Million, (2017-2027)
Figure 48: Germany Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 49: Germany Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 50: France Market Size of SMA in USD Million, (2017-2027)
Figure 51: France Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 52: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 53: UK Market Size of SMA in USD Million, (2017-2027)
Figure 54: UK Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 55: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 56: Spain Market Size of SMA in USD Million, (2017-2027)
Figure 57: Spain Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 58: Spain Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 59: Italy Market Size of SMA in USD Million, (2017-2027)
Figure 60: Italy Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 61: Italy Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 62: Japan Market Size of SMA in USD Million (2017-2027)
Figure 63: Japan Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 64: Japan Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)

 

Table 1 Types of SMA linked to Chromosome-5
Table 2 Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Table 3 Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Table 4 Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Table 5 Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Table 6 Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Table 7 Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Table 8 Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Table 9 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Table 10 Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Table 11 Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Table 12 Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Table 13 Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Table 14 Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Table 15 Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Table 16 Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Table 17 Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Table 18 Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Table 19 Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Table 20 Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Table 21 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Table 22 Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Table 23 Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Table 24 Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Table 25 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Table 26 Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Table 27 Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Table 28 Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Table 29  Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Table 30 United States Association Current Recommendations for SMA
Table 31 European Association Current Recommendations for SMA
Table 32 Japanese Association Current Recommendations for SMA
Table 33 List of Marketed Drugs for SMA
Table 34 Market Size of SMA in 7MM (USD Million) (2017-2027)
Table 35 7MM Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 36 7MM Drug-Specific Patient Share of SMA, (2017-2027)
Table 37 United States Market Size of SMA in USD Million, (2017-2027)
Table 38 United States Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 39 United States Drug-Specific Patient Share of SMA, (2017-2027)
Table 40 EU5 Market Size of SMA in USD Million, (2017-2027)
Table 41 EU5 Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 42 EU5 Drug-Specific Patient Share of SMA, (2017-2027)
Table 43 Germany Market Size of SMA in USD Million, (2017-2027)
Table 44 Germany Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 45 Germany Drug-Specific Patient Share of SMA, (2017-2027)
Table 46 France Market Size of SMA in USD Million, (2017-2027)
Table 47 France Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 48 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 49 UK Market Size of SMA in USD Million, (2017-2027)
Table 50 UK Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 51 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 52 Spain Market Size of SMA in USD Million, (2017-2027)
Table 53 Spain Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 54 Spain Drug-Specific Patient Share of SMA, (2017-2027)
Table 55 Italy Market Size of SMA in USD Million, (2017-2027)
Table 56 Italy Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 57 Italy Drug-Specific Patient Share of SMA, (2017-2027)
Table 58 Japan Market Size of SMA in USD Million, (2017-2027)
Table 59 Japan Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 60 Drug-Specific Patient Share of SMA, (2017-2027)

 

Figure 1: Inheritance of SMA in an autosomal recessive pattern
Figure 2: Classification of SMA
Figure 3: Schematic representation of a portion of chromosome 5 that contains two SMN genes
Figure 4: Targets for therapy in SMA
Figure 5: Diagnosis tests in SMA
Figure 6: Diagnostic Evaluation of SMA
Figure 7: Total SMA Cases in 7MM -2017
Figure 8: Total SMA Cases in 7MM - 2027
Figure 9: SMA Incidence and Prevalence Rates
Figure 10: Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Figure 11: Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Figure 12: Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Figure 13: Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Figure 14: Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Figure 15: Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Figure 16: Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Figure 17: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Figure 18: Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Figure 19: Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Figure 20: Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Figure 21: Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Figure 22: Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Figure 23: Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Figure 24: Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Figure 25: Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Figure 26: Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Figure 27: Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Figure 28: Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Figure 29: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Figure 30: Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Figure 31: Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Figure 32: Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Figure 33: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Figure 34: Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Figure 35: Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Figure 36: Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Figure 37: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Figure 38: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 39: 7MM Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 40: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 41: United States Market Size of SMA in USD Million, (2017-2027)
Figure 42: US Estimated revenue of Marketed and Pipeline Drugs in USD Million (2017-2027)
Figure 43: US Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 44: SMA market in EU5 countries in USD Million, (2017-2027)
Figure 45: EU5 Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 46: EU5 Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 47: Germany Market Size of SMA in USD Million, (2017-2027)
Figure 48: Germany Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 49: Germany Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 50: France Market Size of SMA in USD Million, (2017-2027)
Figure 51: France Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 52: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 53: UK Market Size of SMA in USD Million, (2017-2027)
Figure 54: UK Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 55: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 56: Spain Market Size of SMA in USD Million, (2017-2027)
Figure 57: Spain Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 58: Spain Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 59: Italy Market Size of SMA in USD Million, (2017-2027)
Figure 60: Italy Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 61: Italy Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 62: Japan Market Size of SMA in USD Million (2017-2027)
Figure 63: Japan Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 64: Japan Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)

 

Table 1 Types of SMA linked to Chromosome-5
Table 2 Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Table 3 Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Table 4 Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Table 5 Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Table 6 Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Table 7 Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Table 8 Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Table 9 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Table 10 Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Table 11 Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Table 12 Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Table 13 Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Table 14 Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Table 15 Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Table 16 Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Table 17 Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Table 18 Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Table 19 Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Table 20 Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Table 21 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Table 22 Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Table 23 Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Table 24 Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Table 25 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Table 26 Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Table 27 Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Table 28 Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Table 29  Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Table 30 United States Association Current Recommendations for SMA
Table 31 European Association Current Recommendations for SMA
Table 32 Japanese Association Current Recommendations for SMA
Table 33 List of Marketed Drugs for SMA
Table 34 Market Size of SMA in 7MM (USD Million) (2017-2027)
Table 35 7MM Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 36 7MM Drug-Specific Patient Share of SMA, (2017-2027)
Table 37 United States Market Size of SMA in USD Million, (2017-2027)
Table 38 United States Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 39 United States Drug-Specific Patient Share of SMA, (2017-2027)
Table 40 EU5 Market Size of SMA in USD Million, (2017-2027)
Table 41 EU5 Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 42 EU5 Drug-Specific Patient Share of SMA, (2017-2027)
Table 43 Germany Market Size of SMA in USD Million, (2017-2027)
Table 44 Germany Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 45 Germany Drug-Specific Patient Share of SMA, (2017-2027)
Table 46 France Market Size of SMA in USD Million, (2017-2027)
Table 47 France Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 48 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 49 UK Market Size of SMA in USD Million, (2017-2027)
Table 50 UK Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 51 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 52 Spain Market Size of SMA in USD Million, (2017-2027)
Table 53 Spain Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 54 Spain Drug-Specific Patient Share of SMA, (2017-2027)
Table 55 Italy Market Size of SMA in USD Million, (2017-2027)
Table 56 Italy Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 57 Italy Drug-Specific Patient Share of SMA, (2017-2027)
Table 58 Japan Market Size of SMA in USD Million, (2017-2027)
Table 59 Japan Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 60 Drug-Specific Patient Share of SMA, (2017-2027)

 

Figure 1: Inheritance of SMA in an autosomal recessive pattern
Figure 2: Classification of SMA
Figure 3: Schematic representation of a portion of chromosome 5 that contains two SMN genes
Figure 4: Targets for therapy in SMA
Figure 5: Diagnosis tests in SMA
Figure 6: Diagnostic Evaluation of SMA
Figure 7: Total SMA Cases in 7MM -2017
Figure 8: Total SMA Cases in 7MM - 2027
Figure 9: SMA Incidence and Prevalence Rates
Figure 10: Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Figure 11: Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Figure 12: Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Figure 13: Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Figure 14: Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Figure 15: Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Figure 16: Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Figure 17: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Figure 18: Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Figure 19: Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Figure 20: Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Figure 21: Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Figure 22: Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Figure 23: Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Figure 24: Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Figure 25: Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Figure 26: Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Figure 27: Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Figure 28: Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Figure 29: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Figure 30: Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Figure 31: Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Figure 32: Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Figure 33: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Figure 34: Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Figure 35: Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Figure 36: Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Figure 37: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Figure 38: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 39: 7MM Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 40: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 41: United States Market Size of SMA in USD Million, (2017-2027)
Figure 42: US Estimated revenue of Marketed and Pipeline Drugs in USD Million (2017-2027)
Figure 43: US Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 44: SMA market in EU5 countries in USD Million, (2017-2027)
Figure 45: EU5 Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 46: EU5 Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 47: Germany Market Size of SMA in USD Million, (2017-2027)
Figure 48: Germany Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 49: Germany Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 50: France Market Size of SMA in USD Million, (2017-2027)
Figure 51: France Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 52: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 53: UK Market Size of SMA in USD Million, (2017-2027)
Figure 54: UK Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 55: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 56: Spain Market Size of SMA in USD Million, (2017-2027)
Figure 57: Spain Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 58: Spain Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 59: Italy Market Size of SMA in USD Million, (2017-2027)
Figure 60: Italy Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 61: Italy Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 62: Japan Market Size of SMA in USD Million (2017-2027)
Figure 63: Japan Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 64: Japan Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)

 

Table 1 Types of SMA linked to Chromosome-5
Table 2 Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Table 3 Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Table 4 Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Table 5 Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Table 6 Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Table 7 Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Table 8 Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Table 9 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Table 10 Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Table 11 Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Table 12 Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Table 13 Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Table 14 Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Table 15 Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Table 16 Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Table 17 Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Table 18 Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Table 19 Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Table 20 Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Table 21 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Table 22 Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Table 23 Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Table 24 Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Table 25 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Table 26 Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Table 27 Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Table 28 Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Table 29  Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Table 30 United States Association Current Recommendations for SMA
Table 31 European Association Current Recommendations for SMA
Table 32 Japanese Association Current Recommendations for SMA
Table 33 List of Marketed Drugs for SMA
Table 34 Market Size of SMA in 7MM (USD Million) (2017-2027)
Table 35 7MM Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 36 7MM Drug-Specific Patient Share of SMA, (2017-2027)
Table 37 United States Market Size of SMA in USD Million, (2017-2027)
Table 38 United States Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 39 United States Drug-Specific Patient Share of SMA, (2017-2027)
Table 40 EU5 Market Size of SMA in USD Million, (2017-2027)
Table 41 EU5 Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 42 EU5 Drug-Specific Patient Share of SMA, (2017-2027)
Table 43 Germany Market Size of SMA in USD Million, (2017-2027)
Table 44 Germany Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 45 Germany Drug-Specific Patient Share of SMA, (2017-2027)
Table 46 France Market Size of SMA in USD Million, (2017-2027)
Table 47 France Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 48 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 49 UK Market Size of SMA in USD Million, (2017-2027)
Table 50 UK Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 51 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 52 Spain Market Size of SMA in USD Million, (2017-2027)
Table 53 Spain Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 54 Spain Drug-Specific Patient Share of SMA, (2017-2027)
Table 55 Italy Market Size of SMA in USD Million, (2017-2027)
Table 56 Italy Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 57 Italy Drug-Specific Patient Share of SMA, (2017-2027)
Table 58 Japan Market Size of SMA in USD Million, (2017-2027)
Table 59 Japan Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 60 Drug-Specific Patient Share of SMA, (2017-2027)

 

Figure 1: Inheritance of SMA in an autosomal recessive pattern
Figure 2: Classification of SMA
Figure 3: Schematic representation of a portion of chromosome 5 that contains two SMN genes
Figure 4: Targets for therapy in SMA
Figure 5: Diagnosis tests in SMA
Figure 6: Diagnostic Evaluation of SMA
Figure 7: Total SMA Cases in 7MM -2017
Figure 8: Total SMA Cases in 7MM - 2027
Figure 9: SMA Incidence and Prevalence Rates
Figure 10: Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Figure 11: Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Figure 12: Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Figure 13: Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Figure 14: Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Figure 15: Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Figure 16: Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Figure 17: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Figure 18: Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Figure 19: Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Figure 20: Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Figure 21: Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Figure 22: Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Figure 23: Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Figure 24: Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Figure 25: Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Figure 26: Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Figure 27: Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Figure 28: Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Figure 29: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Figure 30: Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Figure 31: Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Figure 32: Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Figure 33: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Figure 34: Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Figure 35: Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Figure 36: Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Figure 37: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Figure 38: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 39: 7MM Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 40: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 41: United States Market Size of SMA in USD Million, (2017-2027)
Figure 42: US Estimated revenue of Marketed and Pipeline Drugs in USD Million (2017-2027)
Figure 43: US Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 44: SMA market in EU5 countries in USD Million, (2017-2027)
Figure 45: EU5 Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 46: EU5 Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 47: Germany Market Size of SMA in USD Million, (2017-2027)
Figure 48: Germany Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 49: Germany Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 50: France Market Size of SMA in USD Million, (2017-2027)
Figure 51: France Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 52: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 53: UK Market Size of SMA in USD Million, (2017-2027)
Figure 54: UK Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 55: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 56: Spain Market Size of SMA in USD Million, (2017-2027)
Figure 57: Spain Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 58: Spain Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 59: Italy Market Size of SMA in USD Million, (2017-2027)
Figure 60: Italy Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 61: Italy Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 62: Japan Market Size of SMA in USD Million (2017-2027)
Figure 63: Japan Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 64: Japan Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)

 

Table 1 Types of SMA linked to Chromosome-5
Table 2 Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Table 3 Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Table 4 Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Table 5 Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Table 6 Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Table 7 Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Table 8 Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Table 9 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Table 10 Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Table 11 Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Table 12 Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Table 13 Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Table 14 Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Table 15 Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Table 16 Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Table 17 Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Table 18 Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Table 19 Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Table 20 Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Table 21 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Table 22 Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Table 23 Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Table 24 Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Table 25 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Table 26 Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Table 27 Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Table 28 Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Table 29  Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Table 30 United States Association Current Recommendations for SMA
Table 31 European Association Current Recommendations for SMA
Table 32 Japanese Association Current Recommendations for SMA
Table 33 List of Marketed Drugs for SMA
Table 34 Market Size of SMA in 7MM (USD Million) (2017-2027)
Table 35 7MM Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 36 7MM Drug-Specific Patient Share of SMA, (2017-2027)
Table 37 United States Market Size of SMA in USD Million, (2017-2027)
Table 38 United States Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 39 United States Drug-Specific Patient Share of SMA, (2017-2027)
Table 40 EU5 Market Size of SMA in USD Million, (2017-2027)
Table 41 EU5 Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 42 EU5 Drug-Specific Patient Share of SMA, (2017-2027)
Table 43 Germany Market Size of SMA in USD Million, (2017-2027)
Table 44 Germany Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 45 Germany Drug-Specific Patient Share of SMA, (2017-2027)
Table 46 France Market Size of SMA in USD Million, (2017-2027)
Table 47 France Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 48 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 49 UK Market Size of SMA in USD Million, (2017-2027)
Table 50 UK Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 51 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 52 Spain Market Size of SMA in USD Million, (2017-2027)
Table 53 Spain Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 54 Spain Drug-Specific Patient Share of SMA, (2017-2027)
Table 55 Italy Market Size of SMA in USD Million, (2017-2027)
Table 56 Italy Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 57 Italy Drug-Specific Patient Share of SMA, (2017-2027)
Table 58 Japan Market Size of SMA in USD Million, (2017-2027)
Table 59 Japan Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 60 Drug-Specific Patient Share of SMA, (2017-2027)

 

Figure 1: Inheritance of SMA in an autosomal recessive pattern
Figure 2: Classification of SMA
Figure 3: Schematic representation of a portion of chromosome 5 that contains two SMN genes
Figure 4: Targets for therapy in SMA
Figure 5: Diagnosis tests in SMA
Figure 6: Diagnostic Evaluation of SMA
Figure 7: Total SMA Cases in 7MM -2017
Figure 8: Total SMA Cases in 7MM - 2027
Figure 9: SMA Incidence and Prevalence Rates
Figure 10: Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Figure 11: Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Figure 12: Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Figure 13: Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Figure 14: Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Figure 15: Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Figure 16: Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Figure 17: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Figure 18: Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Figure 19: Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Figure 20: Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Figure 21: Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Figure 22: Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Figure 23: Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Figure 24: Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Figure 25: Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Figure 26: Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Figure 27: Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Figure 28: Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Figure 29: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Figure 30: Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Figure 31: Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Figure 32: Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Figure 33: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Figure 34: Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Figure 35: Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Figure 36: Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Figure 37: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Figure 38: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 39: 7MM Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 40: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 41: United States Market Size of SMA in USD Million, (2017-2027)
Figure 42: US Estimated revenue of Marketed and Pipeline Drugs in USD Million (2017-2027)
Figure 43: US Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 44: SMA market in EU5 countries in USD Million, (2017-2027)
Figure 45: EU5 Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 46: EU5 Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 47: Germany Market Size of SMA in USD Million, (2017-2027)
Figure 48: Germany Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 49: Germany Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 50: France Market Size of SMA in USD Million, (2017-2027)
Figure 51: France Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 52: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 53: UK Market Size of SMA in USD Million, (2017-2027)
Figure 54: UK Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 55: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 56: Spain Market Size of SMA in USD Million, (2017-2027)
Figure 57: Spain Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 58: Spain Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 59: Italy Market Size of SMA in USD Million, (2017-2027)
Figure 60: Italy Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 61: Italy Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 62: Japan Market Size of SMA in USD Million (2017-2027)
Figure 63: Japan Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 64: Japan Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)

 

Table 1 Types of SMA linked to Chromosome-5
Table 2 Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Table 3 Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Table 4 Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Table 5 Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Table 6 Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Table 7 Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Table 8 Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Table 9 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Table 10 Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Table 11 Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Table 12 Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Table 13 Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Table 14 Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Table 15 Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Table 16 Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Table 17 Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Table 18 Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Table 19 Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Table 20 Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Table 21 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Table 22 Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Table 23 Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Table 24 Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Table 25 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Table 26 Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Table 27 Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Table 28 Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Table 29  Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Table 30 United States Association Current Recommendations for SMA
Table 31 European Association Current Recommendations for SMA
Table 32 Japanese Association Current Recommendations for SMA
Table 33 List of Marketed Drugs for SMA
Table 34 Market Size of SMA in 7MM (USD Million) (2017-2027)
Table 35 7MM Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 36 7MM Drug-Specific Patient Share of SMA, (2017-2027)
Table 37 United States Market Size of SMA in USD Million, (2017-2027)
Table 38 United States Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 39 United States Drug-Specific Patient Share of SMA, (2017-2027)
Table 40 EU5 Market Size of SMA in USD Million, (2017-2027)
Table 41 EU5 Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 42 EU5 Drug-Specific Patient Share of SMA, (2017-2027)
Table 43 Germany Market Size of SMA in USD Million, (2017-2027)
Table 44 Germany Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 45 Germany Drug-Specific Patient Share of SMA, (2017-2027)
Table 46 France Market Size of SMA in USD Million, (2017-2027)
Table 47 France Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 48 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 49 UK Market Size of SMA in USD Million, (2017-2027)
Table 50 UK Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 51 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 52 Spain Market Size of SMA in USD Million, (2017-2027)
Table 53 Spain Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 54 Spain Drug-Specific Patient Share of SMA, (2017-2027)
Table 55 Italy Market Size of SMA in USD Million, (2017-2027)
Table 56 Italy Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 57 Italy Drug-Specific Patient Share of SMA, (2017-2027)
Table 58 Japan Market Size of SMA in USD Million, (2017-2027)
Table 59 Japan Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 60 Drug-Specific Patient Share of SMA, (2017-2027)

 

Figure 1: Inheritance of SMA in an autosomal recessive pattern
Figure 2: Classification of SMA
Figure 3: Schematic representation of a portion of chromosome 5 that contains two SMN genes
Figure 4: Targets for therapy in SMA
Figure 5: Diagnosis tests in SMA
Figure 6: Diagnostic Evaluation of SMA
Figure 7: Total SMA Cases in 7MM -2017
Figure 8: Total SMA Cases in 7MM - 2027
Figure 9: SMA Incidence and Prevalence Rates
Figure 10: Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Figure 11: Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Figure 12: Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Figure 13: Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Figure 14: Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Figure 15: Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Figure 16: Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Figure 17: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Figure 18: Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Figure 19: Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Figure 20: Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Figure 21: Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Figure 22: Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Figure 23: Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Figure 24: Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Figure 25: Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Figure 26: Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Figure 27: Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Figure 28: Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Figure 29: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Figure 30: Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Figure 31: Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Figure 32: Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Figure 33: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Figure 34: Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Figure 35: Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Figure 36: Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Figure 37: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Figure 38: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 39: 7MM Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 40: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 41: United States Market Size of SMA in USD Million, (2017-2027)
Figure 42: US Estimated revenue of Marketed and Pipeline Drugs in USD Million (2017-2027)
Figure 43: US Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 44: SMA market in EU5 countries in USD Million, (2017-2027)
Figure 45: EU5 Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 46: EU5 Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 47: Germany Market Size of SMA in USD Million, (2017-2027)
Figure 48: Germany Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 49: Germany Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 50: France Market Size of SMA in USD Million, (2017-2027)
Figure 51: France Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 52: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 53: UK Market Size of SMA in USD Million, (2017-2027)
Figure 54: UK Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 55: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 56: Spain Market Size of SMA in USD Million, (2017-2027)
Figure 57: Spain Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 58: Spain Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 59: Italy Market Size of SMA in USD Million, (2017-2027)
Figure 60: Italy Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 61: Italy Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 62: Japan Market Size of SMA in USD Million (2017-2027)
Figure 63: Japan Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 64: Japan Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)

 

Table 1 Types of SMA linked to Chromosome-5
Table 2 Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Table 3 Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Table 4 Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Table 5 Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Table 6 Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Table 7 Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Table 8 Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Table 9 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Table 10 Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Table 11 Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Table 12 Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Table 13 Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Table 14 Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Table 15 Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Table 16 Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Table 17 Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Table 18 Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Table 19 Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Table 20 Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Table 21 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Table 22 Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Table 23 Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Table 24 Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Table 25 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Table 26 Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Table 27 Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Table 28 Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Table 29  Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Table 30 United States Association Current Recommendations for SMA
Table 31 European Association Current Recommendations for SMA
Table 32 Japanese Association Current Recommendations for SMA
Table 33 List of Marketed Drugs for SMA
Table 34 Market Size of SMA in 7MM (USD Million) (2017-2027)
Table 35 7MM Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 36 7MM Drug-Specific Patient Share of SMA, (2017-2027)
Table 37 United States Market Size of SMA in USD Million, (2017-2027)
Table 38 United States Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 39 United States Drug-Specific Patient Share of SMA, (2017-2027)
Table 40 EU5 Market Size of SMA in USD Million, (2017-2027)
Table 41 EU5 Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 42 EU5 Drug-Specific Patient Share of SMA, (2017-2027)
Table 43 Germany Market Size of SMA in USD Million, (2017-2027)
Table 44 Germany Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 45 Germany Drug-Specific Patient Share of SMA, (2017-2027)
Table 46 France Market Size of SMA in USD Million, (2017-2027)
Table 47 France Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 48 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 49 UK Market Size of SMA in USD Million, (2017-2027)
Table 50 UK Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 51 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 52 Spain Market Size of SMA in USD Million, (2017-2027)
Table 53 Spain Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 54 Spain Drug-Specific Patient Share of SMA, (2017-2027)
Table 55 Italy Market Size of SMA in USD Million, (2017-2027)
Table 56 Italy Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 57 Italy Drug-Specific Patient Share of SMA, (2017-2027)
Table 58 Japan Market Size of SMA in USD Million, (2017-2027)
Table 59 Japan Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 60 Drug-Specific Patient Share of SMA, (2017-2027)

 

Figure 1: Inheritance of SMA in an autosomal recessive pattern
Figure 2: Classification of SMA
Figure 3: Schematic representation of a portion of chromosome 5 that contains two SMN genes
Figure 4: Targets for therapy in SMA
Figure 5: Diagnosis tests in SMA
Figure 6: Diagnostic Evaluation of SMA
Figure 7: Total SMA Cases in 7MM -2017
Figure 8: Total SMA Cases in 7MM - 2027
Figure 9: SMA Incidence and Prevalence Rates
Figure 10: Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Figure 11: Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Figure 12: Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Figure 13: Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Figure 14: Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Figure 15: Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Figure 16: Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Figure 17: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Figure 18: Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Figure 19: Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Figure 20: Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Figure 21: Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Figure 22: Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Figure 23: Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Figure 24: Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Figure 25: Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Figure 26: Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Figure 27: Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Figure 28: Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Figure 29: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Figure 30: Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Figure 31: Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Figure 32: Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Figure 33: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Figure 34: Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Figure 35: Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Figure 36: Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Figure 37: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Figure 38: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 39: 7MM Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 40: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 41: United States Market Size of SMA in USD Million, (2017-2027)
Figure 42: US Estimated revenue of Marketed and Pipeline Drugs in USD Million (2017-2027)
Figure 43: US Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 44: SMA market in EU5 countries in USD Million, (2017-2027)
Figure 45: EU5 Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 46: EU5 Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 47: Germany Market Size of SMA in USD Million, (2017-2027)
Figure 48: Germany Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 49: Germany Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 50: France Market Size of SMA in USD Million, (2017-2027)
Figure 51: France Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 52: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 53: UK Market Size of SMA in USD Million, (2017-2027)
Figure 54: UK Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 55: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 56: Spain Market Size of SMA in USD Million, (2017-2027)
Figure 57: Spain Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 58: Spain Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 59: Italy Market Size of SMA in USD Million, (2017-2027)
Figure 60: Italy Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 61: Italy Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 62: Japan Market Size of SMA in USD Million (2017-2027)
Figure 63: Japan Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 64: Japan Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)

 

Table 1 Types of SMA linked to Chromosome-5
Table 2 Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Table 3 Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Table 4 Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Table 5 Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Table 6 Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Table 7 Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Table 8 Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Table 9 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Table 10 Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Table 11 Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Table 12 Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Table 13 Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Table 14 Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Table 15 Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Table 16 Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Table 17 Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Table 18 Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Table 19 Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Table 20 Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Table 21 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Table 22 Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Table 23 Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Table 24 Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Table 25 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Table 26 Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Table 27 Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Table 28 Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Table 29  Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Table 30 United States Association Current Recommendations for SMA
Table 31 European Association Current Recommendations for SMA
Table 32 Japanese Association Current Recommendations for SMA
Table 33 List of Marketed Drugs for SMA
Table 34 Market Size of SMA in 7MM (USD Million) (2017-2027)
Table 35 7MM Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 36 7MM Drug-Specific Patient Share of SMA, (2017-2027)
Table 37 United States Market Size of SMA in USD Million, (2017-2027)
Table 38 United States Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 39 United States Drug-Specific Patient Share of SMA, (2017-2027)
Table 40 EU5 Market Size of SMA in USD Million, (2017-2027)
Table 41 EU5 Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 42 EU5 Drug-Specific Patient Share of SMA, (2017-2027)
Table 43 Germany Market Size of SMA in USD Million, (2017-2027)
Table 44 Germany Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 45 Germany Drug-Specific Patient Share of SMA, (2017-2027)
Table 46 France Market Size of SMA in USD Million, (2017-2027)
Table 47 France Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 48 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 49 UK Market Size of SMA in USD Million, (2017-2027)
Table 50 UK Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 51 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 52 Spain Market Size of SMA in USD Million, (2017-2027)
Table 53 Spain Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 54 Spain Drug-Specific Patient Share of SMA, (2017-2027)
Table 55 Italy Market Size of SMA in USD Million, (2017-2027)
Table 56 Italy Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 57 Italy Drug-Specific Patient Share of SMA, (2017-2027)
Table 58 Japan Market Size of SMA in USD Million, (2017-2027)
Table 59 Japan Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 60 Drug-Specific Patient Share of SMA, (2017-2027)

 

Figure 1: Inheritance of SMA in an autosomal recessive pattern
Figure 2: Classification of SMA
Figure 3: Schematic representation of a portion of chromosome 5 that contains two SMN genes
Figure 4: Targets for therapy in SMA
Figure 5: Diagnosis tests in SMA
Figure 6: Diagnostic Evaluation of SMA
Figure 7: Total SMA Cases in 7MM -2017
Figure 8: Total SMA Cases in 7MM - 2027
Figure 9: SMA Incidence and Prevalence Rates
Figure 10: Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Figure 11: Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Figure 12: Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Figure 13: Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Figure 14: Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Figure 15: Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Figure 16: Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Figure 17: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Figure 18: Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Figure 19: Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Figure 20: Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Figure 21: Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Figure 22: Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Figure 23: Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Figure 24: Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Figure 25: Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Figure 26: Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Figure 27: Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Figure 28: Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Figure 29: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Figure 30: Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Figure 31: Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Figure 32: Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Figure 33: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Figure 34: Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Figure 35: Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Figure 36: Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Figure 37: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Figure 38: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 39: 7MM Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 40: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 41: United States Market Size of SMA in USD Million, (2017-2027)
Figure 42: US Estimated revenue of Marketed and Pipeline Drugs in USD Million (2017-2027)
Figure 43: US Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 44: SMA market in EU5 countries in USD Million, (2017-2027)
Figure 45: EU5 Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 46: EU5 Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 47: Germany Market Size of SMA in USD Million, (2017-2027)
Figure 48: Germany Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 49: Germany Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 50: France Market Size of SMA in USD Million, (2017-2027)
Figure 51: France Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 52: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 53: UK Market Size of SMA in USD Million, (2017-2027)
Figure 54: UK Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 55: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 56: Spain Market Size of SMA in USD Million, (2017-2027)
Figure 57: Spain Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 58: Spain Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 59: Italy Market Size of SMA in USD Million, (2017-2027)
Figure 60: Italy Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 61: Italy Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 62: Japan Market Size of SMA in USD Million (2017-2027)
Figure 63: Japan Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 64: Japan Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)

 

Table 1 Types of SMA linked to Chromosome-5
Table 2 Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Table 3 Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Table 4 Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Table 5 Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Table 6 Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Table 7 Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Table 8 Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Table 9 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Table 10 Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Table 11 Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Table 12 Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Table 13 Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Table 14 Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Table 15 Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Table 16 Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Table 17 Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Table 18 Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Table 19 Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Table 20 Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Table 21 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Table 22 Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Table 23 Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Table 24 Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Table 25 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Table 26 Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Table 27 Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Table 28 Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Table 29  Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Table 30 United States Association Current Recommendations for SMA
Table 31 European Association Current Recommendations for SMA
Table 32 Japanese Association Current Recommendations for SMA
Table 33 List of Marketed Drugs for SMA
Table 34 Market Size of SMA in 7MM (USD Million) (2017-2027)
Table 35 7MM Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 36 7MM Drug-Specific Patient Share of SMA, (2017-2027)
Table 37 United States Market Size of SMA in USD Million, (2017-2027)
Table 38 United States Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 39 United States Drug-Specific Patient Share of SMA, (2017-2027)
Table 40 EU5 Market Size of SMA in USD Million, (2017-2027)
Table 41 EU5 Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 42 EU5 Drug-Specific Patient Share of SMA, (2017-2027)
Table 43 Germany Market Size of SMA in USD Million, (2017-2027)
Table 44 Germany Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 45 Germany Drug-Specific Patient Share of SMA, (2017-2027)
Table 46 France Market Size of SMA in USD Million, (2017-2027)
Table 47 France Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 48 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 49 UK Market Size of SMA in USD Million, (2017-2027)
Table 50 UK Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 51 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 52 Spain Market Size of SMA in USD Million, (2017-2027)
Table 53 Spain Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 54 Spain Drug-Specific Patient Share of SMA, (2017-2027)
Table 55 Italy Market Size of SMA in USD Million, (2017-2027)
Table 56 Italy Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 57 Italy Drug-Specific Patient Share of SMA, (2017-2027)
Table 58 Japan Market Size of SMA in USD Million, (2017-2027)
Table 59 Japan Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 60 Drug-Specific Patient Share of SMA, (2017-2027)

 

Figure 1: Inheritance of SMA in an autosomal recessive pattern
Figure 2: Classification of SMA
Figure 3: Schematic representation of a portion of chromosome 5 that contains two SMN genes
Figure 4: Targets for therapy in SMA
Figure 5: Diagnosis tests in SMA
Figure 6: Diagnostic Evaluation of SMA
Figure 7: Total SMA Cases in 7MM -2017
Figure 8: Total SMA Cases in 7MM - 2027
Figure 9: SMA Incidence and Prevalence Rates
Figure 10: Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Figure 11: Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Figure 12: Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Figure 13: Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Figure 14: Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Figure 15: Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Figure 16: Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Figure 17: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Figure 18: Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Figure 19: Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Figure 20: Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Figure 21: Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Figure 22: Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Figure 23: Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Figure 24: Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Figure 25: Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Figure 26: Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Figure 27: Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Figure 28: Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Figure 29: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Figure 30: Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Figure 31: Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Figure 32: Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Figure 33: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Figure 34: Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Figure 35: Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Figure 36: Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Figure 37: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Figure 38: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 39: 7MM Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 40: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 41: United States Market Size of SMA in USD Million, (2017-2027)
Figure 42: US Estimated revenue of Marketed and Pipeline Drugs in USD Million (2017-2027)
Figure 43: US Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 44: SMA market in EU5 countries in USD Million, (2017-2027)
Figure 45: EU5 Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 46: EU5 Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 47: Germany Market Size of SMA in USD Million, (2017-2027)
Figure 48: Germany Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 49: Germany Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 50: France Market Size of SMA in USD Million, (2017-2027)
Figure 51: France Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 52: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 53: UK Market Size of SMA in USD Million, (2017-2027)
Figure 54: UK Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 55: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 56: Spain Market Size of SMA in USD Million, (2017-2027)
Figure 57: Spain Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 58: Spain Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 59: Italy Market Size of SMA in USD Million, (2017-2027)
Figure 60: Italy Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 61: Italy Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 62: Japan Market Size of SMA in USD Million (2017-2027)
Figure 63: Japan Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 64: Japan Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)

 

Table 1 Types of SMA linked to Chromosome-5
Table 2 Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Table 3 Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Table 4 Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Table 5 Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Table 6 Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Table 7 Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Table 8 Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Table 9 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Table 10 Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Table 11 Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Table 12 Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Table 13 Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Table 14 Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Table 15 Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Table 16 Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Table 17 Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Table 18 Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Table 19 Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Table 20 Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Table 21 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Table 22 Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Table 23 Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Table 24 Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Table 25 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Table 26 Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Table 27 Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Table 28 Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Table 29  Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Table 30 United States Association Current Recommendations for SMA
Table 31 European Association Current Recommendations for SMA
Table 32 Japanese Association Current Recommendations for SMA
Table 33 List of Marketed Drugs for SMA
Table 34 Market Size of SMA in 7MM (USD Million) (2017-2027)
Table 35 7MM Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 36 7MM Drug-Specific Patient Share of SMA, (2017-2027)
Table 37 United States Market Size of SMA in USD Million, (2017-2027)
Table 38 United States Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 39 United States Drug-Specific Patient Share of SMA, (2017-2027)
Table 40 EU5 Market Size of SMA in USD Million, (2017-2027)
Table 41 EU5 Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 42 EU5 Drug-Specific Patient Share of SMA, (2017-2027)
Table 43 Germany Market Size of SMA in USD Million, (2017-2027)
Table 44 Germany Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 45 Germany Drug-Specific Patient Share of SMA, (2017-2027)
Table 46 France Market Size of SMA in USD Million, (2017-2027)
Table 47 France Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 48 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 49 UK Market Size of SMA in USD Million, (2017-2027)
Table 50 UK Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 51 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 52 Spain Market Size of SMA in USD Million, (2017-2027)
Table 53 Spain Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 54 Spain Drug-Specific Patient Share of SMA, (2017-2027)
Table 55 Italy Market Size of SMA in USD Million, (2017-2027)
Table 56 Italy Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 57 Italy Drug-Specific Patient Share of SMA, (2017-2027)
Table 58 Japan Market Size of SMA in USD Million, (2017-2027)
Table 59 Japan Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 60 Drug-Specific Patient Share of SMA, (2017-2027)

 

Figure 1: Inheritance of SMA in an autosomal recessive pattern
Figure 2: Classification of SMA
Figure 3: Schematic representation of a portion of chromosome 5 that contains two SMN genes
Figure 4: Targets for therapy in SMA
Figure 5: Diagnosis tests in SMA
Figure 6: Diagnostic Evaluation of SMA
Figure 7: Total SMA Cases in 7MM -2017
Figure 8: Total SMA Cases in 7MM - 2027
Figure 9: SMA Incidence and Prevalence Rates
Figure 10: Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Figure 11: Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Figure 12: Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Figure 13: Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Figure 14: Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Figure 15: Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Figure 16: Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Figure 17: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Figure 18: Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Figure 19: Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Figure 20: Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Figure 21: Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Figure 22: Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Figure 23: Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Figure 24: Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Figure 25: Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Figure 26: Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Figure 27: Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Figure 28: Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Figure 29: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Figure 30: Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Figure 31: Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Figure 32: Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Figure 33: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Figure 34: Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Figure 35: Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Figure 36: Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Figure 37: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Figure 38: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 39: 7MM Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 40: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 41: United States Market Size of SMA in USD Million, (2017-2027)
Figure 42: US Estimated revenue of Marketed and Pipeline Drugs in USD Million (2017-2027)
Figure 43: US Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 44: SMA market in EU5 countries in USD Million, (2017-2027)
Figure 45: EU5 Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 46: EU5 Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 47: Germany Market Size of SMA in USD Million, (2017-2027)
Figure 48: Germany Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 49: Germany Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 50: France Market Size of SMA in USD Million, (2017-2027)
Figure 51: France Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 52: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 53: UK Market Size of SMA in USD Million, (2017-2027)
Figure 54: UK Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 55: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 56: Spain Market Size of SMA in USD Million, (2017-2027)
Figure 57: Spain Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 58: Spain Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 59: Italy Market Size of SMA in USD Million, (2017-2027)
Figure 60: Italy Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 61: Italy Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 62: Japan Market Size of SMA in USD Million (2017-2027)
Figure 63: Japan Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 64: Japan Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)

 

Table 1 Types of SMA linked to Chromosome-5
Table 2 Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Table 3 Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Table 4 Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Table 5 Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Table 6 Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Table 7 Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Table 8 Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Table 9 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Table 10 Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Table 11 Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Table 12 Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Table 13 Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Table 14 Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Table 15 Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Table 16 Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Table 17 Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Table 18 Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Table 19 Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Table 20 Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Table 21 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Table 22 Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Table 23 Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Table 24 Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Table 25 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Table 26 Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Table 27 Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Table 28 Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Table 29  Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Table 30 United States Association Current Recommendations for SMA
Table 31 European Association Current Recommendations for SMA
Table 32 Japanese Association Current Recommendations for SMA
Table 33 List of Marketed Drugs for SMA
Table 34 Market Size of SMA in 7MM (USD Million) (2017-2027)
Table 35 7MM Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 36 7MM Drug-Specific Patient Share of SMA, (2017-2027)
Table 37 United States Market Size of SMA in USD Million, (2017-2027)
Table 38 United States Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 39 United States Drug-Specific Patient Share of SMA, (2017-2027)
Table 40 EU5 Market Size of SMA in USD Million, (2017-2027)
Table 41 EU5 Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 42 EU5 Drug-Specific Patient Share of SMA, (2017-2027)
Table 43 Germany Market Size of SMA in USD Million, (2017-2027)
Table 44 Germany Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 45 Germany Drug-Specific Patient Share of SMA, (2017-2027)
Table 46 France Market Size of SMA in USD Million, (2017-2027)
Table 47 France Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 48 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 49 UK Market Size of SMA in USD Million, (2017-2027)
Table 50 UK Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 51 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 52 Spain Market Size of SMA in USD Million, (2017-2027)
Table 53 Spain Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 54 Spain Drug-Specific Patient Share of SMA, (2017-2027)
Table 55 Italy Market Size of SMA in USD Million, (2017-2027)
Table 56 Italy Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 57 Italy Drug-Specific Patient Share of SMA, (2017-2027)
Table 58 Japan Market Size of SMA in USD Million, (2017-2027)
Table 59 Japan Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 60 Drug-Specific Patient Share of SMA, (2017-2027)

 

Figure 1: Inheritance of SMA in an autosomal recessive pattern
Figure 2: Classification of SMA
Figure 3: Schematic representation of a portion of chromosome 5 that contains two SMN genes
Figure 4: Targets for therapy in SMA
Figure 5: Diagnosis tests in SMA
Figure 6: Diagnostic Evaluation of SMA
Figure 7: Total SMA Cases in 7MM -2017
Figure 8: Total SMA Cases in 7MM - 2027
Figure 9: SMA Incidence and Prevalence Rates
Figure 10: Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Figure 11: Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Figure 12: Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Figure 13: Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Figure 14: Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Figure 15: Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Figure 16: Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Figure 17: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Figure 18: Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Figure 19: Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Figure 20: Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Figure 21: Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Figure 22: Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Figure 23: Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Figure 24: Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Figure 25: Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Figure 26: Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Figure 27: Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Figure 28: Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Figure 29: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Figure 30: Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Figure 31: Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Figure 32: Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Figure 33: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Figure 34: Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Figure 35: Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Figure 36: Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Figure 37: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Figure 38: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 39: 7MM Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 40: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 41: United States Market Size of SMA in USD Million, (2017-2027)
Figure 42: US Estimated revenue of Marketed and Pipeline Drugs in USD Million (2017-2027)
Figure 43: US Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 44: SMA market in EU5 countries in USD Million, (2017-2027)
Figure 45: EU5 Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 46: EU5 Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 47: Germany Market Size of SMA in USD Million, (2017-2027)
Figure 48: Germany Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 49: Germany Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 50: France Market Size of SMA in USD Million, (2017-2027)
Figure 51: France Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 52: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 53: UK Market Size of SMA in USD Million, (2017-2027)
Figure 54: UK Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 55: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 56: Spain Market Size of SMA in USD Million, (2017-2027)
Figure 57: Spain Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 58: Spain Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 59: Italy Market Size of SMA in USD Million, (2017-2027)
Figure 60: Italy Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 61: Italy Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 62: Japan Market Size of SMA in USD Million (2017-2027)
Figure 63: Japan Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 64: Japan Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)

 

Table 1 Types of SMA linked to Chromosome-5
Table 2 Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Table 3 Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Table 4 Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Table 5 Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Table 6 Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Table 7 Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Table 8 Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Table 9 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Table 10 Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Table 11 Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Table 12 Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Table 13 Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Table 14 Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Table 15 Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Table 16 Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Table 17 Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Table 18 Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Table 19 Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Table 20 Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Table 21 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Table 22 Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Table 23 Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Table 24 Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Table 25 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Table 26 Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Table 27 Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Table 28 Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Table 29  Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Table 30 United States Association Current Recommendations for SMA
Table 31 European Association Current Recommendations for SMA
Table 32 Japanese Association Current Recommendations for SMA
Table 33 List of Marketed Drugs for SMA
Table 34 Market Size of SMA in 7MM (USD Million) (2017-2027)
Table 35 7MM Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 36 7MM Drug-Specific Patient Share of SMA, (2017-2027)
Table 37 United States Market Size of SMA in USD Million, (2017-2027)
Table 38 United States Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 39 United States Drug-Specific Patient Share of SMA, (2017-2027)
Table 40 EU5 Market Size of SMA in USD Million, (2017-2027)
Table 41 EU5 Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 42 EU5 Drug-Specific Patient Share of SMA, (2017-2027)
Table 43 Germany Market Size of SMA in USD Million, (2017-2027)
Table 44 Germany Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 45 Germany Drug-Specific Patient Share of SMA, (2017-2027)
Table 46 France Market Size of SMA in USD Million, (2017-2027)
Table 47 France Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 48 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 49 UK Market Size of SMA in USD Million, (2017-2027)
Table 50 UK Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 51 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 52 Spain Market Size of SMA in USD Million, (2017-2027)
Table 53 Spain Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 54 Spain Drug-Specific Patient Share of SMA, (2017-2027)
Table 55 Italy Market Size of SMA in USD Million, (2017-2027)
Table 56 Italy Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 57 Italy Drug-Specific Patient Share of SMA, (2017-2027)
Table 58 Japan Market Size of SMA in USD Million, (2017-2027)
Table 59 Japan Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 60 Drug-Specific Patient Share of SMA, (2017-2027)

 

Figure 1: Inheritance of SMA in an autosomal recessive pattern
Figure 2: Classification of SMA
Figure 3: Schematic representation of a portion of chromosome 5 that contains two SMN genes
Figure 4: Targets for therapy in SMA
Figure 5: Diagnosis tests in SMA
Figure 6: Diagnostic Evaluation of SMA
Figure 7: Total SMA Cases in 7MM -2017
Figure 8: Total SMA Cases in 7MM - 2027
Figure 9: SMA Incidence and Prevalence Rates
Figure 10: Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Figure 11: Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Figure 12: Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Figure 13: Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Figure 14: Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Figure 15: Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Figure 16: Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Figure 17: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Figure 18: Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Figure 19: Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Figure 20: Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Figure 21: Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Figure 22: Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Figure 23: Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Figure 24: Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Figure 25: Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Figure 26: Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Figure 27: Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Figure 28: Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Figure 29: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Figure 30: Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Figure 31: Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Figure 32: Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Figure 33: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Figure 34: Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Figure 35: Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Figure 36: Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Figure 37: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Figure 38: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 39: 7MM Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 40: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 41: United States Market Size of SMA in USD Million, (2017-2027)
Figure 42: US Estimated revenue of Marketed and Pipeline Drugs in USD Million (2017-2027)
Figure 43: US Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 44: SMA market in EU5 countries in USD Million, (2017-2027)
Figure 45: EU5 Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 46: EU5 Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 47: Germany Market Size of SMA in USD Million, (2017-2027)
Figure 48: Germany Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 49: Germany Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 50: France Market Size of SMA in USD Million, (2017-2027)
Figure 51: France Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 52: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 53: UK Market Size of SMA in USD Million, (2017-2027)
Figure 54: UK Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 55: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 56: Spain Market Size of SMA in USD Million, (2017-2027)
Figure 57: Spain Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 58: Spain Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 59: Italy Market Size of SMA in USD Million, (2017-2027)
Figure 60: Italy Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 61: Italy Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 62: Japan Market Size of SMA in USD Million (2017-2027)
Figure 63: Japan Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 64: Japan Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)

 

Table 1 Types of SMA linked to Chromosome-5
Table 2 Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Table 3 Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Table 4 Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Table 5 Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Table 6 Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Table 7 Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Table 8 Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Table 9 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Table 10 Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Table 11 Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Table 12 Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Table 13 Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Table 14 Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Table 15 Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Table 16 Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Table 17 Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Table 18 Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Table 19 Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Table 20 Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Table 21 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Table 22 Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Table 23 Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Table 24 Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Table 25 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Table 26 Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Table 27 Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Table 28 Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Table 29  Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Table 30 United States Association Current Recommendations for SMA
Table 31 European Association Current Recommendations for SMA
Table 32 Japanese Association Current Recommendations for SMA
Table 33 List of Marketed Drugs for SMA
Table 34 Market Size of SMA in 7MM (USD Million) (2017-2027)
Table 35 7MM Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 36 7MM Drug-Specific Patient Share of SMA, (2017-2027)
Table 37 United States Market Size of SMA in USD Million, (2017-2027)
Table 38 United States Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 39 United States Drug-Specific Patient Share of SMA, (2017-2027)
Table 40 EU5 Market Size of SMA in USD Million, (2017-2027)
Table 41 EU5 Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 42 EU5 Drug-Specific Patient Share of SMA, (2017-2027)
Table 43 Germany Market Size of SMA in USD Million, (2017-2027)
Table 44 Germany Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 45 Germany Drug-Specific Patient Share of SMA, (2017-2027)
Table 46 France Market Size of SMA in USD Million, (2017-2027)
Table 47 France Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 48 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 49 UK Market Size of SMA in USD Million, (2017-2027)
Table 50 UK Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 51 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 52 Spain Market Size of SMA in USD Million, (2017-2027)
Table 53 Spain Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 54 Spain Drug-Specific Patient Share of SMA, (2017-2027)
Table 55 Italy Market Size of SMA in USD Million, (2017-2027)
Table 56 Italy Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 57 Italy Drug-Specific Patient Share of SMA, (2017-2027)
Table 58 Japan Market Size of SMA in USD Million, (2017-2027)
Table 59 Japan Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 60 Drug-Specific Patient Share of SMA, (2017-2027)

 

Figure 1: Inheritance of SMA in an autosomal recessive pattern
Figure 2: Classification of SMA
Figure 3: Schematic representation of a portion of chromosome 5 that contains two SMN genes
Figure 4: Targets for therapy in SMA
Figure 5: Diagnosis tests in SMA
Figure 6: Diagnostic Evaluation of SMA
Figure 7: Total SMA Cases in 7MM -2017
Figure 8: Total SMA Cases in 7MM - 2027
Figure 9: SMA Incidence and Prevalence Rates
Figure 10: Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Figure 11: Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Figure 12: Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Figure 13: Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Figure 14: Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Figure 15: Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Figure 16: Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Figure 17: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Figure 18: Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Figure 19: Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Figure 20: Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Figure 21: Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Figure 22: Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Figure 23: Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Figure 24: Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Figure 25: Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Figure 26: Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Figure 27: Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Figure 28: Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Figure 29: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Figure 30: Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Figure 31: Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Figure 32: Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Figure 33: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Figure 34: Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Figure 35: Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Figure 36: Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Figure 37: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Figure 38: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 39: 7MM Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 40: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 41: United States Market Size of SMA in USD Million, (2017-2027)
Figure 42: US Estimated revenue of Marketed and Pipeline Drugs in USD Million (2017-2027)
Figure 43: US Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 44: SMA market in EU5 countries in USD Million, (2017-2027)
Figure 45: EU5 Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 46: EU5 Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 47: Germany Market Size of SMA in USD Million, (2017-2027)
Figure 48: Germany Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 49: Germany Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 50: France Market Size of SMA in USD Million, (2017-2027)
Figure 51: France Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 52: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 53: UK Market Size of SMA in USD Million, (2017-2027)
Figure 54: UK Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 55: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 56: Spain Market Size of SMA in USD Million, (2017-2027)
Figure 57: Spain Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 58: Spain Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 59: Italy Market Size of SMA in USD Million, (2017-2027)
Figure 60: Italy Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 61: Italy Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 62: Japan Market Size of SMA in USD Million (2017-2027)
Figure 63: Japan Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 64: Japan Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)

 

Table 1 Types of SMA linked to Chromosome-5
Table 2 Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Table 3 Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Table 4 Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Table 5 Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Table 6 Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Table 7 Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Table 8 Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Table 9 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Table 10 Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Table 11 Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Table 12 Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Table 13 Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Table 14 Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Table 15 Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Table 16 Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Table 17 Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Table 18 Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Table 19 Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Table 20 Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Table 21 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Table 22 Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Table 23 Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Table 24 Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Table 25 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Table 26 Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Table 27 Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Table 28 Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Table 29  Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Table 30 United States Association Current Recommendations for SMA
Table 31 European Association Current Recommendations for SMA
Table 32 Japanese Association Current Recommendations for SMA
Table 33 List of Marketed Drugs for SMA
Table 34 Market Size of SMA in 7MM (USD Million) (2017-2027)
Table 35 7MM Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 36 7MM Drug-Specific Patient Share of SMA, (2017-2027)
Table 37 United States Market Size of SMA in USD Million, (2017-2027)
Table 38 United States Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 39 United States Drug-Specific Patient Share of SMA, (2017-2027)
Table 40 EU5 Market Size of SMA in USD Million, (2017-2027)
Table 41 EU5 Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 42 EU5 Drug-Specific Patient Share of SMA, (2017-2027)
Table 43 Germany Market Size of SMA in USD Million, (2017-2027)
Table 44 Germany Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 45 Germany Drug-Specific Patient Share of SMA, (2017-2027)
Table 46 France Market Size of SMA in USD Million, (2017-2027)
Table 47 France Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 48 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 49 UK Market Size of SMA in USD Million, (2017-2027)
Table 50 UK Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 51 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 52 Spain Market Size of SMA in USD Million, (2017-2027)
Table 53 Spain Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 54 Spain Drug-Specific Patient Share of SMA, (2017-2027)
Table 55 Italy Market Size of SMA in USD Million, (2017-2027)
Table 56 Italy Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 57 Italy Drug-Specific Patient Share of SMA, (2017-2027)
Table 58 Japan Market Size of SMA in USD Million, (2017-2027)
Table 59 Japan Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 60 Drug-Specific Patient Share of SMA, (2017-2027)

 

Figure 1: Inheritance of SMA in an autosomal recessive pattern
Figure 2: Classification of SMA
Figure 3: Schematic representation of a portion of chromosome 5 that contains two SMN genes
Figure 4: Targets for therapy in SMA
Figure 5: Diagnosis tests in SMA
Figure 6: Diagnostic Evaluation of SMA
Figure 7: Total SMA Cases in 7MM -2017
Figure 8: Total SMA Cases in 7MM - 2027
Figure 9: SMA Incidence and Prevalence Rates
Figure 10: Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Figure 11: Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Figure 12: Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Figure 13: Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Figure 14: Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Figure 15: Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Figure 16: Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Figure 17: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Figure 18: Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Figure 19: Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Figure 20: Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Figure 21: Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Figure 22: Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Figure 23: Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Figure 24: Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Figure 25: Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Figure 26: Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Figure 27: Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Figure 28: Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Figure 29: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Figure 30: Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Figure 31: Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Figure 32: Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Figure 33: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Figure 34: Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Figure 35: Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Figure 36: Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Figure 37: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Figure 38: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 39: 7MM Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 40: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 41: United States Market Size of SMA in USD Million, (2017-2027)
Figure 42: US Estimated revenue of Marketed and Pipeline Drugs in USD Million (2017-2027)
Figure 43: US Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 44: SMA market in EU5 countries in USD Million, (2017-2027)
Figure 45: EU5 Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 46: EU5 Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 47: Germany Market Size of SMA in USD Million, (2017-2027)
Figure 48: Germany Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 49: Germany Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 50: France Market Size of SMA in USD Million, (2017-2027)
Figure 51: France Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 52: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 53: UK Market Size of SMA in USD Million, (2017-2027)
Figure 54: UK Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 55: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 56: Spain Market Size of SMA in USD Million, (2017-2027)
Figure 57: Spain Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 58: Spain Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 59: Italy Market Size of SMA in USD Million, (2017-2027)
Figure 60: Italy Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 61: Italy Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 62: Japan Market Size of SMA in USD Million (2017-2027)
Figure 63: Japan Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 64: Japan Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)

 

Table 1 Types of SMA linked to Chromosome-5
Table 2 Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Table 3 Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Table 4 Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Table 5 Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Table 6 Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Table 7 Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Table 8 Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Table 9 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Table 10 Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Table 11 Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Table 12 Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Table 13 Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Table 14 Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Table 15 Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Table 16 Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Table 17 Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Table 18 Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Table 19 Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Table 20 Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Table 21 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Table 22 Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Table 23 Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Table 24 Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Table 25 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Table 26 Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Table 27 Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Table 28 Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Table 29  Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Table 30 United States Association Current Recommendations for SMA
Table 31 European Association Current Recommendations for SMA
Table 32 Japanese Association Current Recommendations for SMA
Table 33 List of Marketed Drugs for SMA
Table 34 Market Size of SMA in 7MM (USD Million) (2017-2027)
Table 35 7MM Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 36 7MM Drug-Specific Patient Share of SMA, (2017-2027)
Table 37 United States Market Size of SMA in USD Million, (2017-2027)
Table 38 United States Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 39 United States Drug-Specific Patient Share of SMA, (2017-2027)
Table 40 EU5 Market Size of SMA in USD Million, (2017-2027)
Table 41 EU5 Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 42 EU5 Drug-Specific Patient Share of SMA, (2017-2027)
Table 43 Germany Market Size of SMA in USD Million, (2017-2027)
Table 44 Germany Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 45 Germany Drug-Specific Patient Share of SMA, (2017-2027)
Table 46 France Market Size of SMA in USD Million, (2017-2027)
Table 47 France Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 48 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 49 UK Market Size of SMA in USD Million, (2017-2027)
Table 50 UK Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 51 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 52 Spain Market Size of SMA in USD Million, (2017-2027)
Table 53 Spain Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 54 Spain Drug-Specific Patient Share of SMA, (2017-2027)
Table 55 Italy Market Size of SMA in USD Million, (2017-2027)
Table 56 Italy Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 57 Italy Drug-Specific Patient Share of SMA, (2017-2027)
Table 58 Japan Market Size of SMA in USD Million, (2017-2027)
Table 59 Japan Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 60 Drug-Specific Patient Share of SMA, (2017-2027)

 

Figure 1: Inheritance of SMA in an autosomal recessive pattern
Figure 2: Classification of SMA
Figure 3: Schematic representation of a portion of chromosome 5 that contains two SMN genes
Figure 4: Targets for therapy in SMA
Figure 5: Diagnosis tests in SMA
Figure 6: Diagnostic Evaluation of SMA
Figure 7: Total SMA Cases in 7MM -2017
Figure 8: Total SMA Cases in 7MM - 2027
Figure 9: SMA Incidence and Prevalence Rates
Figure 10: Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Figure 11: Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Figure 12: Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Figure 13: Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Figure 14: Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Figure 15: Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Figure 16: Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Figure 17: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Figure 18: Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Figure 19: Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Figure 20: Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Figure 21: Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Figure 22: Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Figure 23: Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Figure 24: Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Figure 25: Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Figure 26: Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Figure 27: Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Figure 28: Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Figure 29: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Figure 30: Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Figure 31: Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Figure 32: Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Figure 33: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Figure 34: Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Figure 35: Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Figure 36: Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Figure 37: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Figure 38: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 39: 7MM Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 40: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 41: United States Market Size of SMA in USD Million, (2017-2027)
Figure 42: US Estimated revenue of Marketed and Pipeline Drugs in USD Million (2017-2027)
Figure 43: US Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 44: SMA market in EU5 countries in USD Million, (2017-2027)
Figure 45: EU5 Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 46: EU5 Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 47: Germany Market Size of SMA in USD Million, (2017-2027)
Figure 48: Germany Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 49: Germany Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 50: France Market Size of SMA in USD Million, (2017-2027)
Figure 51: France Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 52: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 53: UK Market Size of SMA in USD Million, (2017-2027)
Figure 54: UK Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 55: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 56: Spain Market Size of SMA in USD Million, (2017-2027)
Figure 57: Spain Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 58: Spain Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 59: Italy Market Size of SMA in USD Million, (2017-2027)
Figure 60: Italy Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 61: Italy Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 62: Japan Market Size of SMA in USD Million (2017-2027)
Figure 63: Japan Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 64: Japan Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)

 

Table 1 Types of SMA linked to Chromosome-5
Table 2 Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Table 3 Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Table 4 Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Table 5 Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Table 6 Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Table 7 Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Table 8 Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Table 9 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Table 10 Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Table 11 Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Table 12 Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Table 13 Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Table 14 Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Table 15 Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Table 16 Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Table 17 Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Table 18 Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Table 19 Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Table 20 Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Table 21 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Table 22 Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Table 23 Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Table 24 Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Table 25 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Table 26 Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Table 27 Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Table 28 Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Table 29  Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Table 30 United States Association Current Recommendations for SMA
Table 31 European Association Current Recommendations for SMA
Table 32 Japanese Association Current Recommendations for SMA
Table 33 List of Marketed Drugs for SMA
Table 34 Market Size of SMA in 7MM (USD Million) (2017-2027)
Table 35 7MM Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 36 7MM Drug-Specific Patient Share of SMA, (2017-2027)
Table 37 United States Market Size of SMA in USD Million, (2017-2027)
Table 38 United States Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 39 United States Drug-Specific Patient Share of SMA, (2017-2027)
Table 40 EU5 Market Size of SMA in USD Million, (2017-2027)
Table 41 EU5 Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 42 EU5 Drug-Specific Patient Share of SMA, (2017-2027)
Table 43 Germany Market Size of SMA in USD Million, (2017-2027)
Table 44 Germany Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 45 Germany Drug-Specific Patient Share of SMA, (2017-2027)
Table 46 France Market Size of SMA in USD Million, (2017-2027)
Table 47 France Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 48 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 49 UK Market Size of SMA in USD Million, (2017-2027)
Table 50 UK Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 51 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 52 Spain Market Size of SMA in USD Million, (2017-2027)
Table 53 Spain Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 54 Spain Drug-Specific Patient Share of SMA, (2017-2027)
Table 55 Italy Market Size of SMA in USD Million, (2017-2027)
Table 56 Italy Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 57 Italy Drug-Specific Patient Share of SMA, (2017-2027)
Table 58 Japan Market Size of SMA in USD Million, (2017-2027)
Table 59 Japan Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 60 Drug-Specific Patient Share of SMA, (2017-2027)

 

Figure 1: Inheritance of SMA in an autosomal recessive pattern
Figure 2: Classification of SMA
Figure 3: Schematic representation of a portion of chromosome 5 that contains two SMN genes
Figure 4: Targets for therapy in SMA
Figure 5: Diagnosis tests in SMA
Figure 6: Diagnostic Evaluation of SMA
Figure 7: Total SMA Cases in 7MM -2017
Figure 8: Total SMA Cases in 7MM - 2027
Figure 9: SMA Incidence and Prevalence Rates
Figure 10: Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Figure 11: Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Figure 12: Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Figure 13: Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Figure 14: Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Figure 15: Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Figure 16: Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Figure 17: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Figure 18: Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Figure 19: Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Figure 20: Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Figure 21: Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Figure 22: Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Figure 23: Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Figure 24: Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Figure 25: Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Figure 26: Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Figure 27: Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Figure 28: Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Figure 29: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Figure 30: Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Figure 31: Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Figure 32: Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Figure 33: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Figure 34: Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Figure 35: Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Figure 36: Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Figure 37: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Figure 38: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 39: 7MM Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 40: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 41: United States Market Size of SMA in USD Million, (2017-2027)
Figure 42: US Estimated revenue of Marketed and Pipeline Drugs in USD Million (2017-2027)
Figure 43: US Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 44: SMA market in EU5 countries in USD Million, (2017-2027)
Figure 45: EU5 Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 46: EU5 Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 47: Germany Market Size of SMA in USD Million, (2017-2027)
Figure 48: Germany Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 49: Germany Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 50: France Market Size of SMA in USD Million, (2017-2027)
Figure 51: France Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 52: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 53: UK Market Size of SMA in USD Million, (2017-2027)
Figure 54: UK Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 55: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 56: Spain Market Size of SMA in USD Million, (2017-2027)
Figure 57: Spain Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 58: Spain Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 59: Italy Market Size of SMA in USD Million, (2017-2027)
Figure 60: Italy Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 61: Italy Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 62: Japan Market Size of SMA in USD Million (2017-2027)
Figure 63: Japan Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 64: Japan Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)

 

Table 1 Types of SMA linked to Chromosome-5
Table 2 Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Table 3 Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Table 4 Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Table 5 Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Table 6 Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Table 7 Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Table 8 Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Table 9 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Table 10 Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Table 11 Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Table 12 Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Table 13 Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Table 14 Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Table 15 Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Table 16 Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Table 17 Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Table 18 Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Table 19 Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Table 20 Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Table 21 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Table 22 Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Table 23 Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Table 24 Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Table 25 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Table 26 Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Table 27 Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Table 28 Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Table 29  Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Table 30 United States Association Current Recommendations for SMA
Table 31 European Association Current Recommendations for SMA
Table 32 Japanese Association Current Recommendations for SMA
Table 33 List of Marketed Drugs for SMA
Table 34 Market Size of SMA in 7MM (USD Million) (2017-2027)
Table 35 7MM Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 36 7MM Drug-Specific Patient Share of SMA, (2017-2027)
Table 37 United States Market Size of SMA in USD Million, (2017-2027)
Table 38 United States Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 39 United States Drug-Specific Patient Share of SMA, (2017-2027)
Table 40 EU5 Market Size of SMA in USD Million, (2017-2027)
Table 41 EU5 Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 42 EU5 Drug-Specific Patient Share of SMA, (2017-2027)
Table 43 Germany Market Size of SMA in USD Million, (2017-2027)
Table 44 Germany Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 45 Germany Drug-Specific Patient Share of SMA, (2017-2027)
Table 46 France Market Size of SMA in USD Million, (2017-2027)
Table 47 France Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 48 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 49 UK Market Size of SMA in USD Million, (2017-2027)
Table 50 UK Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 51 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 52 Spain Market Size of SMA in USD Million, (2017-2027)
Table 53 Spain Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 54 Spain Drug-Specific Patient Share of SMA, (2017-2027)
Table 55 Italy Market Size of SMA in USD Million, (2017-2027)
Table 56 Italy Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 57 Italy Drug-Specific Patient Share of SMA, (2017-2027)
Table 58 Japan Market Size of SMA in USD Million, (2017-2027)
Table 59 Japan Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 60 Drug-Specific Patient Share of SMA, (2017-2027)

 

Figure 1: Inheritance of SMA in an autosomal recessive pattern
Figure 2: Classification of SMA
Figure 3: Schematic representation of a portion of chromosome 5 that contains two SMN genes
Figure 4: Targets for therapy in SMA
Figure 5: Diagnosis tests in SMA
Figure 6: Diagnostic Evaluation of SMA
Figure 7: Total SMA Cases in 7MM -2017
Figure 8: Total SMA Cases in 7MM - 2027
Figure 9: SMA Incidence and Prevalence Rates
Figure 10: Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Figure 11: Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Figure 12: Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Figure 13: Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Figure 14: Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Figure 15: Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Figure 16: Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Figure 17: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Figure 18: Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Figure 19: Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Figure 20: Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Figure 21: Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Figure 22: Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Figure 23: Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Figure 24: Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Figure 25: Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Figure 26: Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Figure 27: Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Figure 28: Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Figure 29: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Figure 30: Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Figure 31: Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Figure 32: Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Figure 33: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Figure 34: Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Figure 35: Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Figure 36: Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Figure 37: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Figure 38: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 39: 7MM Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 40: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 41: United States Market Size of SMA in USD Million, (2017-2027)
Figure 42: US Estimated revenue of Marketed and Pipeline Drugs in USD Million (2017-2027)
Figure 43: US Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 44: SMA market in EU5 countries in USD Million, (2017-2027)
Figure 45: EU5 Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 46: EU5 Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 47: Germany Market Size of SMA in USD Million, (2017-2027)
Figure 48: Germany Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 49: Germany Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 50: France Market Size of SMA in USD Million, (2017-2027)
Figure 51: France Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 52: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 53: UK Market Size of SMA in USD Million, (2017-2027)
Figure 54: UK Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 55: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 56: Spain Market Size of SMA in USD Million, (2017-2027)
Figure 57: Spain Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 58: Spain Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 59: Italy Market Size of SMA in USD Million, (2017-2027)
Figure 60: Italy Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 61: Italy Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 62: Japan Market Size of SMA in USD Million (2017-2027)
Figure 63: Japan Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 64: Japan Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)

 

Table 1 Types of SMA linked to Chromosome-5
Table 2 Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Table 3 Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Table 4 Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Table 5 Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Table 6 Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Table 7 Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Table 8 Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Table 9 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Table 10 Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Table 11 Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Table 12 Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Table 13 Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Table 14 Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Table 15 Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Table 16 Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Table 17 Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Table 18 Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Table 19 Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Table 20 Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Table 21 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Table 22 Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Table 23 Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Table 24 Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Table 25 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Table 26 Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Table 27 Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Table 28 Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Table 29  Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Table 30 United States Association Current Recommendations for SMA
Table 31 European Association Current Recommendations for SMA
Table 32 Japanese Association Current Recommendations for SMA
Table 33 List of Marketed Drugs for SMA
Table 34 Market Size of SMA in 7MM (USD Million) (2017-2027)
Table 35 7MM Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 36 7MM Drug-Specific Patient Share of SMA, (2017-2027)
Table 37 United States Market Size of SMA in USD Million, (2017-2027)
Table 38 United States Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 39 United States Drug-Specific Patient Share of SMA, (2017-2027)
Table 40 EU5 Market Size of SMA in USD Million, (2017-2027)
Table 41 EU5 Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 42 EU5 Drug-Specific Patient Share of SMA, (2017-2027)
Table 43 Germany Market Size of SMA in USD Million, (2017-2027)
Table 44 Germany Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 45 Germany Drug-Specific Patient Share of SMA, (2017-2027)
Table 46 France Market Size of SMA in USD Million, (2017-2027)
Table 47 France Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 48 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 49 UK Market Size of SMA in USD Million, (2017-2027)
Table 50 UK Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 51 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 52 Spain Market Size of SMA in USD Million, (2017-2027)
Table 53 Spain Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 54 Spain Drug-Specific Patient Share of SMA, (2017-2027)
Table 55 Italy Market Size of SMA in USD Million, (2017-2027)
Table 56 Italy Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 57 Italy Drug-Specific Patient Share of SMA, (2017-2027)
Table 58 Japan Market Size of SMA in USD Million, (2017-2027)
Table 59 Japan Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 60 Drug-Specific Patient Share of SMA, (2017-2027)

 

Figure 1: Inheritance of SMA in an autosomal recessive pattern
Figure 2: Classification of SMA
Figure 3: Schematic representation of a portion of chromosome 5 that contains two SMN genes
Figure 4: Targets for therapy in SMA
Figure 5: Diagnosis tests in SMA
Figure 6: Diagnostic Evaluation of SMA
Figure 7: Total SMA Cases in 7MM -2017
Figure 8: Total SMA Cases in 7MM - 2027
Figure 9: SMA Incidence and Prevalence Rates
Figure 10: Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Figure 11: Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Figure 12: Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Figure 13: Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Figure 14: Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Figure 15: Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Figure 16: Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Figure 17: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Figure 18: Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Figure 19: Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Figure 20: Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Figure 21: Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Figure 22: Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Figure 23: Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Figure 24: Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Figure 25: Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Figure 26: Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Figure 27: Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Figure 28: Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Figure 29: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Figure 30: Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Figure 31: Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Figure 32: Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Figure 33: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Figure 34: Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Figure 35: Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Figure 36: Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Figure 37: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Figure 38: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 39: 7MM Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 40: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 41: United States Market Size of SMA in USD Million, (2017-2027)
Figure 42: US Estimated revenue of Marketed and Pipeline Drugs in USD Million (2017-2027)
Figure 43: US Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 44: SMA market in EU5 countries in USD Million, (2017-2027)
Figure 45: EU5 Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 46: EU5 Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 47: Germany Market Size of SMA in USD Million, (2017-2027)
Figure 48: Germany Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 49: Germany Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 50: France Market Size of SMA in USD Million, (2017-2027)
Figure 51: France Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 52: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 53: UK Market Size of SMA in USD Million, (2017-2027)
Figure 54: UK Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 55: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 56: Spain Market Size of SMA in USD Million, (2017-2027)
Figure 57: Spain Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 58: Spain Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 59: Italy Market Size of SMA in USD Million, (2017-2027)
Figure 60: Italy Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 61: Italy Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 62: Japan Market Size of SMA in USD Million (2017-2027)
Figure 63: Japan Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 64: Japan Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)

 

Table 1 Types of SMA linked to Chromosome-5
Table 2 Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Table 3 Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Table 4 Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Table 5 Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Table 6 Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Table 7 Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Table 8 Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Table 9 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Table 10 Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Table 11 Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Table 12 Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Table 13 Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Table 14 Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Table 15 Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Table 16 Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Table 17 Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Table 18 Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Table 19 Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Table 20 Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Table 21 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Table 22 Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Table 23 Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Table 24 Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Table 25 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Table 26 Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Table 27 Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Table 28 Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Table 29  Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Table 30 United States Association Current Recommendations for SMA
Table 31 European Association Current Recommendations for SMA
Table 32 Japanese Association Current Recommendations for SMA
Table 33 List of Marketed Drugs for SMA
Table 34 Market Size of SMA in 7MM (USD Million) (2017-2027)
Table 35 7MM Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 36 7MM Drug-Specific Patient Share of SMA, (2017-2027)
Table 37 United States Market Size of SMA in USD Million, (2017-2027)
Table 38 United States Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 39 United States Drug-Specific Patient Share of SMA, (2017-2027)
Table 40 EU5 Market Size of SMA in USD Million, (2017-2027)
Table 41 EU5 Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 42 EU5 Drug-Specific Patient Share of SMA, (2017-2027)
Table 43 Germany Market Size of SMA in USD Million, (2017-2027)
Table 44 Germany Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 45 Germany Drug-Specific Patient Share of SMA, (2017-2027)
Table 46 France Market Size of SMA in USD Million, (2017-2027)
Table 47 France Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 48 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 49 UK Market Size of SMA in USD Million, (2017-2027)
Table 50 UK Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 51 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 52 Spain Market Size of SMA in USD Million, (2017-2027)
Table 53 Spain Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 54 Spain Drug-Specific Patient Share of SMA, (2017-2027)
Table 55 Italy Market Size of SMA in USD Million, (2017-2027)
Table 56 Italy Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 57 Italy Drug-Specific Patient Share of SMA, (2017-2027)
Table 58 Japan Market Size of SMA in USD Million, (2017-2027)
Table 59 Japan Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 60 Drug-Specific Patient Share of SMA, (2017-2027)

 

Figure 1: Inheritance of SMA in an autosomal recessive pattern
Figure 2: Classification of SMA
Figure 3: Schematic representation of a portion of chromosome 5 that contains two SMN genes
Figure 4: Targets for therapy in SMA
Figure 5: Diagnosis tests in SMA
Figure 6: Diagnostic Evaluation of SMA
Figure 7: Total SMA Cases in 7MM -2017
Figure 8: Total SMA Cases in 7MM - 2027
Figure 9: SMA Incidence and Prevalence Rates
Figure 10: Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Figure 11: Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Figure 12: Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Figure 13: Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Figure 14: Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Figure 15: Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Figure 16: Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Figure 17: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Figure 18: Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Figure 19: Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Figure 20: Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Figure 21: Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Figure 22: Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Figure 23: Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Figure 24: Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Figure 25: Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Figure 26: Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Figure 27: Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Figure 28: Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Figure 29: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Figure 30: Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Figure 31: Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Figure 32: Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Figure 33: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Figure 34: Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Figure 35: Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Figure 36: Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Figure 37: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Figure 38: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 39: 7MM Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 40: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 41: United States Market Size of SMA in USD Million, (2017-2027)
Figure 42: US Estimated revenue of Marketed and Pipeline Drugs in USD Million (2017-2027)
Figure 43: US Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 44: SMA market in EU5 countries in USD Million, (2017-2027)
Figure 45: EU5 Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 46: EU5 Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 47: Germany Market Size of SMA in USD Million, (2017-2027)
Figure 48: Germany Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 49: Germany Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 50: France Market Size of SMA in USD Million, (2017-2027)
Figure 51: France Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 52: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 53: UK Market Size of SMA in USD Million, (2017-2027)
Figure 54: UK Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 55: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 56: Spain Market Size of SMA in USD Million, (2017-2027)
Figure 57: Spain Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 58: Spain Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 59: Italy Market Size of SMA in USD Million, (2017-2027)
Figure 60: Italy Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 61: Italy Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 62: Japan Market Size of SMA in USD Million (2017-2027)
Figure 63: Japan Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 64: Japan Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)

 

Table 1 Types of SMA linked to Chromosome-5
Table 2 Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Table 3 Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Table 4 Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Table 5 Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Table 6 Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Table 7 Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Table 8 Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Table 9 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Table 10 Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Table 11 Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Table 12 Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Table 13 Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Table 14 Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Table 15 Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Table 16 Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Table 17 Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Table 18 Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Table 19 Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Table 20 Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Table 21 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Table 22 Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Table 23 Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Table 24 Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Table 25 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Table 26 Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Table 27 Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Table 28 Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Table 29  Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Table 30 United States Association Current Recommendations for SMA
Table 31 European Association Current Recommendations for SMA
Table 32 Japanese Association Current Recommendations for SMA
Table 33 List of Marketed Drugs for SMA
Table 34 Market Size of SMA in 7MM (USD Million) (2017-2027)
Table 35 7MM Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 36 7MM Drug-Specific Patient Share of SMA, (2017-2027)
Table 37 United States Market Size of SMA in USD Million, (2017-2027)
Table 38 United States Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 39 United States Drug-Specific Patient Share of SMA, (2017-2027)
Table 40 EU5 Market Size of SMA in USD Million, (2017-2027)
Table 41 EU5 Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 42 EU5 Drug-Specific Patient Share of SMA, (2017-2027)
Table 43 Germany Market Size of SMA in USD Million, (2017-2027)
Table 44 Germany Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 45 Germany Drug-Specific Patient Share of SMA, (2017-2027)
Table 46 France Market Size of SMA in USD Million, (2017-2027)
Table 47 France Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 48 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 49 UK Market Size of SMA in USD Million, (2017-2027)
Table 50 UK Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 51 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 52 Spain Market Size of SMA in USD Million, (2017-2027)
Table 53 Spain Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 54 Spain Drug-Specific Patient Share of SMA, (2017-2027)
Table 55 Italy Market Size of SMA in USD Million, (2017-2027)
Table 56 Italy Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 57 Italy Drug-Specific Patient Share of SMA, (2017-2027)
Table 58 Japan Market Size of SMA in USD Million, (2017-2027)
Table 59 Japan Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 60 Drug-Specific Patient Share of SMA, (2017-2027)

 

Figure 1: Inheritance of SMA in an autosomal recessive pattern
Figure 2: Classification of SMA
Figure 3: Schematic representation of a portion of chromosome 5 that contains two SMN genes
Figure 4: Targets for therapy in SMA
Figure 5: Diagnosis tests in SMA
Figure 6: Diagnostic Evaluation of SMA
Figure 7: Total SMA Cases in 7MM -2017
Figure 8: Total SMA Cases in 7MM - 2027
Figure 9: SMA Incidence and Prevalence Rates
Figure 10: Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Figure 11: Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Figure 12: Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Figure 13: Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Figure 14: Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Figure 15: Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Figure 16: Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Figure 17: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Figure 18: Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Figure 19: Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Figure 20: Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Figure 21: Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Figure 22: Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Figure 23: Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Figure 24: Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Figure 25: Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Figure 26: Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Figure 27: Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Figure 28: Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Figure 29: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Figure 30: Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Figure 31: Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Figure 32: Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Figure 33: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Figure 34: Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Figure 35: Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Figure 36: Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Figure 37: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Figure 38: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 39: 7MM Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 40: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 41: United States Market Size of SMA in USD Million, (2017-2027)
Figure 42: US Estimated revenue of Marketed and Pipeline Drugs in USD Million (2017-2027)
Figure 43: US Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 44: SMA market in EU5 countries in USD Million, (2017-2027)
Figure 45: EU5 Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 46: EU5 Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 47: Germany Market Size of SMA in USD Million, (2017-2027)
Figure 48: Germany Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 49: Germany Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 50: France Market Size of SMA in USD Million, (2017-2027)
Figure 51: France Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 52: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 53: UK Market Size of SMA in USD Million, (2017-2027)
Figure 54: UK Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 55: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 56: Spain Market Size of SMA in USD Million, (2017-2027)
Figure 57: Spain Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 58: Spain Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 59: Italy Market Size of SMA in USD Million, (2017-2027)
Figure 60: Italy Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 61: Italy Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 62: Japan Market Size of SMA in USD Million (2017-2027)
Figure 63: Japan Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 64: Japan Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)

 

Table 1 Types of SMA linked to Chromosome-5
Table 2 Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Table 3 Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Table 4 Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Table 5 Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Table 6 Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Table 7 Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Table 8 Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Table 9 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Table 10 Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Table 11 Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Table 12 Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Table 13 Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Table 14 Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Table 15 Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Table 16 Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Table 17 Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Table 18 Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Table 19 Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Table 20 Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Table 21 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Table 22 Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Table 23 Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Table 24 Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Table 25 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Table 26 Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Table 27 Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Table 28 Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Table 29  Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Table 30 United States Association Current Recommendations for SMA
Table 31 European Association Current Recommendations for SMA
Table 32 Japanese Association Current Recommendations for SMA
Table 33 List of Marketed Drugs for SMA
Table 34 Market Size of SMA in 7MM (USD Million) (2017-2027)
Table 35 7MM Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 36 7MM Drug-Specific Patient Share of SMA, (2017-2027)
Table 37 United States Market Size of SMA in USD Million, (2017-2027)
Table 38 United States Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 39 United States Drug-Specific Patient Share of SMA, (2017-2027)
Table 40 EU5 Market Size of SMA in USD Million, (2017-2027)
Table 41 EU5 Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 42 EU5 Drug-Specific Patient Share of SMA, (2017-2027)
Table 43 Germany Market Size of SMA in USD Million, (2017-2027)
Table 44 Germany Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 45 Germany Drug-Specific Patient Share of SMA, (2017-2027)
Table 46 France Market Size of SMA in USD Million, (2017-2027)
Table 47 France Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 48 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 49 UK Market Size of SMA in USD Million, (2017-2027)
Table 50 UK Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 51 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 52 Spain Market Size of SMA in USD Million, (2017-2027)
Table 53 Spain Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 54 Spain Drug-Specific Patient Share of SMA, (2017-2027)
Table 55 Italy Market Size of SMA in USD Million, (2017-2027)
Table 56 Italy Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 57 Italy Drug-Specific Patient Share of SMA, (2017-2027)
Table 58 Japan Market Size of SMA in USD Million, (2017-2027)
Table 59 Japan Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 60 Drug-Specific Patient Share of SMA, (2017-2027)

 

Figure 1: Inheritance of SMA in an autosomal recessive pattern
Figure 2: Classification of SMA
Figure 3: Schematic representation of a portion of chromosome 5 that contains two SMN genes
Figure 4: Targets for therapy in SMA
Figure 5: Diagnosis tests in SMA
Figure 6: Diagnostic Evaluation of SMA
Figure 7: Total SMA Cases in 7MM -2017
Figure 8: Total SMA Cases in 7MM - 2027
Figure 9: SMA Incidence and Prevalence Rates
Figure 10: Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Figure 11: Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Figure 12: Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Figure 13: Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Figure 14: Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Figure 15: Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Figure 16: Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Figure 17: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Figure 18: Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Figure 19: Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Figure 20: Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Figure 21: Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Figure 22: Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Figure 23: Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Figure 24: Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Figure 25: Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Figure 26: Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Figure 27: Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Figure 28: Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Figure 29: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Figure 30: Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Figure 31: Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Figure 32: Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Figure 33: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Figure 34: Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Figure 35: Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Figure 36: Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Figure 37: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Figure 38: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 39: 7MM Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 40: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 41: United States Market Size of SMA in USD Million, (2017-2027)
Figure 42: US Estimated revenue of Marketed and Pipeline Drugs in USD Million (2017-2027)
Figure 43: US Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 44: SMA market in EU5 countries in USD Million, (2017-2027)
Figure 45: EU5 Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 46: EU5 Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 47: Germany Market Size of SMA in USD Million, (2017-2027)
Figure 48: Germany Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 49: Germany Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 50: France Market Size of SMA in USD Million, (2017-2027)
Figure 51: France Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 52: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 53: UK Market Size of SMA in USD Million, (2017-2027)
Figure 54: UK Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 55: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 56: Spain Market Size of SMA in USD Million, (2017-2027)
Figure 57: Spain Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 58: Spain Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 59: Italy Market Size of SMA in USD Million, (2017-2027)
Figure 60: Italy Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 61: Italy Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 62: Japan Market Size of SMA in USD Million (2017-2027)
Figure 63: Japan Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 64: Japan Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)

 

Table 1 Types of SMA linked to Chromosome-5
Table 2 Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Table 3 Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Table 4 Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Table 5 Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Table 6 Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Table 7 Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Table 8 Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Table 9 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Table 10 Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Table 11 Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Table 12 Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Table 13 Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Table 14 Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Table 15 Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Table 16 Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Table 17 Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Table 18 Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Table 19 Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Table 20 Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Table 21 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Table 22 Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Table 23 Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Table 24 Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Table 25 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Table 26 Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Table 27 Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Table 28 Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Table 29  Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Table 30 United States Association Current Recommendations for SMA
Table 31 European Association Current Recommendations for SMA
Table 32 Japanese Association Current Recommendations for SMA
Table 33 List of Marketed Drugs for SMA
Table 34 Market Size of SMA in 7MM (USD Million) (2017-2027)
Table 35 7MM Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 36 7MM Drug-Specific Patient Share of SMA, (2017-2027)
Table 37 United States Market Size of SMA in USD Million, (2017-2027)
Table 38 United States Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 39 United States Drug-Specific Patient Share of SMA, (2017-2027)
Table 40 EU5 Market Size of SMA in USD Million, (2017-2027)
Table 41 EU5 Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 42 EU5 Drug-Specific Patient Share of SMA, (2017-2027)
Table 43 Germany Market Size of SMA in USD Million, (2017-2027)
Table 44 Germany Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 45 Germany Drug-Specific Patient Share of SMA, (2017-2027)
Table 46 France Market Size of SMA in USD Million, (2017-2027)
Table 47 France Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 48 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 49 UK Market Size of SMA in USD Million, (2017-2027)
Table 50 UK Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 51 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 52 Spain Market Size of SMA in USD Million, (2017-2027)
Table 53 Spain Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 54 Spain Drug-Specific Patient Share of SMA, (2017-2027)
Table 55 Italy Market Size of SMA in USD Million, (2017-2027)
Table 56 Italy Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 57 Italy Drug-Specific Patient Share of SMA, (2017-2027)
Table 58 Japan Market Size of SMA in USD Million, (2017-2027)
Table 59 Japan Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 60 Drug-Specific Patient Share of SMA, (2017-2027)

 

Figure 1: Inheritance of SMA in an autosomal recessive pattern
Figure 2: Classification of SMA
Figure 3: Schematic representation of a portion of chromosome 5 that contains two SMN genes
Figure 4: Targets for therapy in SMA
Figure 5: Diagnosis tests in SMA
Figure 6: Diagnostic Evaluation of SMA
Figure 7: Total SMA Cases in 7MM -2017
Figure 8: Total SMA Cases in 7MM - 2027
Figure 9: SMA Incidence and Prevalence Rates
Figure 10: Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Figure 11: Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Figure 12: Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Figure 13: Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Figure 14: Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Figure 15: Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Figure 16: Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Figure 17: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Figure 18: Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Figure 19: Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Figure 20: Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Figure 21: Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Figure 22: Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Figure 23: Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Figure 24: Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Figure 25: Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Figure 26: Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Figure 27: Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Figure 28: Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Figure 29: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Figure 30: Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Figure 31: Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Figure 32: Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Figure 33: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Figure 34: Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Figure 35: Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Figure 36: Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Figure 37: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Figure 38: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 39: 7MM Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 40: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 41: United States Market Size of SMA in USD Million, (2017-2027)
Figure 42: US Estimated revenue of Marketed and Pipeline Drugs in USD Million (2017-2027)
Figure 43: US Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 44: SMA market in EU5 countries in USD Million, (2017-2027)
Figure 45: EU5 Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 46: EU5 Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 47: Germany Market Size of SMA in USD Million, (2017-2027)
Figure 48: Germany Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 49: Germany Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 50: France Market Size of SMA in USD Million, (2017-2027)
Figure 51: France Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 52: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 53: UK Market Size of SMA in USD Million, (2017-2027)
Figure 54: UK Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 55: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 56: Spain Market Size of SMA in USD Million, (2017-2027)
Figure 57: Spain Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 58: Spain Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 59: Italy Market Size of SMA in USD Million, (2017-2027)
Figure 60: Italy Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 61: Italy Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 62: Japan Market Size of SMA in USD Million (2017-2027)
Figure 63: Japan Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 64: Japan Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)

 

Table 1 Types of SMA linked to Chromosome-5
Table 2 Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Table 3 Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Table 4 Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Table 5 Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Table 6 Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Table 7 Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Table 8 Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Table 9 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Table 10 Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Table 11 Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Table 12 Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Table 13 Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Table 14 Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Table 15 Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Table 16 Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Table 17 Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Table 18 Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Table 19 Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Table 20 Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Table 21 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Table 22 Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Table 23 Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Table 24 Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Table 25 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Table 26 Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Table 27 Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Table 28 Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Table 29  Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Table 30 United States Association Current Recommendations for SMA
Table 31 European Association Current Recommendations for SMA
Table 32 Japanese Association Current Recommendations for SMA
Table 33 List of Marketed Drugs for SMA
Table 34 Market Size of SMA in 7MM (USD Million) (2017-2027)
Table 35 7MM Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 36 7MM Drug-Specific Patient Share of SMA, (2017-2027)
Table 37 United States Market Size of SMA in USD Million, (2017-2027)
Table 38 United States Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 39 United States Drug-Specific Patient Share of SMA, (2017-2027)
Table 40 EU5 Market Size of SMA in USD Million, (2017-2027)
Table 41 EU5 Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 42 EU5 Drug-Specific Patient Share of SMA, (2017-2027)
Table 43 Germany Market Size of SMA in USD Million, (2017-2027)
Table 44 Germany Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 45 Germany Drug-Specific Patient Share of SMA, (2017-2027)
Table 46 France Market Size of SMA in USD Million, (2017-2027)
Table 47 France Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 48 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 49 UK Market Size of SMA in USD Million, (2017-2027)
Table 50 UK Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 51 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 52 Spain Market Size of SMA in USD Million, (2017-2027)
Table 53 Spain Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 54 Spain Drug-Specific Patient Share of SMA, (2017-2027)
Table 55 Italy Market Size of SMA in USD Million, (2017-2027)
Table 56 Italy Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 57 Italy Drug-Specific Patient Share of SMA, (2017-2027)
Table 58 Japan Market Size of SMA in USD Million, (2017-2027)
Table 59 Japan Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 60 Drug-Specific Patient Share of SMA, (2017-2027)

 

Figure 1: Inheritance of SMA in an autosomal recessive pattern
Figure 2: Classification of SMA
Figure 3: Schematic representation of a portion of chromosome 5 that contains two SMN genes
Figure 4: Targets for therapy in SMA
Figure 5: Diagnosis tests in SMA
Figure 6: Diagnostic Evaluation of SMA
Figure 7: Total SMA Cases in 7MM -2017
Figure 8: Total SMA Cases in 7MM - 2027
Figure 9: SMA Incidence and Prevalence Rates
Figure 10: Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Figure 11: Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Figure 12: Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Figure 13: Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Figure 14: Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Figure 15: Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Figure 16: Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Figure 17: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Figure 18: Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Figure 19: Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Figure 20: Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Figure 21: Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Figure 22: Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Figure 23: Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Figure 24: Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Figure 25: Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Figure 26: Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Figure 27: Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Figure 28: Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Figure 29: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Figure 30: Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Figure 31: Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Figure 32: Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Figure 33: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Figure 34: Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Figure 35: Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Figure 36: Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Figure 37: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Figure 38: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 39: 7MM Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 40: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 41: United States Market Size of SMA in USD Million, (2017-2027)
Figure 42: US Estimated revenue of Marketed and Pipeline Drugs in USD Million (2017-2027)
Figure 43: US Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 44: SMA market in EU5 countries in USD Million, (2017-2027)
Figure 45: EU5 Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 46: EU5 Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 47: Germany Market Size of SMA in USD Million, (2017-2027)
Figure 48: Germany Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 49: Germany Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 50: France Market Size of SMA in USD Million, (2017-2027)
Figure 51: France Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 52: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 53: UK Market Size of SMA in USD Million, (2017-2027)
Figure 54: UK Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 55: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 56: Spain Market Size of SMA in USD Million, (2017-2027)
Figure 57: Spain Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 58: Spain Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 59: Italy Market Size of SMA in USD Million, (2017-2027)
Figure 60: Italy Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 61: Italy Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 62: Japan Market Size of SMA in USD Million (2017-2027)
Figure 63: Japan Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 64: Japan Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)

 

Table 1 Types of SMA linked to Chromosome-5
Table 2 Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Table 3 Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Table 4 Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Table 5 Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Table 6 Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Table 7 Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Table 8 Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Table 9 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Table 10 Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Table 11 Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Table 12 Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Table 13 Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Table 14 Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Table 15 Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Table 16 Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Table 17 Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Table 18 Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Table 19 Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Table 20 Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Table 21 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Table 22 Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Table 23 Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Table 24 Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Table 25 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Table 26 Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Table 27 Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Table 28 Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Table 29  Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Table 30 United States Association Current Recommendations for SMA
Table 31 European Association Current Recommendations for SMA
Table 32 Japanese Association Current Recommendations for SMA
Table 33 List of Marketed Drugs for SMA
Table 34 Market Size of SMA in 7MM (USD Million) (2017-2027)
Table 35 7MM Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 36 7MM Drug-Specific Patient Share of SMA, (2017-2027)
Table 37 United States Market Size of SMA in USD Million, (2017-2027)
Table 38 United States Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 39 United States Drug-Specific Patient Share of SMA, (2017-2027)
Table 40 EU5 Market Size of SMA in USD Million, (2017-2027)
Table 41 EU5 Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 42 EU5 Drug-Specific Patient Share of SMA, (2017-2027)
Table 43 Germany Market Size of SMA in USD Million, (2017-2027)
Table 44 Germany Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 45 Germany Drug-Specific Patient Share of SMA, (2017-2027)
Table 46 France Market Size of SMA in USD Million, (2017-2027)
Table 47 France Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 48 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 49 UK Market Size of SMA in USD Million, (2017-2027)
Table 50 UK Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 51 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 52 Spain Market Size of SMA in USD Million, (2017-2027)
Table 53 Spain Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 54 Spain Drug-Specific Patient Share of SMA, (2017-2027)
Table 55 Italy Market Size of SMA in USD Million, (2017-2027)
Table 56 Italy Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 57 Italy Drug-Specific Patient Share of SMA, (2017-2027)
Table 58 Japan Market Size of SMA in USD Million, (2017-2027)
Table 59 Japan Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 60 Drug-Specific Patient Share of SMA, (2017-2027)

 

Figure 1: Inheritance of SMA in an autosomal recessive pattern
Figure 2: Classification of SMA
Figure 3: Schematic representation of a portion of chromosome 5 that contains two SMN genes
Figure 4: Targets for therapy in SMA
Figure 5: Diagnosis tests in SMA
Figure 6: Diagnostic Evaluation of SMA
Figure 7: Total SMA Cases in 7MM -2017
Figure 8: Total SMA Cases in 7MM - 2027
Figure 9: SMA Incidence and Prevalence Rates
Figure 10: Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Figure 11: Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Figure 12: Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Figure 13: Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Figure 14: Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Figure 15: Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Figure 16: Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Figure 17: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Figure 18: Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Figure 19: Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Figure 20: Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Figure 21: Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Figure 22: Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Figure 23: Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Figure 24: Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Figure 25: Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Figure 26: Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Figure 27: Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Figure 28: Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Figure 29: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Figure 30: Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Figure 31: Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Figure 32: Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Figure 33: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Figure 34: Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Figure 35: Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Figure 36: Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Figure 37: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Figure 38: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 39: 7MM Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 40: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 41: United States Market Size of SMA in USD Million, (2017-2027)
Figure 42: US Estimated revenue of Marketed and Pipeline Drugs in USD Million (2017-2027)
Figure 43: US Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 44: SMA market in EU5 countries in USD Million, (2017-2027)
Figure 45: EU5 Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 46: EU5 Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 47: Germany Market Size of SMA in USD Million, (2017-2027)
Figure 48: Germany Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 49: Germany Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 50: France Market Size of SMA in USD Million, (2017-2027)
Figure 51: France Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 52: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 53: UK Market Size of SMA in USD Million, (2017-2027)
Figure 54: UK Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 55: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 56: Spain Market Size of SMA in USD Million, (2017-2027)
Figure 57: Spain Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 58: Spain Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 59: Italy Market Size of SMA in USD Million, (2017-2027)
Figure 60: Italy Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 61: Italy Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 62: Japan Market Size of SMA in USD Million (2017-2027)
Figure 63: Japan Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 64: Japan Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)

 

Table 1 Types of SMA linked to Chromosome-5
Table 2 Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Table 3 Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Table 4 Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Table 5 Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Table 6 Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Table 7 Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Table 8 Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Table 9 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Table 10 Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Table 11 Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Table 12 Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Table 13 Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Table 14 Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Table 15 Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Table 16 Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Table 17 Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Table 18 Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Table 19 Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Table 20 Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Table 21 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Table 22 Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Table 23 Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Table 24 Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Table 25 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Table 26 Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Table 27 Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Table 28 Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Table 29  Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Table 30 United States Association Current Recommendations for SMA
Table 31 European Association Current Recommendations for SMA
Table 32 Japanese Association Current Recommendations for SMA
Table 33 List of Marketed Drugs for SMA
Table 34 Market Size of SMA in 7MM (USD Million) (2017-2027)
Table 35 7MM Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 36 7MM Drug-Specific Patient Share of SMA, (2017-2027)
Table 37 United States Market Size of SMA in USD Million, (2017-2027)
Table 38 United States Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 39 United States Drug-Specific Patient Share of SMA, (2017-2027)
Table 40 EU5 Market Size of SMA in USD Million, (2017-2027)
Table 41 EU5 Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 42 EU5 Drug-Specific Patient Share of SMA, (2017-2027)
Table 43 Germany Market Size of SMA in USD Million, (2017-2027)
Table 44 Germany Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 45 Germany Drug-Specific Patient Share of SMA, (2017-2027)
Table 46 France Market Size of SMA in USD Million, (2017-2027)
Table 47 France Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 48 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 49 UK Market Size of SMA in USD Million, (2017-2027)
Table 50 UK Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 51 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 52 Spain Market Size of SMA in USD Million, (2017-2027)
Table 53 Spain Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 54 Spain Drug-Specific Patient Share of SMA, (2017-2027)
Table 55 Italy Market Size of SMA in USD Million, (2017-2027)
Table 56 Italy Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 57 Italy Drug-Specific Patient Share of SMA, (2017-2027)
Table 58 Japan Market Size of SMA in USD Million, (2017-2027)
Table 59 Japan Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 60 Drug-Specific Patient Share of SMA, (2017-2027)

 

Figure 1: Inheritance of SMA in an autosomal recessive pattern
Figure 2: Classification of SMA
Figure 3: Schematic representation of a portion of chromosome 5 that contains two SMN genes
Figure 4: Targets for therapy in SMA
Figure 5: Diagnosis tests in SMA
Figure 6: Diagnostic Evaluation of SMA
Figure 7: Total SMA Cases in 7MM -2017
Figure 8: Total SMA Cases in 7MM - 2027
Figure 9: SMA Incidence and Prevalence Rates
Figure 10: Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Figure 11: Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Figure 12: Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Figure 13: Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Figure 14: Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Figure 15: Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Figure 16: Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Figure 17: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Figure 18: Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Figure 19: Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Figure 20: Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Figure 21: Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Figure 22: Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Figure 23: Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Figure 24: Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Figure 25: Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Figure 26: Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Figure 27: Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Figure 28: Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Figure 29: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Figure 30: Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Figure 31: Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Figure 32: Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Figure 33: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Figure 34: Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Figure 35: Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Figure 36: Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Figure 37: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Figure 38: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 39: 7MM Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 40: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 41: United States Market Size of SMA in USD Million, (2017-2027)
Figure 42: US Estimated revenue of Marketed and Pipeline Drugs in USD Million (2017-2027)
Figure 43: US Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 44: SMA market in EU5 countries in USD Million, (2017-2027)
Figure 45: EU5 Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 46: EU5 Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 47: Germany Market Size of SMA in USD Million, (2017-2027)
Figure 48: Germany Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 49: Germany Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 50: France Market Size of SMA in USD Million, (2017-2027)
Figure 51: France Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 52: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 53: UK Market Size of SMA in USD Million, (2017-2027)
Figure 54: UK Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 55: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 56: Spain Market Size of SMA in USD Million, (2017-2027)
Figure 57: Spain Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 58: Spain Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 59: Italy Market Size of SMA in USD Million, (2017-2027)
Figure 60: Italy Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 61: Italy Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 62: Japan Market Size of SMA in USD Million (2017-2027)
Figure 63: Japan Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 64: Japan Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)

 

Table 1 Types of SMA linked to Chromosome-5
Table 2 Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Table 3 Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Table 4 Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Table 5 Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Table 6 Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Table 7 Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Table 8 Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Table 9 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Table 10 Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Table 11 Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Table 12 Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Table 13 Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Table 14 Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Table 15 Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Table 16 Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Table 17 Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Table 18 Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Table 19 Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Table 20 Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Table 21 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Table 22 Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Table 23 Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Table 24 Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Table 25 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Table 26 Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Table 27 Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Table 28 Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Table 29  Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Table 30 United States Association Current Recommendations for SMA
Table 31 European Association Current Recommendations for SMA
Table 32 Japanese Association Current Recommendations for SMA
Table 33 List of Marketed Drugs for SMA
Table 34 Market Size of SMA in 7MM (USD Million) (2017-2027)
Table 35 7MM Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 36 7MM Drug-Specific Patient Share of SMA, (2017-2027)
Table 37 United States Market Size of SMA in USD Million, (2017-2027)
Table 38 United States Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 39 United States Drug-Specific Patient Share of SMA, (2017-2027)
Table 40 EU5 Market Size of SMA in USD Million, (2017-2027)
Table 41 EU5 Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 42 EU5 Drug-Specific Patient Share of SMA, (2017-2027)
Table 43 Germany Market Size of SMA in USD Million, (2017-2027)
Table 44 Germany Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 45 Germany Drug-Specific Patient Share of SMA, (2017-2027)
Table 46 France Market Size of SMA in USD Million, (2017-2027)
Table 47 France Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 48 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 49 UK Market Size of SMA in USD Million, (2017-2027)
Table 50 UK Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 51 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 52 Spain Market Size of SMA in USD Million, (2017-2027)
Table 53 Spain Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 54 Spain Drug-Specific Patient Share of SMA, (2017-2027)
Table 55 Italy Market Size of SMA in USD Million, (2017-2027)
Table 56 Italy Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 57 Italy Drug-Specific Patient Share of SMA, (2017-2027)
Table 58 Japan Market Size of SMA in USD Million, (2017-2027)
Table 59 Japan Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 60 Drug-Specific Patient Share of SMA, (2017-2027)

 

Figure 1: Inheritance of SMA in an autosomal recessive pattern
Figure 2: Classification of SMA
Figure 3: Schematic representation of a portion of chromosome 5 that contains two SMN genes
Figure 4: Targets for therapy in SMA
Figure 5: Diagnosis tests in SMA
Figure 6: Diagnostic Evaluation of SMA
Figure 7: Total SMA Cases in 7MM -2017
Figure 8: Total SMA Cases in 7MM - 2027
Figure 9: SMA Incidence and Prevalence Rates
Figure 10: Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Figure 11: Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Figure 12: Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Figure 13: Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Figure 14: Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Figure 15: Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Figure 16: Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Figure 17: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Figure 18: Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Figure 19: Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Figure 20: Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Figure 21: Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Figure 22: Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Figure 23: Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Figure 24: Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Figure 25: Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Figure 26: Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Figure 27: Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Figure 28: Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Figure 29: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Figure 30: Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Figure 31: Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Figure 32: Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Figure 33: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Figure 34: Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Figure 35: Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Figure 36: Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Figure 37: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Figure 38: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 39: 7MM Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 40: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 41: United States Market Size of SMA in USD Million, (2017-2027)
Figure 42: US Estimated revenue of Marketed and Pipeline Drugs in USD Million (2017-2027)
Figure 43: US Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 44: SMA market in EU5 countries in USD Million, (2017-2027)
Figure 45: EU5 Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 46: EU5 Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 47: Germany Market Size of SMA in USD Million, (2017-2027)
Figure 48: Germany Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 49: Germany Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 50: France Market Size of SMA in USD Million, (2017-2027)
Figure 51: France Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 52: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 53: UK Market Size of SMA in USD Million, (2017-2027)
Figure 54: UK Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 55: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 56: Spain Market Size of SMA in USD Million, (2017-2027)
Figure 57: Spain Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 58: Spain Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 59: Italy Market Size of SMA in USD Million, (2017-2027)
Figure 60: Italy Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 61: Italy Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 62: Japan Market Size of SMA in USD Million (2017-2027)
Figure 63: Japan Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 64: Japan Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)

 

Table 1 Types of SMA linked to Chromosome-5
Table 2 Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Table 3 Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Table 4 Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Table 5 Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Table 6 Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Table 7 Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Table 8 Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Table 9 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Table 10 Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Table 11 Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Table 12 Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Table 13 Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Table 14 Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Table 15 Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Table 16 Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Table 17 Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Table 18 Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Table 19 Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Table 20 Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Table 21 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Table 22 Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Table 23 Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Table 24 Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Table 25 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Table 26 Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Table 27 Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Table 28 Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Table 29  Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Table 30 United States Association Current Recommendations for SMA
Table 31 European Association Current Recommendations for SMA
Table 32 Japanese Association Current Recommendations for SMA
Table 33 List of Marketed Drugs for SMA
Table 34 Market Size of SMA in 7MM (USD Million) (2017-2027)
Table 35 7MM Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 36 7MM Drug-Specific Patient Share of SMA, (2017-2027)
Table 37 United States Market Size of SMA in USD Million, (2017-2027)
Table 38 United States Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 39 United States Drug-Specific Patient Share of SMA, (2017-2027)
Table 40 EU5 Market Size of SMA in USD Million, (2017-2027)
Table 41 EU5 Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 42 EU5 Drug-Specific Patient Share of SMA, (2017-2027)
Table 43 Germany Market Size of SMA in USD Million, (2017-2027)
Table 44 Germany Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 45 Germany Drug-Specific Patient Share of SMA, (2017-2027)
Table 46 France Market Size of SMA in USD Million, (2017-2027)
Table 47 France Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 48 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 49 UK Market Size of SMA in USD Million, (2017-2027)
Table 50 UK Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 51 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 52 Spain Market Size of SMA in USD Million, (2017-2027)
Table 53 Spain Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 54 Spain Drug-Specific Patient Share of SMA, (2017-2027)
Table 55 Italy Market Size of SMA in USD Million, (2017-2027)
Table 56 Italy Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 57 Italy Drug-Specific Patient Share of SMA, (2017-2027)
Table 58 Japan Market Size of SMA in USD Million, (2017-2027)
Table 59 Japan Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 60 Drug-Specific Patient Share of SMA, (2017-2027)

 

Figure 1: Inheritance of SMA in an autosomal recessive pattern
Figure 2: Classification of SMA
Figure 3: Schematic representation of a portion of chromosome 5 that contains two SMN genes
Figure 4: Targets for therapy in SMA
Figure 5: Diagnosis tests in SMA
Figure 6: Diagnostic Evaluation of SMA
Figure 7: Total SMA Cases in 7MM -2017
Figure 8: Total SMA Cases in 7MM - 2027
Figure 9: SMA Incidence and Prevalence Rates
Figure 10: Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Figure 11: Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Figure 12: Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Figure 13: Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Figure 14: Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Figure 15: Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Figure 16: Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Figure 17: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Figure 18: Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Figure 19: Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Figure 20: Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Figure 21: Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Figure 22: Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Figure 23: Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Figure 24: Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Figure 25: Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Figure 26: Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Figure 27: Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Figure 28: Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Figure 29: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Figure 30: Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Figure 31: Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Figure 32: Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Figure 33: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Figure 34: Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Figure 35: Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Figure 36: Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Figure 37: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Figure 38: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 39: 7MM Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 40: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 41: United States Market Size of SMA in USD Million, (2017-2027)
Figure 42: US Estimated revenue of Marketed and Pipeline Drugs in USD Million (2017-2027)
Figure 43: US Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 44: SMA market in EU5 countries in USD Million, (2017-2027)
Figure 45: EU5 Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 46: EU5 Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 47: Germany Market Size of SMA in USD Million, (2017-2027)
Figure 48: Germany Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 49: Germany Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 50: France Market Size of SMA in USD Million, (2017-2027)
Figure 51: France Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 52: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 53: UK Market Size of SMA in USD Million, (2017-2027)
Figure 54: UK Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 55: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 56: Spain Market Size of SMA in USD Million, (2017-2027)
Figure 57: Spain Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 58: Spain Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 59: Italy Market Size of SMA in USD Million, (2017-2027)
Figure 60: Italy Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 61: Italy Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 62: Japan Market Size of SMA in USD Million (2017-2027)
Figure 63: Japan Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 64: Japan Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)

 

Table 1 Types of SMA linked to Chromosome-5
Table 2 Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Table 3 Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Table 4 Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Table 5 Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Table 6 Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Table 7 Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Table 8 Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Table 9 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Table 10 Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Table 11 Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Table 12 Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Table 13 Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Table 14 Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Table 15 Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Table 16 Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Table 17 Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Table 18 Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Table 19 Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Table 20 Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Table 21 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Table 22 Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Table 23 Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Table 24 Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Table 25 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Table 26 Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Table 27 Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Table 28 Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Table 29  Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Table 30 United States Association Current Recommendations for SMA
Table 31 European Association Current Recommendations for SMA
Table 32 Japanese Association Current Recommendations for SMA
Table 33 List of Marketed Drugs for SMA
Table 34 Market Size of SMA in 7MM (USD Million) (2017-2027)
Table 35 7MM Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 36 7MM Drug-Specific Patient Share of SMA, (2017-2027)
Table 37 United States Market Size of SMA in USD Million, (2017-2027)
Table 38 United States Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 39 United States Drug-Specific Patient Share of SMA, (2017-2027)
Table 40 EU5 Market Size of SMA in USD Million, (2017-2027)
Table 41 EU5 Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 42 EU5 Drug-Specific Patient Share of SMA, (2017-2027)
Table 43 Germany Market Size of SMA in USD Million, (2017-2027)
Table 44 Germany Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 45 Germany Drug-Specific Patient Share of SMA, (2017-2027)
Table 46 France Market Size of SMA in USD Million, (2017-2027)
Table 47 France Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 48 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 49 UK Market Size of SMA in USD Million, (2017-2027)
Table 50 UK Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 51 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 52 Spain Market Size of SMA in USD Million, (2017-2027)
Table 53 Spain Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 54 Spain Drug-Specific Patient Share of SMA, (2017-2027)
Table 55 Italy Market Size of SMA in USD Million, (2017-2027)
Table 56 Italy Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 57 Italy Drug-Specific Patient Share of SMA, (2017-2027)
Table 58 Japan Market Size of SMA in USD Million, (2017-2027)
Table 59 Japan Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 60 Drug-Specific Patient Share of SMA, (2017-2027)

 

Figure 1: Inheritance of SMA in an autosomal recessive pattern
Figure 2: Classification of SMA
Figure 3: Schematic representation of a portion of chromosome 5 that contains two SMN genes
Figure 4: Targets for therapy in SMA
Figure 5: Diagnosis tests in SMA
Figure 6: Diagnostic Evaluation of SMA
Figure 7: Total SMA Cases in 7MM -2017
Figure 8: Total SMA Cases in 7MM - 2027
Figure 9: SMA Incidence and Prevalence Rates
Figure 10: Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Figure 11: Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Figure 12: Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Figure 13: Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Figure 14: Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Figure 15: Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Figure 16: Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Figure 17: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Figure 18: Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Figure 19: Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Figure 20: Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Figure 21: Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Figure 22: Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Figure 23: Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Figure 24: Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Figure 25: Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Figure 26: Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Figure 27: Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Figure 28: Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Figure 29: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Figure 30: Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Figure 31: Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Figure 32: Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Figure 33: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Figure 34: Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Figure 35: Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Figure 36: Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Figure 37: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Figure 38: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 39: 7MM Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 40: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 41: United States Market Size of SMA in USD Million, (2017-2027)
Figure 42: US Estimated revenue of Marketed and Pipeline Drugs in USD Million (2017-2027)
Figure 43: US Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 44: SMA market in EU5 countries in USD Million, (2017-2027)
Figure 45: EU5 Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 46: EU5 Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 47: Germany Market Size of SMA in USD Million, (2017-2027)
Figure 48: Germany Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 49: Germany Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 50: France Market Size of SMA in USD Million, (2017-2027)
Figure 51: France Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 52: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 53: UK Market Size of SMA in USD Million, (2017-2027)
Figure 54: UK Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 55: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 56: Spain Market Size of SMA in USD Million, (2017-2027)
Figure 57: Spain Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 58: Spain Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 59: Italy Market Size of SMA in USD Million, (2017-2027)
Figure 60: Italy Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 61: Italy Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 62: Japan Market Size of SMA in USD Million (2017-2027)
Figure 63: Japan Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 64: Japan Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)

 

Table 1 Types of SMA linked to Chromosome-5
Table 2 Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Table 3 Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Table 4 Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Table 5 Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Table 6 Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Table 7 Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Table 8 Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Table 9 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Table 10 Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Table 11 Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Table 12 Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Table 13 Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Table 14 Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Table 15 Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Table 16 Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Table 17 Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Table 18 Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Table 19 Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Table 20 Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Table 21 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Table 22 Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Table 23 Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Table 24 Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Table 25 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Table 26 Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Table 27 Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Table 28 Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Table 29  Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Table 30 United States Association Current Recommendations for SMA
Table 31 European Association Current Recommendations for SMA
Table 32 Japanese Association Current Recommendations for SMA
Table 33 List of Marketed Drugs for SMA
Table 34 Market Size of SMA in 7MM (USD Million) (2017-2027)
Table 35 7MM Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 36 7MM Drug-Specific Patient Share of SMA, (2017-2027)
Table 37 United States Market Size of SMA in USD Million, (2017-2027)
Table 38 United States Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 39 United States Drug-Specific Patient Share of SMA, (2017-2027)
Table 40 EU5 Market Size of SMA in USD Million, (2017-2027)
Table 41 EU5 Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 42 EU5 Drug-Specific Patient Share of SMA, (2017-2027)
Table 43 Germany Market Size of SMA in USD Million, (2017-2027)
Table 44 Germany Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 45 Germany Drug-Specific Patient Share of SMA, (2017-2027)
Table 46 France Market Size of SMA in USD Million, (2017-2027)
Table 47 France Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 48 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 49 UK Market Size of SMA in USD Million, (2017-2027)
Table 50 UK Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 51 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 52 Spain Market Size of SMA in USD Million, (2017-2027)
Table 53 Spain Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 54 Spain Drug-Specific Patient Share of SMA, (2017-2027)
Table 55 Italy Market Size of SMA in USD Million, (2017-2027)
Table 56 Italy Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 57 Italy Drug-Specific Patient Share of SMA, (2017-2027)
Table 58 Japan Market Size of SMA in USD Million, (2017-2027)
Table 59 Japan Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 60 Drug-Specific Patient Share of SMA, (2017-2027)

 

Figure 1: Inheritance of SMA in an autosomal recessive pattern
Figure 2: Classification of SMA
Figure 3: Schematic representation of a portion of chromosome 5 that contains two SMN genes
Figure 4: Targets for therapy in SMA
Figure 5: Diagnosis tests in SMA
Figure 6: Diagnostic Evaluation of SMA
Figure 7: Total SMA Cases in 7MM -2017
Figure 8: Total SMA Cases in 7MM - 2027
Figure 9: SMA Incidence and Prevalence Rates
Figure 10: Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Figure 11: Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Figure 12: Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Figure 13: Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Figure 14: Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Figure 15: Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Figure 16: Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Figure 17: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Figure 18: Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Figure 19: Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Figure 20: Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Figure 21: Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Figure 22: Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Figure 23: Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Figure 24: Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Figure 25: Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Figure 26: Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Figure 27: Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Figure 28: Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Figure 29: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Figure 30: Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Figure 31: Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Figure 32: Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Figure 33: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Figure 34: Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Figure 35: Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Figure 36: Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Figure 37: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Figure 38: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 39: 7MM Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 40: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 41: United States Market Size of SMA in USD Million, (2017-2027)
Figure 42: US Estimated revenue of Marketed and Pipeline Drugs in USD Million (2017-2027)
Figure 43: US Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 44: SMA market in EU5 countries in USD Million, (2017-2027)
Figure 45: EU5 Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 46: EU5 Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 47: Germany Market Size of SMA in USD Million, (2017-2027)
Figure 48: Germany Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 49: Germany Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 50: France Market Size of SMA in USD Million, (2017-2027)
Figure 51: France Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 52: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 53: UK Market Size of SMA in USD Million, (2017-2027)
Figure 54: UK Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 55: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 56: Spain Market Size of SMA in USD Million, (2017-2027)
Figure 57: Spain Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 58: Spain Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 59: Italy Market Size of SMA in USD Million, (2017-2027)
Figure 60: Italy Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 61: Italy Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 62: Japan Market Size of SMA in USD Million (2017-2027)
Figure 63: Japan Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 64: Japan Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)

 

Table 1 Types of SMA linked to Chromosome-5
Table 2 Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Table 3 Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Table 4 Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Table 5 Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Table 6 Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Table 7 Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Table 8 Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Table 9 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Table 10 Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Table 11 Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Table 12 Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Table 13 Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Table 14 Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Table 15 Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Table 16 Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Table 17 Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Table 18 Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Table 19 Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Table 20 Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Table 21 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Table 22 Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Table 23 Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Table 24 Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Table 25 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Table 26 Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Table 27 Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Table 28 Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Table 29  Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Table 30 United States Association Current Recommendations for SMA
Table 31 European Association Current Recommendations for SMA
Table 32 Japanese Association Current Recommendations for SMA
Table 33 List of Marketed Drugs for SMA
Table 34 Market Size of SMA in 7MM (USD Million) (2017-2027)
Table 35 7MM Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 36 7MM Drug-Specific Patient Share of SMA, (2017-2027)
Table 37 United States Market Size of SMA in USD Million, (2017-2027)
Table 38 United States Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 39 United States Drug-Specific Patient Share of SMA, (2017-2027)
Table 40 EU5 Market Size of SMA in USD Million, (2017-2027)
Table 41 EU5 Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 42 EU5 Drug-Specific Patient Share of SMA, (2017-2027)
Table 43 Germany Market Size of SMA in USD Million, (2017-2027)
Table 44 Germany Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 45 Germany Drug-Specific Patient Share of SMA, (2017-2027)
Table 46 France Market Size of SMA in USD Million, (2017-2027)
Table 47 France Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 48 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 49 UK Market Size of SMA in USD Million, (2017-2027)
Table 50 UK Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 51 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 52 Spain Market Size of SMA in USD Million, (2017-2027)
Table 53 Spain Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 54 Spain Drug-Specific Patient Share of SMA, (2017-2027)
Table 55 Italy Market Size of SMA in USD Million, (2017-2027)
Table 56 Italy Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 57 Italy Drug-Specific Patient Share of SMA, (2017-2027)
Table 58 Japan Market Size of SMA in USD Million, (2017-2027)
Table 59 Japan Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 60 Drug-Specific Patient Share of SMA, (2017-2027)

 

Figure 1: Inheritance of SMA in an autosomal recessive pattern
Figure 2: Classification of SMA
Figure 3: Schematic representation of a portion of chromosome 5 that contains two SMN genes
Figure 4: Targets for therapy in SMA
Figure 5: Diagnosis tests in SMA
Figure 6: Diagnostic Evaluation of SMA
Figure 7: Total SMA Cases in 7MM -2017
Figure 8: Total SMA Cases in 7MM - 2027
Figure 9: SMA Incidence and Prevalence Rates
Figure 10: Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Figure 11: Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Figure 12: Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Figure 13: Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Figure 14: Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Figure 15: Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Figure 16: Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Figure 17: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Figure 18: Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Figure 19: Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Figure 20: Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Figure 21: Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Figure 22: Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Figure 23: Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Figure 24: Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Figure 25: Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Figure 26: Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Figure 27: Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Figure 28: Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Figure 29: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Figure 30: Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Figure 31: Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Figure 32: Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Figure 33: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Figure 34: Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Figure 35: Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Figure 36: Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Figure 37: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Figure 38: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 39: 7MM Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 40: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 41: United States Market Size of SMA in USD Million, (2017-2027)
Figure 42: US Estimated revenue of Marketed and Pipeline Drugs in USD Million (2017-2027)
Figure 43: US Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 44: SMA market in EU5 countries in USD Million, (2017-2027)
Figure 45: EU5 Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 46: EU5 Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 47: Germany Market Size of SMA in USD Million, (2017-2027)
Figure 48: Germany Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 49: Germany Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 50: France Market Size of SMA in USD Million, (2017-2027)
Figure 51: France Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 52: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 53: UK Market Size of SMA in USD Million, (2017-2027)
Figure 54: UK Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 55: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 56: Spain Market Size of SMA in USD Million, (2017-2027)
Figure 57: Spain Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 58: Spain Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 59: Italy Market Size of SMA in USD Million, (2017-2027)
Figure 60: Italy Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 61: Italy Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 62: Japan Market Size of SMA in USD Million (2017-2027)
Figure 63: Japan Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 64: Japan Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)

 

Table 1 Types of SMA linked to Chromosome-5
Table 2 Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Table 3 Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Table 4 Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Table 5 Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Table 6 Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Table 7 Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Table 8 Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Table 9 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Table 10 Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Table 11 Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Table 12 Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Table 13 Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Table 14 Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Table 15 Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Table 16 Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Table 17 Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Table 18 Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Table 19 Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Table 20 Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Table 21 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Table 22 Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Table 23 Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Table 24 Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Table 25 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Table 26 Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Table 27 Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Table 28 Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Table 29  Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Table 30 United States Association Current Recommendations for SMA
Table 31 European Association Current Recommendations for SMA
Table 32 Japanese Association Current Recommendations for SMA
Table 33 List of Marketed Drugs for SMA
Table 34 Market Size of SMA in 7MM (USD Million) (2017-2027)
Table 35 7MM Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 36 7MM Drug-Specific Patient Share of SMA, (2017-2027)
Table 37 United States Market Size of SMA in USD Million, (2017-2027)
Table 38 United States Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 39 United States Drug-Specific Patient Share of SMA, (2017-2027)
Table 40 EU5 Market Size of SMA in USD Million, (2017-2027)
Table 41 EU5 Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 42 EU5 Drug-Specific Patient Share of SMA, (2017-2027)
Table 43 Germany Market Size of SMA in USD Million, (2017-2027)
Table 44 Germany Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 45 Germany Drug-Specific Patient Share of SMA, (2017-2027)
Table 46 France Market Size of SMA in USD Million, (2017-2027)
Table 47 France Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 48 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 49 UK Market Size of SMA in USD Million, (2017-2027)
Table 50 UK Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 51 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 52 Spain Market Size of SMA in USD Million, (2017-2027)
Table 53 Spain Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 54 Spain Drug-Specific Patient Share of SMA, (2017-2027)
Table 55 Italy Market Size of SMA in USD Million, (2017-2027)
Table 56 Italy Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 57 Italy Drug-Specific Patient Share of SMA, (2017-2027)
Table 58 Japan Market Size of SMA in USD Million, (2017-2027)
Table 59 Japan Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 60 Drug-Specific Patient Share of SMA, (2017-2027)

 

Figure 1: Inheritance of SMA in an autosomal recessive pattern
Figure 2: Classification of SMA
Figure 3: Schematic representation of a portion of chromosome 5 that contains two SMN genes
Figure 4: Targets for therapy in SMA
Figure 5: Diagnosis tests in SMA
Figure 6: Diagnostic Evaluation of SMA
Figure 7: Total SMA Cases in 7MM -2017
Figure 8: Total SMA Cases in 7MM - 2027
Figure 9: SMA Incidence and Prevalence Rates
Figure 10: Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Figure 11: Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Figure 12: Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Figure 13: Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Figure 14: Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Figure 15: Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Figure 16: Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Figure 17: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Figure 18: Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Figure 19: Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Figure 20: Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Figure 21: Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Figure 22: Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Figure 23: Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Figure 24: Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Figure 25: Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Figure 26: Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Figure 27: Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Figure 28: Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Figure 29: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Figure 30: Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Figure 31: Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Figure 32: Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Figure 33: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Figure 34: Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Figure 35: Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Figure 36: Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Figure 37: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Figure 38: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 39: 7MM Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 40: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 41: United States Market Size of SMA in USD Million, (2017-2027)
Figure 42: US Estimated revenue of Marketed and Pipeline Drugs in USD Million (2017-2027)
Figure 43: US Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 44: SMA market in EU5 countries in USD Million, (2017-2027)
Figure 45: EU5 Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 46: EU5 Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 47: Germany Market Size of SMA in USD Million, (2017-2027)
Figure 48: Germany Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 49: Germany Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 50: France Market Size of SMA in USD Million, (2017-2027)
Figure 51: France Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 52: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 53: UK Market Size of SMA in USD Million, (2017-2027)
Figure 54: UK Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 55: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 56: Spain Market Size of SMA in USD Million, (2017-2027)
Figure 57: Spain Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 58: Spain Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 59: Italy Market Size of SMA in USD Million, (2017-2027)
Figure 60: Italy Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 61: Italy Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 62: Japan Market Size of SMA in USD Million (2017-2027)
Figure 63: Japan Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 64: Japan Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)

 

Table 1 Types of SMA linked to Chromosome-5
Table 2 Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Table 3 Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Table 4 Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Table 5 Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Table 6 Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Table 7 Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Table 8 Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Table 9 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Table 10 Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Table 11 Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Table 12 Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Table 13 Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Table 14 Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Table 15 Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Table 16 Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Table 17 Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Table 18 Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Table 19 Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Table 20 Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Table 21 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Table 22 Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Table 23 Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Table 24 Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Table 25 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Table 26 Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Table 27 Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Table 28 Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Table 29  Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Table 30 United States Association Current Recommendations for SMA
Table 31 European Association Current Recommendations for SMA
Table 32 Japanese Association Current Recommendations for SMA
Table 33 List of Marketed Drugs for SMA
Table 34 Market Size of SMA in 7MM (USD Million) (2017-2027)
Table 35 7MM Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 36 7MM Drug-Specific Patient Share of SMA, (2017-2027)
Table 37 United States Market Size of SMA in USD Million, (2017-2027)
Table 38 United States Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 39 United States Drug-Specific Patient Share of SMA, (2017-2027)
Table 40 EU5 Market Size of SMA in USD Million, (2017-2027)
Table 41 EU5 Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 42 EU5 Drug-Specific Patient Share of SMA, (2017-2027)
Table 43 Germany Market Size of SMA in USD Million, (2017-2027)
Table 44 Germany Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 45 Germany Drug-Specific Patient Share of SMA, (2017-2027)
Table 46 France Market Size of SMA in USD Million, (2017-2027)
Table 47 France Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 48 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 49 UK Market Size of SMA in USD Million, (2017-2027)
Table 50 UK Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 51 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 52 Spain Market Size of SMA in USD Million, (2017-2027)
Table 53 Spain Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 54 Spain Drug-Specific Patient Share of SMA, (2017-2027)
Table 55 Italy Market Size of SMA in USD Million, (2017-2027)
Table 56 Italy Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 57 Italy Drug-Specific Patient Share of SMA, (2017-2027)
Table 58 Japan Market Size of SMA in USD Million, (2017-2027)
Table 59 Japan Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 60 Drug-Specific Patient Share of SMA, (2017-2027)

 

Figure 1: Inheritance of SMA in an autosomal recessive pattern
Figure 2: Classification of SMA
Figure 3: Schematic representation of a portion of chromosome 5 that contains two SMN genes
Figure 4: Targets for therapy in SMA
Figure 5: Diagnosis tests in SMA
Figure 6: Diagnostic Evaluation of SMA
Figure 7: Total SMA Cases in 7MM -2017
Figure 8: Total SMA Cases in 7MM - 2027
Figure 9: SMA Incidence and Prevalence Rates
Figure 10: Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Figure 11: Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Figure 12: Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Figure 13: Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Figure 14: Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Figure 15: Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Figure 16: Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Figure 17: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Figure 18: Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Figure 19: Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Figure 20: Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Figure 21: Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Figure 22: Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Figure 23: Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Figure 24: Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Figure 25: Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Figure 26: Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Figure 27: Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Figure 28: Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Figure 29: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Figure 30: Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Figure 31: Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Figure 32: Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Figure 33: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Figure 34: Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Figure 35: Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Figure 36: Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Figure 37: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Figure 38: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 39: 7MM Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 40: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 41: United States Market Size of SMA in USD Million, (2017-2027)
Figure 42: US Estimated revenue of Marketed and Pipeline Drugs in USD Million (2017-2027)
Figure 43: US Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 44: SMA market in EU5 countries in USD Million, (2017-2027)
Figure 45: EU5 Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 46: EU5 Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 47: Germany Market Size of SMA in USD Million, (2017-2027)
Figure 48: Germany Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 49: Germany Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 50: France Market Size of SMA in USD Million, (2017-2027)
Figure 51: France Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 52: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 53: UK Market Size of SMA in USD Million, (2017-2027)
Figure 54: UK Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 55: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 56: Spain Market Size of SMA in USD Million, (2017-2027)
Figure 57: Spain Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 58: Spain Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 59: Italy Market Size of SMA in USD Million, (2017-2027)
Figure 60: Italy Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 61: Italy Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 62: Japan Market Size of SMA in USD Million (2017-2027)
Figure 63: Japan Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 64: Japan Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)

 

Table 1 Types of SMA linked to Chromosome-5
Table 2 Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Table 3 Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Table 4 Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Table 5 Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Table 6 Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Table 7 Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Table 8 Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Table 9 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Table 10 Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Table 11 Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Table 12 Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Table 13 Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Table 14 Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Table 15 Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Table 16 Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Table 17 Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Table 18 Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Table 19 Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Table 20 Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Table 21 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Table 22 Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Table 23 Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Table 24 Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Table 25 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Table 26 Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Table 27 Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Table 28 Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Table 29  Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Table 30 United States Association Current Recommendations for SMA
Table 31 European Association Current Recommendations for SMA
Table 32 Japanese Association Current Recommendations for SMA
Table 33 List of Marketed Drugs for SMA
Table 34 Market Size of SMA in 7MM (USD Million) (2017-2027)
Table 35 7MM Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 36 7MM Drug-Specific Patient Share of SMA, (2017-2027)
Table 37 United States Market Size of SMA in USD Million, (2017-2027)
Table 38 United States Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 39 United States Drug-Specific Patient Share of SMA, (2017-2027)
Table 40 EU5 Market Size of SMA in USD Million, (2017-2027)
Table 41 EU5 Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 42 EU5 Drug-Specific Patient Share of SMA, (2017-2027)
Table 43 Germany Market Size of SMA in USD Million, (2017-2027)
Table 44 Germany Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 45 Germany Drug-Specific Patient Share of SMA, (2017-2027)
Table 46 France Market Size of SMA in USD Million, (2017-2027)
Table 47 France Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 48 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 49 UK Market Size of SMA in USD Million, (2017-2027)
Table 50 UK Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 51 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 52 Spain Market Size of SMA in USD Million, (2017-2027)
Table 53 Spain Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 54 Spain Drug-Specific Patient Share of SMA, (2017-2027)
Table 55 Italy Market Size of SMA in USD Million, (2017-2027)
Table 56 Italy Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 57 Italy Drug-Specific Patient Share of SMA, (2017-2027)
Table 58 Japan Market Size of SMA in USD Million, (2017-2027)
Table 59 Japan Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 60 Drug-Specific Patient Share of SMA, (2017-2027)

 

Figure 1: Inheritance of SMA in an autosomal recessive pattern
Figure 2: Classification of SMA
Figure 3: Schematic representation of a portion of chromosome 5 that contains two SMN genes
Figure 4: Targets for therapy in SMA
Figure 5: Diagnosis tests in SMA
Figure 6: Diagnostic Evaluation of SMA
Figure 7: Total SMA Cases in 7MM -2017
Figure 8: Total SMA Cases in 7MM - 2027
Figure 9: SMA Incidence and Prevalence Rates
Figure 10: Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Figure 11: Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Figure 12: Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Figure 13: Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Figure 14: Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Figure 15: Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Figure 16: Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Figure 17: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Figure 18: Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Figure 19: Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Figure 20: Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Figure 21: Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Figure 22: Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Figure 23: Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Figure 24: Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Figure 25: Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Figure 26: Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Figure 27: Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Figure 28: Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Figure 29: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Figure 30: Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Figure 31: Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Figure 32: Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Figure 33: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Figure 34: Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Figure 35: Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Figure 36: Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Figure 37: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Figure 38: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 39: 7MM Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 40: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 41: United States Market Size of SMA in USD Million, (2017-2027)
Figure 42: US Estimated revenue of Marketed and Pipeline Drugs in USD Million (2017-2027)
Figure 43: US Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 44: SMA market in EU5 countries in USD Million, (2017-2027)
Figure 45: EU5 Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 46: EU5 Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 47: Germany Market Size of SMA in USD Million, (2017-2027)
Figure 48: Germany Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 49: Germany Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 50: France Market Size of SMA in USD Million, (2017-2027)
Figure 51: France Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 52: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 53: UK Market Size of SMA in USD Million, (2017-2027)
Figure 54: UK Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 55: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 56: Spain Market Size of SMA in USD Million, (2017-2027)
Figure 57: Spain Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 58: Spain Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 59: Italy Market Size of SMA in USD Million, (2017-2027)
Figure 60: Italy Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 61: Italy Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 62: Japan Market Size of SMA in USD Million (2017-2027)
Figure 63: Japan Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 64: Japan Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)

 

Table 1 Types of SMA linked to Chromosome-5
Table 2 Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Table 3 Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Table 4 Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Table 5 Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Table 6 Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Table 7 Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Table 8 Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Table 9 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Table 10 Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Table 11 Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Table 12 Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Table 13 Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Table 14 Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Table 15 Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Table 16 Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Table 17 Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Table 18 Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Table 19 Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Table 20 Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Table 21 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Table 22 Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Table 23 Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Table 24 Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Table 25 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Table 26 Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Table 27 Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Table 28 Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Table 29  Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Table 30 United States Association Current Recommendations for SMA
Table 31 European Association Current Recommendations for SMA
Table 32 Japanese Association Current Recommendations for SMA
Table 33 List of Marketed Drugs for SMA
Table 34 Market Size of SMA in 7MM (USD Million) (2017-2027)
Table 35 7MM Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 36 7MM Drug-Specific Patient Share of SMA, (2017-2027)
Table 37 United States Market Size of SMA in USD Million, (2017-2027)
Table 38 United States Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 39 United States Drug-Specific Patient Share of SMA, (2017-2027)
Table 40 EU5 Market Size of SMA in USD Million, (2017-2027)
Table 41 EU5 Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 42 EU5 Drug-Specific Patient Share of SMA, (2017-2027)
Table 43 Germany Market Size of SMA in USD Million, (2017-2027)
Table 44 Germany Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 45 Germany Drug-Specific Patient Share of SMA, (2017-2027)
Table 46 France Market Size of SMA in USD Million, (2017-2027)
Table 47 France Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 48 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 49 UK Market Size of SMA in USD Million, (2017-2027)
Table 50 UK Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 51 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 52 Spain Market Size of SMA in USD Million, (2017-2027)
Table 53 Spain Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 54 Spain Drug-Specific Patient Share of SMA, (2017-2027)
Table 55 Italy Market Size of SMA in USD Million, (2017-2027)
Table 56 Italy Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 57 Italy Drug-Specific Patient Share of SMA, (2017-2027)
Table 58 Japan Market Size of SMA in USD Million, (2017-2027)
Table 59 Japan Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 60 Drug-Specific Patient Share of SMA, (2017-2027)

 

Figure 1: Inheritance of SMA in an autosomal recessive pattern
Figure 2: Classification of SMA
Figure 3: Schematic representation of a portion of chromosome 5 that contains two SMN genes
Figure 4: Targets for therapy in SMA
Figure 5: Diagnosis tests in SMA
Figure 6: Diagnostic Evaluation of SMA
Figure 7: Total SMA Cases in 7MM -2017
Figure 8: Total SMA Cases in 7MM - 2027
Figure 9: SMA Incidence and Prevalence Rates
Figure 10: Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Figure 11: Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Figure 12: Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Figure 13: Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Figure 14: Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Figure 15: Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Figure 16: Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Figure 17: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Figure 18: Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Figure 19: Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Figure 20: Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Figure 21: Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Figure 22: Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Figure 23: Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Figure 24: Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Figure 25: Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Figure 26: Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Figure 27: Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Figure 28: Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Figure 29: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Figure 30: Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Figure 31: Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Figure 32: Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Figure 33: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Figure 34: Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Figure 35: Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Figure 36: Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Figure 37: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Figure 38: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 39: 7MM Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 40: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 41: United States Market Size of SMA in USD Million, (2017-2027)
Figure 42: US Estimated revenue of Marketed and Pipeline Drugs in USD Million (2017-2027)
Figure 43: US Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 44: SMA market in EU5 countries in USD Million, (2017-2027)
Figure 45: EU5 Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 46: EU5 Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 47: Germany Market Size of SMA in USD Million, (2017-2027)
Figure 48: Germany Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 49: Germany Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 50: France Market Size of SMA in USD Million, (2017-2027)
Figure 51: France Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 52: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 53: UK Market Size of SMA in USD Million, (2017-2027)
Figure 54: UK Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 55: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 56: Spain Market Size of SMA in USD Million, (2017-2027)
Figure 57: Spain Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 58: Spain Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 59: Italy Market Size of SMA in USD Million, (2017-2027)
Figure 60: Italy Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 61: Italy Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 62: Japan Market Size of SMA in USD Million (2017-2027)
Figure 63: Japan Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 64: Japan Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)

 

Table 1 Types of SMA linked to Chromosome-5
Table 2 Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Table 3 Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Table 4 Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Table 5 Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Table 6 Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Table 7 Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Table 8 Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Table 9 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Table 10 Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Table 11 Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Table 12 Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Table 13 Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Table 14 Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Table 15 Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Table 16 Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Table 17 Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Table 18 Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Table 19 Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Table 20 Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Table 21 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Table 22 Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Table 23 Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Table 24 Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Table 25 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Table 26 Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Table 27 Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Table 28 Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Table 29  Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Table 30 United States Association Current Recommendations for SMA
Table 31 European Association Current Recommendations for SMA
Table 32 Japanese Association Current Recommendations for SMA
Table 33 List of Marketed Drugs for SMA
Table 34 Market Size of SMA in 7MM (USD Million) (2017-2027)
Table 35 7MM Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 36 7MM Drug-Specific Patient Share of SMA, (2017-2027)
Table 37 United States Market Size of SMA in USD Million, (2017-2027)
Table 38 United States Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 39 United States Drug-Specific Patient Share of SMA, (2017-2027)
Table 40 EU5 Market Size of SMA in USD Million, (2017-2027)
Table 41 EU5 Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 42 EU5 Drug-Specific Patient Share of SMA, (2017-2027)
Table 43 Germany Market Size of SMA in USD Million, (2017-2027)
Table 44 Germany Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 45 Germany Drug-Specific Patient Share of SMA, (2017-2027)
Table 46 France Market Size of SMA in USD Million, (2017-2027)
Table 47 France Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 48 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 49 UK Market Size of SMA in USD Million, (2017-2027)
Table 50 UK Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 51 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 52 Spain Market Size of SMA in USD Million, (2017-2027)
Table 53 Spain Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 54 Spain Drug-Specific Patient Share of SMA, (2017-2027)
Table 55 Italy Market Size of SMA in USD Million, (2017-2027)
Table 56 Italy Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 57 Italy Drug-Specific Patient Share of SMA, (2017-2027)
Table 58 Japan Market Size of SMA in USD Million, (2017-2027)
Table 59 Japan Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 60 Drug-Specific Patient Share of SMA, (2017-2027)

 

Figure 1: Inheritance of SMA in an autosomal recessive pattern
Figure 2: Classification of SMA
Figure 3: Schematic representation of a portion of chromosome 5 that contains two SMN genes
Figure 4: Targets for therapy in SMA
Figure 5: Diagnosis tests in SMA
Figure 6: Diagnostic Evaluation of SMA
Figure 7: Total SMA Cases in 7MM -2017
Figure 8: Total SMA Cases in 7MM - 2027
Figure 9: SMA Incidence and Prevalence Rates
Figure 10: Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Figure 11: Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Figure 12: Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Figure 13: Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Figure 14: Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Figure 15: Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Figure 16: Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Figure 17: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Figure 18: Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Figure 19: Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Figure 20: Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Figure 21: Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Figure 22: Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Figure 23: Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Figure 24: Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Figure 25: Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Figure 26: Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Figure 27: Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Figure 28: Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Figure 29: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Figure 30: Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Figure 31: Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Figure 32: Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Figure 33: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Figure 34: Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Figure 35: Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Figure 36: Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Figure 37: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Figure 38: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 39: 7MM Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 40: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 41: United States Market Size of SMA in USD Million, (2017-2027)
Figure 42: US Estimated revenue of Marketed and Pipeline Drugs in USD Million (2017-2027)
Figure 43: US Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 44: SMA market in EU5 countries in USD Million, (2017-2027)
Figure 45: EU5 Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 46: EU5 Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 47: Germany Market Size of SMA in USD Million, (2017-2027)
Figure 48: Germany Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 49: Germany Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 50: France Market Size of SMA in USD Million, (2017-2027)
Figure 51: France Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 52: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 53: UK Market Size of SMA in USD Million, (2017-2027)
Figure 54: UK Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 55: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 56: Spain Market Size of SMA in USD Million, (2017-2027)
Figure 57: Spain Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 58: Spain Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 59: Italy Market Size of SMA in USD Million, (2017-2027)
Figure 60: Italy Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 61: Italy Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 62: Japan Market Size of SMA in USD Million (2017-2027)
Figure 63: Japan Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 64: Japan Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)

 

Table 1 Types of SMA linked to Chromosome-5
Table 2 Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Table 3 Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Table 4 Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Table 5 Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Table 6 Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Table 7 Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Table 8 Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Table 9 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Table 10 Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Table 11 Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Table 12 Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Table 13 Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Table 14 Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Table 15 Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Table 16 Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Table 17 Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Table 18 Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Table 19 Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Table 20 Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Table 21 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Table 22 Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Table 23 Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Table 24 Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Table 25 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Table 26 Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Table 27 Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Table 28 Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Table 29  Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Table 30 United States Association Current Recommendations for SMA
Table 31 European Association Current Recommendations for SMA
Table 32 Japanese Association Current Recommendations for SMA
Table 33 List of Marketed Drugs for SMA
Table 34 Market Size of SMA in 7MM (USD Million) (2017-2027)
Table 35 7MM Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 36 7MM Drug-Specific Patient Share of SMA, (2017-2027)
Table 37 United States Market Size of SMA in USD Million, (2017-2027)
Table 38 United States Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 39 United States Drug-Specific Patient Share of SMA, (2017-2027)
Table 40 EU5 Market Size of SMA in USD Million, (2017-2027)
Table 41 EU5 Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 42 EU5 Drug-Specific Patient Share of SMA, (2017-2027)
Table 43 Germany Market Size of SMA in USD Million, (2017-2027)
Table 44 Germany Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 45 Germany Drug-Specific Patient Share of SMA, (2017-2027)
Table 46 France Market Size of SMA in USD Million, (2017-2027)
Table 47 France Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 48 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 49 UK Market Size of SMA in USD Million, (2017-2027)
Table 50 UK Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 51 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 52 Spain Market Size of SMA in USD Million, (2017-2027)
Table 53 Spain Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 54 Spain Drug-Specific Patient Share of SMA, (2017-2027)
Table 55 Italy Market Size of SMA in USD Million, (2017-2027)
Table 56 Italy Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 57 Italy Drug-Specific Patient Share of SMA, (2017-2027)
Table 58 Japan Market Size of SMA in USD Million, (2017-2027)
Table 59 Japan Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 60 Drug-Specific Patient Share of SMA, (2017-2027)

 

Figure 1: Inheritance of SMA in an autosomal recessive pattern
Figure 2: Classification of SMA
Figure 3: Schematic representation of a portion of chromosome 5 that contains two SMN genes
Figure 4: Targets for therapy in SMA
Figure 5: Diagnosis tests in SMA
Figure 6: Diagnostic Evaluation of SMA
Figure 7: Total SMA Cases in 7MM -2017
Figure 8: Total SMA Cases in 7MM - 2027
Figure 9: SMA Incidence and Prevalence Rates
Figure 10: Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Figure 11: Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Figure 12: Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Figure 13: Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Figure 14: Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Figure 15: Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Figure 16: Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Figure 17: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Figure 18: Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Figure 19: Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Figure 20: Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Figure 21: Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Figure 22: Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Figure 23: Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Figure 24: Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Figure 25: Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Figure 26: Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Figure 27: Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Figure 28: Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Figure 29: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Figure 30: Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Figure 31: Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Figure 32: Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Figure 33: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Figure 34: Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Figure 35: Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Figure 36: Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Figure 37: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Figure 38: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 39: 7MM Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 40: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 41: United States Market Size of SMA in USD Million, (2017-2027)
Figure 42: US Estimated revenue of Marketed and Pipeline Drugs in USD Million (2017-2027)
Figure 43: US Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 44: SMA market in EU5 countries in USD Million, (2017-2027)
Figure 45: EU5 Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 46: EU5 Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 47: Germany Market Size of SMA in USD Million, (2017-2027)
Figure 48: Germany Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 49: Germany Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 50: France Market Size of SMA in USD Million, (2017-2027)
Figure 51: France Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 52: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 53: UK Market Size of SMA in USD Million, (2017-2027)
Figure 54: UK Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 55: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 56: Spain Market Size of SMA in USD Million, (2017-2027)
Figure 57: Spain Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 58: Spain Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 59: Italy Market Size of SMA in USD Million, (2017-2027)
Figure 60: Italy Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 61: Italy Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 62: Japan Market Size of SMA in USD Million (2017-2027)
Figure 63: Japan Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 64: Japan Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)

 

Table 1 Types of SMA linked to Chromosome-5
Table 2 Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Table 3 Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Table 4 Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Table 5 Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Table 6 Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Table 7 Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Table 8 Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Table 9 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Table 10 Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Table 11 Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Table 12 Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Table 13 Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Table 14 Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Table 15 Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Table 16 Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Table 17 Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Table 18 Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Table 19 Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Table 20 Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Table 21 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Table 22 Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Table 23 Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Table 24 Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Table 25 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Table 26 Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Table 27 Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Table 28 Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Table 29  Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Table 30 United States Association Current Recommendations for SMA
Table 31 European Association Current Recommendations for SMA
Table 32 Japanese Association Current Recommendations for SMA
Table 33 List of Marketed Drugs for SMA
Table 34 Market Size of SMA in 7MM (USD Million) (2017-2027)
Table 35 7MM Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 36 7MM Drug-Specific Patient Share of SMA, (2017-2027)
Table 37 United States Market Size of SMA in USD Million, (2017-2027)
Table 38 United States Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 39 United States Drug-Specific Patient Share of SMA, (2017-2027)
Table 40 EU5 Market Size of SMA in USD Million, (2017-2027)
Table 41 EU5 Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 42 EU5 Drug-Specific Patient Share of SMA, (2017-2027)
Table 43 Germany Market Size of SMA in USD Million, (2017-2027)
Table 44 Germany Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 45 Germany Drug-Specific Patient Share of SMA, (2017-2027)
Table 46 France Market Size of SMA in USD Million, (2017-2027)
Table 47 France Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 48 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 49 UK Market Size of SMA in USD Million, (2017-2027)
Table 50 UK Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 51 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 52 Spain Market Size of SMA in USD Million, (2017-2027)
Table 53 Spain Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 54 Spain Drug-Specific Patient Share of SMA, (2017-2027)
Table 55 Italy Market Size of SMA in USD Million, (2017-2027)
Table 56 Italy Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 57 Italy Drug-Specific Patient Share of SMA, (2017-2027)
Table 58 Japan Market Size of SMA in USD Million, (2017-2027)
Table 59 Japan Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 60 Drug-Specific Patient Share of SMA, (2017-2027)

 

Figure 1: Inheritance of SMA in an autosomal recessive pattern
Figure 2: Classification of SMA
Figure 3: Schematic representation of a portion of chromosome 5 that contains two SMN genes
Figure 4: Targets for therapy in SMA
Figure 5: Diagnosis tests in SMA
Figure 6: Diagnostic Evaluation of SMA
Figure 7: Total SMA Cases in 7MM -2017
Figure 8: Total SMA Cases in 7MM - 2027
Figure 9: SMA Incidence and Prevalence Rates
Figure 10: Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Figure 11: Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Figure 12: Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Figure 13: Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Figure 14: Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Figure 15: Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Figure 16: Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Figure 17: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Figure 18: Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Figure 19: Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Figure 20: Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Figure 21: Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Figure 22: Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Figure 23: Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Figure 24: Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Figure 25: Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Figure 26: Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Figure 27: Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Figure 28: Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Figure 29: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Figure 30: Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Figure 31: Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Figure 32: Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Figure 33: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Figure 34: Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Figure 35: Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Figure 36: Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Figure 37: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Figure 38: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 39: 7MM Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 40: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 41: United States Market Size of SMA in USD Million, (2017-2027)
Figure 42: US Estimated revenue of Marketed and Pipeline Drugs in USD Million (2017-2027)
Figure 43: US Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 44: SMA market in EU5 countries in USD Million, (2017-2027)
Figure 45: EU5 Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 46: EU5 Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 47: Germany Market Size of SMA in USD Million, (2017-2027)
Figure 48: Germany Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 49: Germany Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 50: France Market Size of SMA in USD Million, (2017-2027)
Figure 51: France Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 52: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 53: UK Market Size of SMA in USD Million, (2017-2027)
Figure 54: UK Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 55: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 56: Spain Market Size of SMA in USD Million, (2017-2027)
Figure 57: Spain Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 58: Spain Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 59: Italy Market Size of SMA in USD Million, (2017-2027)
Figure 60: Italy Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 61: Italy Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 62: Japan Market Size of SMA in USD Million (2017-2027)
Figure 63: Japan Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 64: Japan Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)

 

Table 1 Types of SMA linked to Chromosome-5
Table 2 Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Table 3 Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Table 4 Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Table 5 Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Table 6 Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Table 7 Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Table 8 Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Table 9 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Table 10 Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Table 11 Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Table 12 Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Table 13 Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Table 14 Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Table 15 Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Table 16 Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Table 17 Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Table 18 Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Table 19 Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Table 20 Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Table 21 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Table 22 Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Table 23 Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Table 24 Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Table 25 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Table 26 Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Table 27 Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Table 28 Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Table 29  Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Table 30 United States Association Current Recommendations for SMA
Table 31 European Association Current Recommendations for SMA
Table 32 Japanese Association Current Recommendations for SMA
Table 33 List of Marketed Drugs for SMA
Table 34 Market Size of SMA in 7MM (USD Million) (2017-2027)
Table 35 7MM Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 36 7MM Drug-Specific Patient Share of SMA, (2017-2027)
Table 37 United States Market Size of SMA in USD Million, (2017-2027)
Table 38 United States Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 39 United States Drug-Specific Patient Share of SMA, (2017-2027)
Table 40 EU5 Market Size of SMA in USD Million, (2017-2027)
Table 41 EU5 Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 42 EU5 Drug-Specific Patient Share of SMA, (2017-2027)
Table 43 Germany Market Size of SMA in USD Million, (2017-2027)
Table 44 Germany Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 45 Germany Drug-Specific Patient Share of SMA, (2017-2027)
Table 46 France Market Size of SMA in USD Million, (2017-2027)
Table 47 France Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 48 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 49 UK Market Size of SMA in USD Million, (2017-2027)
Table 50 UK Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 51 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 52 Spain Market Size of SMA in USD Million, (2017-2027)
Table 53 Spain Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 54 Spain Drug-Specific Patient Share of SMA, (2017-2027)
Table 55 Italy Market Size of SMA in USD Million, (2017-2027)
Table 56 Italy Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 57 Italy Drug-Specific Patient Share of SMA, (2017-2027)
Table 58 Japan Market Size of SMA in USD Million, (2017-2027)
Table 59 Japan Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 60 Drug-Specific Patient Share of SMA, (2017-2027)

 

Figure 1: Inheritance of SMA in an autosomal recessive pattern
Figure 2: Classification of SMA
Figure 3: Schematic representation of a portion of chromosome 5 that contains two SMN genes
Figure 4: Targets for therapy in SMA
Figure 5: Diagnosis tests in SMA
Figure 6: Diagnostic Evaluation of SMA
Figure 7: Total SMA Cases in 7MM -2017
Figure 8: Total SMA Cases in 7MM - 2027
Figure 9: SMA Incidence and Prevalence Rates
Figure 10: Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Figure 11: Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Figure 12: Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Figure 13: Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Figure 14: Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Figure 15: Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Figure 16: Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Figure 17: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Figure 18: Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Figure 19: Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Figure 20: Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Figure 21: Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Figure 22: Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Figure 23: Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Figure 24: Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Figure 25: Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Figure 26: Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Figure 27: Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Figure 28: Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Figure 29: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Figure 30: Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Figure 31: Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Figure 32: Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Figure 33: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Figure 34: Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Figure 35: Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Figure 36: Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Figure 37: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Figure 38: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 39: 7MM Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 40: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 41: United States Market Size of SMA in USD Million, (2017-2027)
Figure 42: US Estimated revenue of Marketed and Pipeline Drugs in USD Million (2017-2027)
Figure 43: US Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 44: SMA market in EU5 countries in USD Million, (2017-2027)
Figure 45: EU5 Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 46: EU5 Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 47: Germany Market Size of SMA in USD Million, (2017-2027)
Figure 48: Germany Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 49: Germany Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 50: France Market Size of SMA in USD Million, (2017-2027)
Figure 51: France Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 52: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 53: UK Market Size of SMA in USD Million, (2017-2027)
Figure 54: UK Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 55: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 56: Spain Market Size of SMA in USD Million, (2017-2027)
Figure 57: Spain Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 58: Spain Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 59: Italy Market Size of SMA in USD Million, (2017-2027)
Figure 60: Italy Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 61: Italy Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 62: Japan Market Size of SMA in USD Million (2017-2027)
Figure 63: Japan Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 64: Japan Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)

 

Table 1 Types of SMA linked to Chromosome-5
Table 2 Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Table 3 Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Table 4 Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Table 5 Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Table 6 Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Table 7 Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Table 8 Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Table 9 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Table 10 Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Table 11 Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Table 12 Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Table 13 Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Table 14 Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Table 15 Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Table 16 Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Table 17 Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Table 18 Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Table 19 Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Table 20 Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Table 21 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Table 22 Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Table 23 Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Table 24 Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Table 25 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Table 26 Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Table 27 Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Table 28 Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Table 29  Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Table 30 United States Association Current Recommendations for SMA
Table 31 European Association Current Recommendations for SMA
Table 32 Japanese Association Current Recommendations for SMA
Table 33 List of Marketed Drugs for SMA
Table 34 Market Size of SMA in 7MM (USD Million) (2017-2027)
Table 35 7MM Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 36 7MM Drug-Specific Patient Share of SMA, (2017-2027)
Table 37 United States Market Size of SMA in USD Million, (2017-2027)
Table 38 United States Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 39 United States Drug-Specific Patient Share of SMA, (2017-2027)
Table 40 EU5 Market Size of SMA in USD Million, (2017-2027)
Table 41 EU5 Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 42 EU5 Drug-Specific Patient Share of SMA, (2017-2027)
Table 43 Germany Market Size of SMA in USD Million, (2017-2027)
Table 44 Germany Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 45 Germany Drug-Specific Patient Share of SMA, (2017-2027)
Table 46 France Market Size of SMA in USD Million, (2017-2027)
Table 47 France Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 48 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 49 UK Market Size of SMA in USD Million, (2017-2027)
Table 50 UK Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 51 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 52 Spain Market Size of SMA in USD Million, (2017-2027)
Table 53 Spain Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 54 Spain Drug-Specific Patient Share of SMA, (2017-2027)
Table 55 Italy Market Size of SMA in USD Million, (2017-2027)
Table 56 Italy Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 57 Italy Drug-Specific Patient Share of SMA, (2017-2027)
Table 58 Japan Market Size of SMA in USD Million, (2017-2027)
Table 59 Japan Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 60 Drug-Specific Patient Share of SMA, (2017-2027)

 

Figure 1: Inheritance of SMA in an autosomal recessive pattern
Figure 2: Classification of SMA
Figure 3: Schematic representation of a portion of chromosome 5 that contains two SMN genes
Figure 4: Targets for therapy in SMA
Figure 5: Diagnosis tests in SMA
Figure 6: Diagnostic Evaluation of SMA
Figure 7: Total SMA Cases in 7MM -2017
Figure 8: Total SMA Cases in 7MM - 2027
Figure 9: SMA Incidence and Prevalence Rates
Figure 10: Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Figure 11: Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Figure 12: Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Figure 13: Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Figure 14: Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Figure 15: Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Figure 16: Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Figure 17: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Figure 18: Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Figure 19: Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Figure 20: Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Figure 21: Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Figure 22: Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Figure 23: Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Figure 24: Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Figure 25: Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Figure 26: Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Figure 27: Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Figure 28: Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Figure 29: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Figure 30: Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Figure 31: Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Figure 32: Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Figure 33: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Figure 34: Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Figure 35: Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Figure 36: Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Figure 37: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Figure 38: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 39: 7MM Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 40: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 41: United States Market Size of SMA in USD Million, (2017-2027)
Figure 42: US Estimated revenue of Marketed and Pipeline Drugs in USD Million (2017-2027)
Figure 43: US Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 44: SMA market in EU5 countries in USD Million, (2017-2027)
Figure 45: EU5 Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 46: EU5 Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 47: Germany Market Size of SMA in USD Million, (2017-2027)
Figure 48: Germany Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 49: Germany Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 50: France Market Size of SMA in USD Million, (2017-2027)
Figure 51: France Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 52: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 53: UK Market Size of SMA in USD Million, (2017-2027)
Figure 54: UK Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 55: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 56: Spain Market Size of SMA in USD Million, (2017-2027)
Figure 57: Spain Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 58: Spain Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 59: Italy Market Size of SMA in USD Million, (2017-2027)
Figure 60: Italy Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 61: Italy Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 62: Japan Market Size of SMA in USD Million (2017-2027)
Figure 63: Japan Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 64: Japan Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)

 

Table 1 Types of SMA linked to Chromosome-5
Table 2 Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Table 3 Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Table 4 Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Table 5 Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Table 6 Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Table 7 Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Table 8 Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Table 9 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Table 10 Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Table 11 Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Table 12 Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Table 13 Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Table 14 Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Table 15 Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Table 16 Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Table 17 Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Table 18 Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Table 19 Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Table 20 Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Table 21 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Table 22 Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Table 23 Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Table 24 Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Table 25 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Table 26 Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Table 27 Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Table 28 Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Table 29  Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Table 30 United States Association Current Recommendations for SMA
Table 31 European Association Current Recommendations for SMA
Table 32 Japanese Association Current Recommendations for SMA
Table 33 List of Marketed Drugs for SMA
Table 34 Market Size of SMA in 7MM (USD Million) (2017-2027)
Table 35 7MM Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 36 7MM Drug-Specific Patient Share of SMA, (2017-2027)
Table 37 United States Market Size of SMA in USD Million, (2017-2027)
Table 38 United States Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 39 United States Drug-Specific Patient Share of SMA, (2017-2027)
Table 40 EU5 Market Size of SMA in USD Million, (2017-2027)
Table 41 EU5 Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 42 EU5 Drug-Specific Patient Share of SMA, (2017-2027)
Table 43 Germany Market Size of SMA in USD Million, (2017-2027)
Table 44 Germany Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 45 Germany Drug-Specific Patient Share of SMA, (2017-2027)
Table 46 France Market Size of SMA in USD Million, (2017-2027)
Table 47 France Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 48 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 49 UK Market Size of SMA in USD Million, (2017-2027)
Table 50 UK Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 51 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 52 Spain Market Size of SMA in USD Million, (2017-2027)
Table 53 Spain Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 54 Spain Drug-Specific Patient Share of SMA, (2017-2027)
Table 55 Italy Market Size of SMA in USD Million, (2017-2027)
Table 56 Italy Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 57 Italy Drug-Specific Patient Share of SMA, (2017-2027)
Table 58 Japan Market Size of SMA in USD Million, (2017-2027)
Table 59 Japan Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 60 Drug-Specific Patient Share of SMA, (2017-2027)

 

Figure 1: Inheritance of SMA in an autosomal recessive pattern
Figure 2: Classification of SMA
Figure 3: Schematic representation of a portion of chromosome 5 that contains two SMN genes
Figure 4: Targets for therapy in SMA
Figure 5: Diagnosis tests in SMA
Figure 6: Diagnostic Evaluation of SMA
Figure 7: Total SMA Cases in 7MM -2017
Figure 8: Total SMA Cases in 7MM - 2027
Figure 9: SMA Incidence and Prevalence Rates
Figure 10: Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Figure 11: Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Figure 12: Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Figure 13: Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Figure 14: Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Figure 15: Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Figure 16: Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Figure 17: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Figure 18: Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Figure 19: Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Figure 20: Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Figure 21: Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Figure 22: Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Figure 23: Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Figure 24: Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Figure 25: Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Figure 26: Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Figure 27: Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Figure 28: Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Figure 29: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Figure 30: Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Figure 31: Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Figure 32: Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Figure 33: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Figure 34: Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Figure 35: Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Figure 36: Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Figure 37: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Figure 38: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 39: 7MM Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 40: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 41: United States Market Size of SMA in USD Million, (2017-2027)
Figure 42: US Estimated revenue of Marketed and Pipeline Drugs in USD Million (2017-2027)
Figure 43: US Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 44: SMA market in EU5 countries in USD Million, (2017-2027)
Figure 45: EU5 Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 46: EU5 Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 47: Germany Market Size of SMA in USD Million, (2017-2027)
Figure 48: Germany Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 49: Germany Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 50: France Market Size of SMA in USD Million, (2017-2027)
Figure 51: France Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 52: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 53: UK Market Size of SMA in USD Million, (2017-2027)
Figure 54: UK Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 55: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 56: Spain Market Size of SMA in USD Million, (2017-2027)
Figure 57: Spain Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 58: Spain Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 59: Italy Market Size of SMA in USD Million, (2017-2027)
Figure 60: Italy Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 61: Italy Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 62: Japan Market Size of SMA in USD Million (2017-2027)
Figure 63: Japan Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 64: Japan Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)

 

Table 1 Types of SMA linked to Chromosome-5
Table 2 Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Table 3 Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Table 4 Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Table 5 Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Table 6 Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Table 7 Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Table 8 Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Table 9 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Table 10 Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Table 11 Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Table 12 Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Table 13 Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Table 14 Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Table 15 Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Table 16 Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Table 17 Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Table 18 Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Table 19 Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Table 20 Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Table 21 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Table 22 Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Table 23 Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Table 24 Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Table 25 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Table 26 Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Table 27 Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Table 28 Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Table 29  Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Table 30 United States Association Current Recommendations for SMA
Table 31 European Association Current Recommendations for SMA
Table 32 Japanese Association Current Recommendations for SMA
Table 33 List of Marketed Drugs for SMA
Table 34 Market Size of SMA in 7MM (USD Million) (2017-2027)
Table 35 7MM Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 36 7MM Drug-Specific Patient Share of SMA, (2017-2027)
Table 37 United States Market Size of SMA in USD Million, (2017-2027)
Table 38 United States Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 39 United States Drug-Specific Patient Share of SMA, (2017-2027)
Table 40 EU5 Market Size of SMA in USD Million, (2017-2027)
Table 41 EU5 Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 42 EU5 Drug-Specific Patient Share of SMA, (2017-2027)
Table 43 Germany Market Size of SMA in USD Million, (2017-2027)
Table 44 Germany Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 45 Germany Drug-Specific Patient Share of SMA, (2017-2027)
Table 46 France Market Size of SMA in USD Million, (2017-2027)
Table 47 France Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 48 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 49 UK Market Size of SMA in USD Million, (2017-2027)
Table 50 UK Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 51 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 52 Spain Market Size of SMA in USD Million, (2017-2027)
Table 53 Spain Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 54 Spain Drug-Specific Patient Share of SMA, (2017-2027)
Table 55 Italy Market Size of SMA in USD Million, (2017-2027)
Table 56 Italy Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 57 Italy Drug-Specific Patient Share of SMA, (2017-2027)
Table 58 Japan Market Size of SMA in USD Million, (2017-2027)
Table 59 Japan Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 60 Drug-Specific Patient Share of SMA, (2017-2027)

 

Figure 1: Inheritance of SMA in an autosomal recessive pattern
Figure 2: Classification of SMA
Figure 3: Schematic representation of a portion of chromosome 5 that contains two SMN genes
Figure 4: Targets for therapy in SMA
Figure 5: Diagnosis tests in SMA
Figure 6: Diagnostic Evaluation of SMA
Figure 7: Total SMA Cases in 7MM -2017
Figure 8: Total SMA Cases in 7MM - 2027
Figure 9: SMA Incidence and Prevalence Rates
Figure 10: Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Figure 11: Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Figure 12: Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Figure 13: Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Figure 14: Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Figure 15: Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Figure 16: Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Figure 17: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Figure 18: Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Figure 19: Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Figure 20: Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Figure 21: Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Figure 22: Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Figure 23: Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Figure 24: Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Figure 25: Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Figure 26: Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Figure 27: Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Figure 28: Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Figure 29: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Figure 30: Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Figure 31: Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Figure 32: Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Figure 33: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Figure 34: Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Figure 35: Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Figure 36: Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Figure 37: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Figure 38: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 39: 7MM Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 40: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 41: United States Market Size of SMA in USD Million, (2017-2027)
Figure 42: US Estimated revenue of Marketed and Pipeline Drugs in USD Million (2017-2027)
Figure 43: US Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 44: SMA market in EU5 countries in USD Million, (2017-2027)
Figure 45: EU5 Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 46: EU5 Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 47: Germany Market Size of SMA in USD Million, (2017-2027)
Figure 48: Germany Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 49: Germany Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 50: France Market Size of SMA in USD Million, (2017-2027)
Figure 51: France Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 52: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 53: UK Market Size of SMA in USD Million, (2017-2027)
Figure 54: UK Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 55: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 56: Spain Market Size of SMA in USD Million, (2017-2027)
Figure 57: Spain Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 58: Spain Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 59: Italy Market Size of SMA in USD Million, (2017-2027)
Figure 60: Italy Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 61: Italy Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 62: Japan Market Size of SMA in USD Million (2017-2027)
Figure 63: Japan Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 64: Japan Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)

 

Table 1 Types of SMA linked to Chromosome-5
Table 2 Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Table 3 Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Table 4 Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Table 5 Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Table 6 Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Table 7 Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Table 8 Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Table 9 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Table 10 Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Table 11 Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Table 12 Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Table 13 Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Table 14 Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Table 15 Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Table 16 Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Table 17 Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Table 18 Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Table 19 Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Table 20 Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Table 21 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Table 22 Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Table 23 Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Table 24 Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Table 25 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Table 26 Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Table 27 Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Table 28 Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Table 29  Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Table 30 United States Association Current Recommendations for SMA
Table 31 European Association Current Recommendations for SMA
Table 32 Japanese Association Current Recommendations for SMA
Table 33 List of Marketed Drugs for SMA
Table 34 Market Size of SMA in 7MM (USD Million) (2017-2027)
Table 35 7MM Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 36 7MM Drug-Specific Patient Share of SMA, (2017-2027)
Table 37 United States Market Size of SMA in USD Million, (2017-2027)
Table 38 United States Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 39 United States Drug-Specific Patient Share of SMA, (2017-2027)
Table 40 EU5 Market Size of SMA in USD Million, (2017-2027)
Table 41 EU5 Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 42 EU5 Drug-Specific Patient Share of SMA, (2017-2027)
Table 43 Germany Market Size of SMA in USD Million, (2017-2027)
Table 44 Germany Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 45 Germany Drug-Specific Patient Share of SMA, (2017-2027)
Table 46 France Market Size of SMA in USD Million, (2017-2027)
Table 47 France Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 48 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 49 UK Market Size of SMA in USD Million, (2017-2027)
Table 50 UK Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 51 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 52 Spain Market Size of SMA in USD Million, (2017-2027)
Table 53 Spain Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 54 Spain Drug-Specific Patient Share of SMA, (2017-2027)
Table 55 Italy Market Size of SMA in USD Million, (2017-2027)
Table 56 Italy Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 57 Italy Drug-Specific Patient Share of SMA, (2017-2027)
Table 58 Japan Market Size of SMA in USD Million, (2017-2027)
Table 59 Japan Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 60 Drug-Specific Patient Share of SMA, (2017-2027)

 

Figure 1: Inheritance of SMA in an autosomal recessive pattern
Figure 2: Classification of SMA
Figure 3: Schematic representation of a portion of chromosome 5 that contains two SMN genes
Figure 4: Targets for therapy in SMA
Figure 5: Diagnosis tests in SMA
Figure 6: Diagnostic Evaluation of SMA
Figure 7: Total SMA Cases in 7MM -2017
Figure 8: Total SMA Cases in 7MM - 2027
Figure 9: SMA Incidence and Prevalence Rates
Figure 10: Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Figure 11: Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Figure 12: Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Figure 13: Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Figure 14: Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Figure 15: Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Figure 16: Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Figure 17: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Figure 18: Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Figure 19: Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Figure 20: Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Figure 21: Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Figure 22: Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Figure 23: Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Figure 24: Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Figure 25: Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Figure 26: Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Figure 27: Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Figure 28: Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Figure 29: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Figure 30: Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Figure 31: Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Figure 32: Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Figure 33: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Figure 34: Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Figure 35: Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Figure 36: Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Figure 37: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Figure 38: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 39: 7MM Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 40: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 41: United States Market Size of SMA in USD Million, (2017-2027)
Figure 42: US Estimated revenue of Marketed and Pipeline Drugs in USD Million (2017-2027)
Figure 43: US Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 44: SMA market in EU5 countries in USD Million, (2017-2027)
Figure 45: EU5 Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 46: EU5 Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 47: Germany Market Size of SMA in USD Million, (2017-2027)
Figure 48: Germany Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 49: Germany Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 50: France Market Size of SMA in USD Million, (2017-2027)
Figure 51: France Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 52: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 53: UK Market Size of SMA in USD Million, (2017-2027)
Figure 54: UK Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 55: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 56: Spain Market Size of SMA in USD Million, (2017-2027)
Figure 57: Spain Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 58: Spain Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 59: Italy Market Size of SMA in USD Million, (2017-2027)
Figure 60: Italy Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 61: Italy Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 62: Japan Market Size of SMA in USD Million (2017-2027)
Figure 63: Japan Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 64: Japan Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)

 

Table 1 Types of SMA linked to Chromosome-5
Table 2 Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Table 3 Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Table 4 Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Table 5 Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Table 6 Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Table 7 Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Table 8 Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Table 9 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Table 10 Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Table 11 Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Table 12 Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Table 13 Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Table 14 Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Table 15 Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Table 16 Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Table 17 Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Table 18 Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Table 19 Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Table 20 Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Table 21 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Table 22 Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Table 23 Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Table 24 Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Table 25 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Table 26 Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Table 27 Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Table 28 Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Table 29  Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Table 30 United States Association Current Recommendations for SMA
Table 31 European Association Current Recommendations for SMA
Table 32 Japanese Association Current Recommendations for SMA
Table 33 List of Marketed Drugs for SMA
Table 34 Market Size of SMA in 7MM (USD Million) (2017-2027)
Table 35 7MM Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 36 7MM Drug-Specific Patient Share of SMA, (2017-2027)
Table 37 United States Market Size of SMA in USD Million, (2017-2027)
Table 38 United States Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 39 United States Drug-Specific Patient Share of SMA, (2017-2027)
Table 40 EU5 Market Size of SMA in USD Million, (2017-2027)
Table 41 EU5 Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 42 EU5 Drug-Specific Patient Share of SMA, (2017-2027)
Table 43 Germany Market Size of SMA in USD Million, (2017-2027)
Table 44 Germany Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 45 Germany Drug-Specific Patient Share of SMA, (2017-2027)
Table 46 France Market Size of SMA in USD Million, (2017-2027)
Table 47 France Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 48 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 49 UK Market Size of SMA in USD Million, (2017-2027)
Table 50 UK Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 51 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 52 Spain Market Size of SMA in USD Million, (2017-2027)
Table 53 Spain Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 54 Spain Drug-Specific Patient Share of SMA, (2017-2027)
Table 55 Italy Market Size of SMA in USD Million, (2017-2027)
Table 56 Italy Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 57 Italy Drug-Specific Patient Share of SMA, (2017-2027)
Table 58 Japan Market Size of SMA in USD Million, (2017-2027)
Table 59 Japan Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 60 Drug-Specific Patient Share of SMA, (2017-2027)

 

Figure 1: Inheritance of SMA in an autosomal recessive pattern
Figure 2: Classification of SMA
Figure 3: Schematic representation of a portion of chromosome 5 that contains two SMN genes
Figure 4: Targets for therapy in SMA
Figure 5: Diagnosis tests in SMA
Figure 6: Diagnostic Evaluation of SMA
Figure 7: Total SMA Cases in 7MM -2017
Figure 8: Total SMA Cases in 7MM - 2027
Figure 9: SMA Incidence and Prevalence Rates
Figure 10: Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Figure 11: Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Figure 12: Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Figure 13: Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Figure 14: Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Figure 15: Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Figure 16: Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Figure 17: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Figure 18: Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Figure 19: Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Figure 20: Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Figure 21: Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Figure 22: Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Figure 23: Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Figure 24: Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Figure 25: Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Figure 26: Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Figure 27: Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Figure 28: Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Figure 29: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Figure 30: Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Figure 31: Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Figure 32: Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Figure 33: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Figure 34: Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Figure 35: Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Figure 36: Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Figure 37: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Figure 38: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 39: 7MM Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 40: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 41: United States Market Size of SMA in USD Million, (2017-2027)
Figure 42: US Estimated revenue of Marketed and Pipeline Drugs in USD Million (2017-2027)
Figure 43: US Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 44: SMA market in EU5 countries in USD Million, (2017-2027)
Figure 45: EU5 Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 46: EU5 Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 47: Germany Market Size of SMA in USD Million, (2017-2027)
Figure 48: Germany Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 49: Germany Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 50: France Market Size of SMA in USD Million, (2017-2027)
Figure 51: France Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 52: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 53: UK Market Size of SMA in USD Million, (2017-2027)
Figure 54: UK Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 55: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 56: Spain Market Size of SMA in USD Million, (2017-2027)
Figure 57: Spain Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 58: Spain Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 59: Italy Market Size of SMA in USD Million, (2017-2027)
Figure 60: Italy Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 61: Italy Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 62: Japan Market Size of SMA in USD Million (2017-2027)
Figure 63: Japan Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 64: Japan Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)

 

Table 1 Types of SMA linked to Chromosome-5
Table 2 Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Table 3 Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Table 4 Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Table 5 Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Table 6 Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Table 7 Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Table 8 Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Table 9 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Table 10 Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Table 11 Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Table 12 Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Table 13 Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Table 14 Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Table 15 Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Table 16 Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Table 17 Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Table 18 Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Table 19 Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Table 20 Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Table 21 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Table 22 Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Table 23 Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Table 24 Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Table 25 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Table 26 Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Table 27 Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Table 28 Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Table 29  Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Table 30 United States Association Current Recommendations for SMA
Table 31 European Association Current Recommendations for SMA
Table 32 Japanese Association Current Recommendations for SMA
Table 33 List of Marketed Drugs for SMA
Table 34 Market Size of SMA in 7MM (USD Million) (2017-2027)
Table 35 7MM Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 36 7MM Drug-Specific Patient Share of SMA, (2017-2027)
Table 37 United States Market Size of SMA in USD Million, (2017-2027)
Table 38 United States Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 39 United States Drug-Specific Patient Share of SMA, (2017-2027)
Table 40 EU5 Market Size of SMA in USD Million, (2017-2027)
Table 41 EU5 Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 42 EU5 Drug-Specific Patient Share of SMA, (2017-2027)
Table 43 Germany Market Size of SMA in USD Million, (2017-2027)
Table 44 Germany Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 45 Germany Drug-Specific Patient Share of SMA, (2017-2027)
Table 46 France Market Size of SMA in USD Million, (2017-2027)
Table 47 France Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 48 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 49 UK Market Size of SMA in USD Million, (2017-2027)
Table 50 UK Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 51 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 52 Spain Market Size of SMA in USD Million, (2017-2027)
Table 53 Spain Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 54 Spain Drug-Specific Patient Share of SMA, (2017-2027)
Table 55 Italy Market Size of SMA in USD Million, (2017-2027)
Table 56 Italy Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 57 Italy Drug-Specific Patient Share of SMA, (2017-2027)
Table 58 Japan Market Size of SMA in USD Million, (2017-2027)
Table 59 Japan Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 60 Drug-Specific Patient Share of SMA, (2017-2027)

 

Figure 1: Inheritance of SMA in an autosomal recessive pattern
Figure 2: Classification of SMA
Figure 3: Schematic representation of a portion of chromosome 5 that contains two SMN genes
Figure 4: Targets for therapy in SMA
Figure 5: Diagnosis tests in SMA
Figure 6: Diagnostic Evaluation of SMA
Figure 7: Total SMA Cases in 7MM -2017
Figure 8: Total SMA Cases in 7MM - 2027
Figure 9: SMA Incidence and Prevalence Rates
Figure 10: Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Figure 11: Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Figure 12: Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Figure 13: Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Figure 14: Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Figure 15: Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Figure 16: Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Figure 17: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Figure 18: Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Figure 19: Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Figure 20: Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Figure 21: Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Figure 22: Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Figure 23: Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Figure 24: Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Figure 25: Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Figure 26: Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Figure 27: Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Figure 28: Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Figure 29: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Figure 30: Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Figure 31: Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Figure 32: Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Figure 33: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Figure 34: Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Figure 35: Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Figure 36: Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Figure 37: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Figure 38: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 39: 7MM Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 40: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 41: United States Market Size of SMA in USD Million, (2017-2027)
Figure 42: US Estimated revenue of Marketed and Pipeline Drugs in USD Million (2017-2027)
Figure 43: US Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 44: SMA market in EU5 countries in USD Million, (2017-2027)
Figure 45: EU5 Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 46: EU5 Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 47: Germany Market Size of SMA in USD Million, (2017-2027)
Figure 48: Germany Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 49: Germany Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 50: France Market Size of SMA in USD Million, (2017-2027)
Figure 51: France Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 52: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 53: UK Market Size of SMA in USD Million, (2017-2027)
Figure 54: UK Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 55: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 56: Spain Market Size of SMA in USD Million, (2017-2027)
Figure 57: Spain Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 58: Spain Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 59: Italy Market Size of SMA in USD Million, (2017-2027)
Figure 60: Italy Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 61: Italy Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 62: Japan Market Size of SMA in USD Million (2017-2027)
Figure 63: Japan Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 64: Japan Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)

 

Table 1 Types of SMA linked to Chromosome-5
Table 2 Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Table 3 Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Table 4 Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Table 5 Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Table 6 Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Table 7 Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Table 8 Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Table 9 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Table 10 Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Table 11 Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Table 12 Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Table 13 Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Table 14 Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Table 15 Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Table 16 Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Table 17 Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Table 18 Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Table 19 Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Table 20 Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Table 21 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Table 22 Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Table 23 Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Table 24 Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Table 25 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Table 26 Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Table 27 Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Table 28 Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Table 29  Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Table 30 United States Association Current Recommendations for SMA
Table 31 European Association Current Recommendations for SMA
Table 32 Japanese Association Current Recommendations for SMA
Table 33 List of Marketed Drugs for SMA
Table 34 Market Size of SMA in 7MM (USD Million) (2017-2027)
Table 35 7MM Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 36 7MM Drug-Specific Patient Share of SMA, (2017-2027)
Table 37 United States Market Size of SMA in USD Million, (2017-2027)
Table 38 United States Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 39 United States Drug-Specific Patient Share of SMA, (2017-2027)
Table 40 EU5 Market Size of SMA in USD Million, (2017-2027)
Table 41 EU5 Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 42 EU5 Drug-Specific Patient Share of SMA, (2017-2027)
Table 43 Germany Market Size of SMA in USD Million, (2017-2027)
Table 44 Germany Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 45 Germany Drug-Specific Patient Share of SMA, (2017-2027)
Table 46 France Market Size of SMA in USD Million, (2017-2027)
Table 47 France Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 48 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 49 UK Market Size of SMA in USD Million, (2017-2027)
Table 50 UK Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 51 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 52 Spain Market Size of SMA in USD Million, (2017-2027)
Table 53 Spain Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 54 Spain Drug-Specific Patient Share of SMA, (2017-2027)
Table 55 Italy Market Size of SMA in USD Million, (2017-2027)
Table 56 Italy Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 57 Italy Drug-Specific Patient Share of SMA, (2017-2027)
Table 58 Japan Market Size of SMA in USD Million, (2017-2027)
Table 59 Japan Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 60 Drug-Specific Patient Share of SMA, (2017-2027)

 

Figure 1: Inheritance of SMA in an autosomal recessive pattern
Figure 2: Classification of SMA
Figure 3: Schematic representation of a portion of chromosome 5 that contains two SMN genes
Figure 4: Targets for therapy in SMA
Figure 5: Diagnosis tests in SMA
Figure 6: Diagnostic Evaluation of SMA
Figure 7: Total SMA Cases in 7MM -2017
Figure 8: Total SMA Cases in 7MM - 2027
Figure 9: SMA Incidence and Prevalence Rates
Figure 10: Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Figure 11: Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Figure 12: Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Figure 13: Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Figure 14: Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Figure 15: Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Figure 16: Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Figure 17: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Figure 18: Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Figure 19: Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Figure 20: Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Figure 21: Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Figure 22: Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Figure 23: Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Figure 24: Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Figure 25: Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Figure 26: Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Figure 27: Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Figure 28: Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Figure 29: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Figure 30: Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Figure 31: Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Figure 32: Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Figure 33: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Figure 34: Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Figure 35: Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Figure 36: Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Figure 37: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Figure 38: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 39: 7MM Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 40: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 41: United States Market Size of SMA in USD Million, (2017-2027)
Figure 42: US Estimated revenue of Marketed and Pipeline Drugs in USD Million (2017-2027)
Figure 43: US Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 44: SMA market in EU5 countries in USD Million, (2017-2027)
Figure 45: EU5 Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 46: EU5 Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 47: Germany Market Size of SMA in USD Million, (2017-2027)
Figure 48: Germany Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 49: Germany Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 50: France Market Size of SMA in USD Million, (2017-2027)
Figure 51: France Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 52: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 53: UK Market Size of SMA in USD Million, (2017-2027)
Figure 54: UK Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 55: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 56: Spain Market Size of SMA in USD Million, (2017-2027)
Figure 57: Spain Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 58: Spain Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 59: Italy Market Size of SMA in USD Million, (2017-2027)
Figure 60: Italy Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 61: Italy Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 62: Japan Market Size of SMA in USD Million (2017-2027)
Figure 63: Japan Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 64: Japan Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)

 

Table 1 Types of SMA linked to Chromosome-5
Table 2 Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Table 3 Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Table 4 Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Table 5 Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Table 6 Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Table 7 Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Table 8 Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Table 9 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Table 10 Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Table 11 Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Table 12 Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Table 13 Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Table 14 Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Table 15 Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Table 16 Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Table 17 Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Table 18 Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Table 19 Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Table 20 Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Table 21 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Table 22 Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Table 23 Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Table 24 Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Table 25 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Table 26 Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Table 27 Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Table 28 Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Table 29  Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Table 30 United States Association Current Recommendations for SMA
Table 31 European Association Current Recommendations for SMA
Table 32 Japanese Association Current Recommendations for SMA
Table 33 List of Marketed Drugs for SMA
Table 34 Market Size of SMA in 7MM (USD Million) (2017-2027)
Table 35 7MM Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 36 7MM Drug-Specific Patient Share of SMA, (2017-2027)
Table 37 United States Market Size of SMA in USD Million, (2017-2027)
Table 38 United States Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 39 United States Drug-Specific Patient Share of SMA, (2017-2027)
Table 40 EU5 Market Size of SMA in USD Million, (2017-2027)
Table 41 EU5 Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 42 EU5 Drug-Specific Patient Share of SMA, (2017-2027)
Table 43 Germany Market Size of SMA in USD Million, (2017-2027)
Table 44 Germany Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 45 Germany Drug-Specific Patient Share of SMA, (2017-2027)
Table 46 France Market Size of SMA in USD Million, (2017-2027)
Table 47 France Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 48 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 49 UK Market Size of SMA in USD Million, (2017-2027)
Table 50 UK Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 51 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 52 Spain Market Size of SMA in USD Million, (2017-2027)
Table 53 Spain Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 54 Spain Drug-Specific Patient Share of SMA, (2017-2027)
Table 55 Italy Market Size of SMA in USD Million, (2017-2027)
Table 56 Italy Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 57 Italy Drug-Specific Patient Share of SMA, (2017-2027)
Table 58 Japan Market Size of SMA in USD Million, (2017-2027)
Table 59 Japan Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 60 Drug-Specific Patient Share of SMA, (2017-2027)

 

Figure 1: Inheritance of SMA in an autosomal recessive pattern
Figure 2: Classification of SMA
Figure 3: Schematic representation of a portion of chromosome 5 that contains two SMN genes
Figure 4: Targets for therapy in SMA
Figure 5: Diagnosis tests in SMA
Figure 6: Diagnostic Evaluation of SMA
Figure 7: Total SMA Cases in 7MM -2017
Figure 8: Total SMA Cases in 7MM - 2027
Figure 9: SMA Incidence and Prevalence Rates
Figure 10: Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Figure 11: Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Figure 12: Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Figure 13: Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Figure 14: Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Figure 15: Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Figure 16: Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Figure 17: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Figure 18: Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Figure 19: Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Figure 20: Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Figure 21: Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Figure 22: Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Figure 23: Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Figure 24: Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Figure 25: Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Figure 26: Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Figure 27: Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Figure 28: Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Figure 29: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Figure 30: Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Figure 31: Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Figure 32: Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Figure 33: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Figure 34: Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Figure 35: Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Figure 36: Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Figure 37: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Figure 38: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 39: 7MM Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 40: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 41: United States Market Size of SMA in USD Million, (2017-2027)
Figure 42: US Estimated revenue of Marketed and Pipeline Drugs in USD Million (2017-2027)
Figure 43: US Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 44: SMA market in EU5 countries in USD Million, (2017-2027)
Figure 45: EU5 Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 46: EU5 Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 47: Germany Market Size of SMA in USD Million, (2017-2027)
Figure 48: Germany Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 49: Germany Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 50: France Market Size of SMA in USD Million, (2017-2027)
Figure 51: France Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 52: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 53: UK Market Size of SMA in USD Million, (2017-2027)
Figure 54: UK Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 55: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 56: Spain Market Size of SMA in USD Million, (2017-2027)
Figure 57: Spain Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 58: Spain Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 59: Italy Market Size of SMA in USD Million, (2017-2027)
Figure 60: Italy Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 61: Italy Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 62: Japan Market Size of SMA in USD Million (2017-2027)
Figure 63: Japan Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 64: Japan Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)

 

Table 1 Types of SMA linked to Chromosome-5
Table 2 Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Table 3 Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Table 4 Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Table 5 Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Table 6 Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Table 7 Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Table 8 Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Table 9 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Table 10 Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Table 11 Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Table 12 Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Table 13 Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Table 14 Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Table 15 Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Table 16 Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Table 17 Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Table 18 Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Table 19 Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Table 20 Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Table 21 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Table 22 Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Table 23 Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Table 24 Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Table 25 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Table 26 Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Table 27 Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Table 28 Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Table 29  Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Table 30 United States Association Current Recommendations for SMA
Table 31 European Association Current Recommendations for SMA
Table 32 Japanese Association Current Recommendations for SMA
Table 33 List of Marketed Drugs for SMA
Table 34 Market Size of SMA in 7MM (USD Million) (2017-2027)
Table 35 7MM Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 36 7MM Drug-Specific Patient Share of SMA, (2017-2027)
Table 37 United States Market Size of SMA in USD Million, (2017-2027)
Table 38 United States Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 39 United States Drug-Specific Patient Share of SMA, (2017-2027)
Table 40 EU5 Market Size of SMA in USD Million, (2017-2027)
Table 41 EU5 Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 42 EU5 Drug-Specific Patient Share of SMA, (2017-2027)
Table 43 Germany Market Size of SMA in USD Million, (2017-2027)
Table 44 Germany Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 45 Germany Drug-Specific Patient Share of SMA, (2017-2027)
Table 46 France Market Size of SMA in USD Million, (2017-2027)
Table 47 France Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 48 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 49 UK Market Size of SMA in USD Million, (2017-2027)
Table 50 UK Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 51 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 52 Spain Market Size of SMA in USD Million, (2017-2027)
Table 53 Spain Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 54 Spain Drug-Specific Patient Share of SMA, (2017-2027)
Table 55 Italy Market Size of SMA in USD Million, (2017-2027)
Table 56 Italy Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 57 Italy Drug-Specific Patient Share of SMA, (2017-2027)
Table 58 Japan Market Size of SMA in USD Million, (2017-2027)
Table 59 Japan Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 60 Drug-Specific Patient Share of SMA, (2017-2027)

 

Figure 1: Inheritance of SMA in an autosomal recessive pattern
Figure 2: Classification of SMA
Figure 3: Schematic representation of a portion of chromosome 5 that contains two SMN genes
Figure 4: Targets for therapy in SMA
Figure 5: Diagnosis tests in SMA
Figure 6: Diagnostic Evaluation of SMA
Figure 7: Total SMA Cases in 7MM -2017
Figure 8: Total SMA Cases in 7MM - 2027
Figure 9: SMA Incidence and Prevalence Rates
Figure 10: Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Figure 11: Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Figure 12: Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Figure 13: Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Figure 14: Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Figure 15: Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Figure 16: Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Figure 17: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Figure 18: Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Figure 19: Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Figure 20: Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Figure 21: Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Figure 22: Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Figure 23: Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Figure 24: Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Figure 25: Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Figure 26: Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Figure 27: Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Figure 28: Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Figure 29: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Figure 30: Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Figure 31: Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Figure 32: Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Figure 33: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Figure 34: Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Figure 35: Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Figure 36: Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Figure 37: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Figure 38: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 39: 7MM Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 40: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 41: United States Market Size of SMA in USD Million, (2017-2027)
Figure 42: US Estimated revenue of Marketed and Pipeline Drugs in USD Million (2017-2027)
Figure 43: US Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 44: SMA market in EU5 countries in USD Million, (2017-2027)
Figure 45: EU5 Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 46: EU5 Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 47: Germany Market Size of SMA in USD Million, (2017-2027)
Figure 48: Germany Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 49: Germany Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 50: France Market Size of SMA in USD Million, (2017-2027)
Figure 51: France Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 52: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 53: UK Market Size of SMA in USD Million, (2017-2027)
Figure 54: UK Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 55: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 56: Spain Market Size of SMA in USD Million, (2017-2027)
Figure 57: Spain Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 58: Spain Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 59: Italy Market Size of SMA in USD Million, (2017-2027)
Figure 60: Italy Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 61: Italy Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 62: Japan Market Size of SMA in USD Million (2017-2027)
Figure 63: Japan Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 64: Japan Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)

 

Table 1 Types of SMA linked to Chromosome-5
Table 2 Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Table 3 Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Table 4 Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Table 5 Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Table 6 Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Table 7 Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Table 8 Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Table 9 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Table 10 Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Table 11 Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Table 12 Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Table 13 Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Table 14 Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Table 15 Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Table 16 Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Table 17 Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Table 18 Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Table 19 Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Table 20 Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Table 21 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Table 22 Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Table 23 Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Table 24 Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Table 25 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Table 26 Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Table 27 Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Table 28 Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Table 29  Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Table 30 United States Association Current Recommendations for SMA
Table 31 European Association Current Recommendations for SMA
Table 32 Japanese Association Current Recommendations for SMA
Table 33 List of Marketed Drugs for SMA
Table 34 Market Size of SMA in 7MM (USD Million) (2017-2027)
Table 35 7MM Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 36 7MM Drug-Specific Patient Share of SMA, (2017-2027)
Table 37 United States Market Size of SMA in USD Million, (2017-2027)
Table 38 United States Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 39 United States Drug-Specific Patient Share of SMA, (2017-2027)
Table 40 EU5 Market Size of SMA in USD Million, (2017-2027)
Table 41 EU5 Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 42 EU5 Drug-Specific Patient Share of SMA, (2017-2027)
Table 43 Germany Market Size of SMA in USD Million, (2017-2027)
Table 44 Germany Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 45 Germany Drug-Specific Patient Share of SMA, (2017-2027)
Table 46 France Market Size of SMA in USD Million, (2017-2027)
Table 47 France Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 48 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 49 UK Market Size of SMA in USD Million, (2017-2027)
Table 50 UK Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 51 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 52 Spain Market Size of SMA in USD Million, (2017-2027)
Table 53 Spain Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 54 Spain Drug-Specific Patient Share of SMA, (2017-2027)
Table 55 Italy Market Size of SMA in USD Million, (2017-2027)
Table 56 Italy Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 57 Italy Drug-Specific Patient Share of SMA, (2017-2027)
Table 58 Japan Market Size of SMA in USD Million, (2017-2027)
Table 59 Japan Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 60 Drug-Specific Patient Share of SMA, (2017-2027)

 

Figure 1: Inheritance of SMA in an autosomal recessive pattern
Figure 2: Classification of SMA
Figure 3: Schematic representation of a portion of chromosome 5 that contains two SMN genes
Figure 4: Targets for therapy in SMA
Figure 5: Diagnosis tests in SMA
Figure 6: Diagnostic Evaluation of SMA
Figure 7: Total SMA Cases in 7MM -2017
Figure 8: Total SMA Cases in 7MM - 2027
Figure 9: SMA Incidence and Prevalence Rates
Figure 10: Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Figure 11: Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Figure 12: Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Figure 13: Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Figure 14: Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Figure 15: Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Figure 16: Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Figure 17: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Figure 18: Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Figure 19: Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Figure 20: Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Figure 21: Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Figure 22: Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Figure 23: Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Figure 24: Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Figure 25: Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Figure 26: Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Figure 27: Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Figure 28: Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Figure 29: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Figure 30: Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Figure 31: Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Figure 32: Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Figure 33: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Figure 34: Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Figure 35: Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Figure 36: Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Figure 37: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Figure 38: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 39: 7MM Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 40: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 41: United States Market Size of SMA in USD Million, (2017-2027)
Figure 42: US Estimated revenue of Marketed and Pipeline Drugs in USD Million (2017-2027)
Figure 43: US Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 44: SMA market in EU5 countries in USD Million, (2017-2027)
Figure 45: EU5 Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 46: EU5 Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 47: Germany Market Size of SMA in USD Million, (2017-2027)
Figure 48: Germany Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 49: Germany Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 50: France Market Size of SMA in USD Million, (2017-2027)
Figure 51: France Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 52: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 53: UK Market Size of SMA in USD Million, (2017-2027)
Figure 54: UK Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 55: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 56: Spain Market Size of SMA in USD Million, (2017-2027)
Figure 57: Spain Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 58: Spain Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 59: Italy Market Size of SMA in USD Million, (2017-2027)
Figure 60: Italy Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 61: Italy Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 62: Japan Market Size of SMA in USD Million (2017-2027)
Figure 63: Japan Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 64: Japan Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)

 

Table 1 Types of SMA linked to Chromosome-5
Table 2 Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Table 3 Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Table 4 Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Table 5 Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Table 6 Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Table 7 Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Table 8 Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Table 9 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Table 10 Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Table 11 Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Table 12 Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Table 13 Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Table 14 Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Table 15 Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Table 16 Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Table 17 Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Table 18 Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Table 19 Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Table 20 Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Table 21 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Table 22 Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Table 23 Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Table 24 Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Table 25 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Table 26 Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Table 27 Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Table 28 Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Table 29  Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Table 30 United States Association Current Recommendations for SMA
Table 31 European Association Current Recommendations for SMA
Table 32 Japanese Association Current Recommendations for SMA
Table 33 List of Marketed Drugs for SMA
Table 34 Market Size of SMA in 7MM (USD Million) (2017-2027)
Table 35 7MM Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 36 7MM Drug-Specific Patient Share of SMA, (2017-2027)
Table 37 United States Market Size of SMA in USD Million, (2017-2027)
Table 38 United States Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 39 United States Drug-Specific Patient Share of SMA, (2017-2027)
Table 40 EU5 Market Size of SMA in USD Million, (2017-2027)
Table 41 EU5 Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 42 EU5 Drug-Specific Patient Share of SMA, (2017-2027)
Table 43 Germany Market Size of SMA in USD Million, (2017-2027)
Table 44 Germany Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 45 Germany Drug-Specific Patient Share of SMA, (2017-2027)
Table 46 France Market Size of SMA in USD Million, (2017-2027)
Table 47 France Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 48 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 49 UK Market Size of SMA in USD Million, (2017-2027)
Table 50 UK Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 51 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 52 Spain Market Size of SMA in USD Million, (2017-2027)
Table 53 Spain Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 54 Spain Drug-Specific Patient Share of SMA, (2017-2027)
Table 55 Italy Market Size of SMA in USD Million, (2017-2027)
Table 56 Italy Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 57 Italy Drug-Specific Patient Share of SMA, (2017-2027)
Table 58 Japan Market Size of SMA in USD Million, (2017-2027)
Table 59 Japan Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 60 Drug-Specific Patient Share of SMA, (2017-2027)

 

Figure 1: Inheritance of SMA in an autosomal recessive pattern
Figure 2: Classification of SMA
Figure 3: Schematic representation of a portion of chromosome 5 that contains two SMN genes
Figure 4: Targets for therapy in SMA
Figure 5: Diagnosis tests in SMA
Figure 6: Diagnostic Evaluation of SMA
Figure 7: Total SMA Cases in 7MM -2017
Figure 8: Total SMA Cases in 7MM - 2027
Figure 9: SMA Incidence and Prevalence Rates
Figure 10: Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Figure 11: Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Figure 12: Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Figure 13: Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Figure 14: Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Figure 15: Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Figure 16: Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Figure 17: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Figure 18: Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Figure 19: Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Figure 20: Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Figure 21: Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Figure 22: Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Figure 23: Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Figure 24: Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Figure 25: Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Figure 26: Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Figure 27: Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Figure 28: Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Figure 29: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Figure 30: Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Figure 31: Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Figure 32: Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Figure 33: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Figure 34: Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Figure 35: Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Figure 36: Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Figure 37: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Figure 38: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 39: 7MM Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 40: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 41: United States Market Size of SMA in USD Million, (2017-2027)
Figure 42: US Estimated revenue of Marketed and Pipeline Drugs in USD Million (2017-2027)
Figure 43: US Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 44: SMA market in EU5 countries in USD Million, (2017-2027)
Figure 45: EU5 Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 46: EU5 Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 47: Germany Market Size of SMA in USD Million, (2017-2027)
Figure 48: Germany Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 49: Germany Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 50: France Market Size of SMA in USD Million, (2017-2027)
Figure 51: France Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 52: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 53: UK Market Size of SMA in USD Million, (2017-2027)
Figure 54: UK Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 55: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 56: Spain Market Size of SMA in USD Million, (2017-2027)
Figure 57: Spain Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 58: Spain Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 59: Italy Market Size of SMA in USD Million, (2017-2027)
Figure 60: Italy Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 61: Italy Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 62: Japan Market Size of SMA in USD Million (2017-2027)
Figure 63: Japan Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 64: Japan Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)

 

Table 1 Types of SMA linked to Chromosome-5
Table 2 Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Table 3 Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Table 4 Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Table 5 Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Table 6 Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Table 7 Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Table 8 Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Table 9 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Table 10 Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Table 11 Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Table 12 Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Table 13 Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Table 14 Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Table 15 Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Table 16 Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Table 17 Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Table 18 Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Table 19 Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Table 20 Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Table 21 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Table 22 Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Table 23 Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Table 24 Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Table 25 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Table 26 Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Table 27 Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Table 28 Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Table 29  Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Table 30 United States Association Current Recommendations for SMA
Table 31 European Association Current Recommendations for SMA
Table 32 Japanese Association Current Recommendations for SMA
Table 33 List of Marketed Drugs for SMA
Table 34 Market Size of SMA in 7MM (USD Million) (2017-2027)
Table 35 7MM Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 36 7MM Drug-Specific Patient Share of SMA, (2017-2027)
Table 37 United States Market Size of SMA in USD Million, (2017-2027)
Table 38 United States Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 39 United States Drug-Specific Patient Share of SMA, (2017-2027)
Table 40 EU5 Market Size of SMA in USD Million, (2017-2027)
Table 41 EU5 Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 42 EU5 Drug-Specific Patient Share of SMA, (2017-2027)
Table 43 Germany Market Size of SMA in USD Million, (2017-2027)
Table 44 Germany Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 45 Germany Drug-Specific Patient Share of SMA, (2017-2027)
Table 46 France Market Size of SMA in USD Million, (2017-2027)
Table 47 France Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 48 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 49 UK Market Size of SMA in USD Million, (2017-2027)
Table 50 UK Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 51 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 52 Spain Market Size of SMA in USD Million, (2017-2027)
Table 53 Spain Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 54 Spain Drug-Specific Patient Share of SMA, (2017-2027)
Table 55 Italy Market Size of SMA in USD Million, (2017-2027)
Table 56 Italy Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 57 Italy Drug-Specific Patient Share of SMA, (2017-2027)
Table 58 Japan Market Size of SMA in USD Million, (2017-2027)
Table 59 Japan Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 60 Drug-Specific Patient Share of SMA, (2017-2027)

 

Figure 1: Inheritance of SMA in an autosomal recessive pattern
Figure 2: Classification of SMA
Figure 3: Schematic representation of a portion of chromosome 5 that contains two SMN genes
Figure 4: Targets for therapy in SMA
Figure 5: Diagnosis tests in SMA
Figure 6: Diagnostic Evaluation of SMA
Figure 7: Total SMA Cases in 7MM -2017
Figure 8: Total SMA Cases in 7MM - 2027
Figure 9: SMA Incidence and Prevalence Rates
Figure 10: Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Figure 11: Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Figure 12: Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Figure 13: Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Figure 14: Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Figure 15: Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Figure 16: Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Figure 17: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Figure 18: Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Figure 19: Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Figure 20: Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Figure 21: Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Figure 22: Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Figure 23: Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Figure 24: Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Figure 25: Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Figure 26: Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Figure 27: Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Figure 28: Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Figure 29: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Figure 30: Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Figure 31: Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Figure 32: Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Figure 33: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Figure 34: Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Figure 35: Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Figure 36: Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Figure 37: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Figure 38: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 39: 7MM Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 40: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 41: United States Market Size of SMA in USD Million, (2017-2027)
Figure 42: US Estimated revenue of Marketed and Pipeline Drugs in USD Million (2017-2027)
Figure 43: US Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 44: SMA market in EU5 countries in USD Million, (2017-2027)
Figure 45: EU5 Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 46: EU5 Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 47: Germany Market Size of SMA in USD Million, (2017-2027)
Figure 48: Germany Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 49: Germany Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 50: France Market Size of SMA in USD Million, (2017-2027)
Figure 51: France Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 52: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 53: UK Market Size of SMA in USD Million, (2017-2027)
Figure 54: UK Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 55: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 56: Spain Market Size of SMA in USD Million, (2017-2027)
Figure 57: Spain Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 58: Spain Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 59: Italy Market Size of SMA in USD Million, (2017-2027)
Figure 60: Italy Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 61: Italy Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 62: Japan Market Size of SMA in USD Million (2017-2027)
Figure 63: Japan Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 64: Japan Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)

 

Table 1 Types of SMA linked to Chromosome-5
Table 2 Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Table 3 Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Table 4 Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Table 5 Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Table 6 Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Table 7 Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Table 8 Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Table 9 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Table 10 Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Table 11 Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Table 12 Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Table 13 Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Table 14 Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Table 15 Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Table 16 Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Table 17 Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Table 18 Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Table 19 Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Table 20 Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Table 21 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Table 22 Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Table 23 Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Table 24 Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Table 25 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Table 26 Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Table 27 Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Table 28 Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Table 29  Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Table 30 United States Association Current Recommendations for SMA
Table 31 European Association Current Recommendations for SMA
Table 32 Japanese Association Current Recommendations for SMA
Table 33 List of Marketed Drugs for SMA
Table 34 Market Size of SMA in 7MM (USD Million) (2017-2027)
Table 35 7MM Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 36 7MM Drug-Specific Patient Share of SMA, (2017-2027)
Table 37 United States Market Size of SMA in USD Million, (2017-2027)
Table 38 United States Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 39 United States Drug-Specific Patient Share of SMA, (2017-2027)
Table 40 EU5 Market Size of SMA in USD Million, (2017-2027)
Table 41 EU5 Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 42 EU5 Drug-Specific Patient Share of SMA, (2017-2027)
Table 43 Germany Market Size of SMA in USD Million, (2017-2027)
Table 44 Germany Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 45 Germany Drug-Specific Patient Share of SMA, (2017-2027)
Table 46 France Market Size of SMA in USD Million, (2017-2027)
Table 47 France Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 48 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 49 UK Market Size of SMA in USD Million, (2017-2027)
Table 50 UK Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 51 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 52 Spain Market Size of SMA in USD Million, (2017-2027)
Table 53 Spain Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 54 Spain Drug-Specific Patient Share of SMA, (2017-2027)
Table 55 Italy Market Size of SMA in USD Million, (2017-2027)
Table 56 Italy Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 57 Italy Drug-Specific Patient Share of SMA, (2017-2027)
Table 58 Japan Market Size of SMA in USD Million, (2017-2027)
Table 59 Japan Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 60 Drug-Specific Patient Share of SMA, (2017-2027)

 

Figure 1: Inheritance of SMA in an autosomal recessive pattern
Figure 2: Classification of SMA
Figure 3: Schematic representation of a portion of chromosome 5 that contains two SMN genes
Figure 4: Targets for therapy in SMA
Figure 5: Diagnosis tests in SMA
Figure 6: Diagnostic Evaluation of SMA
Figure 7: Total SMA Cases in 7MM -2017
Figure 8: Total SMA Cases in 7MM - 2027
Figure 9: SMA Incidence and Prevalence Rates
Figure 10: Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Figure 11: Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Figure 12: Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Figure 13: Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Figure 14: Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Figure 15: Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Figure 16: Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Figure 17: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Figure 18: Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Figure 19: Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Figure 20: Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Figure 21: Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Figure 22: Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Figure 23: Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Figure 24: Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Figure 25: Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Figure 26: Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Figure 27: Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Figure 28: Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Figure 29: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Figure 30: Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Figure 31: Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Figure 32: Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Figure 33: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Figure 34: Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Figure 35: Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Figure 36: Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Figure 37: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Figure 38: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 39: 7MM Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 40: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 41: United States Market Size of SMA in USD Million, (2017-2027)
Figure 42: US Estimated revenue of Marketed and Pipeline Drugs in USD Million (2017-2027)
Figure 43: US Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 44: SMA market in EU5 countries in USD Million, (2017-2027)
Figure 45: EU5 Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 46: EU5 Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 47: Germany Market Size of SMA in USD Million, (2017-2027)
Figure 48: Germany Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 49: Germany Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 50: France Market Size of SMA in USD Million, (2017-2027)
Figure 51: France Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 52: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 53: UK Market Size of SMA in USD Million, (2017-2027)
Figure 54: UK Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 55: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 56: Spain Market Size of SMA in USD Million, (2017-2027)
Figure 57: Spain Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 58: Spain Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 59: Italy Market Size of SMA in USD Million, (2017-2027)
Figure 60: Italy Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 61: Italy Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 62: Japan Market Size of SMA in USD Million (2017-2027)
Figure 63: Japan Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 64: Japan Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)

 

Table 1 Types of SMA linked to Chromosome-5
Table 2 Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Table 3 Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Table 4 Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Table 5 Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Table 6 Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Table 7 Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Table 8 Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Table 9 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Table 10 Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Table 11 Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Table 12 Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Table 13 Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Table 14 Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Table 15 Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Table 16 Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Table 17 Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Table 18 Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Table 19 Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Table 20 Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Table 21 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Table 22 Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Table 23 Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Table 24 Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Table 25 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Table 26 Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Table 27 Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Table 28 Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Table 29  Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Table 30 United States Association Current Recommendations for SMA
Table 31 European Association Current Recommendations for SMA
Table 32 Japanese Association Current Recommendations for SMA
Table 33 List of Marketed Drugs for SMA
Table 34 Market Size of SMA in 7MM (USD Million) (2017-2027)
Table 35 7MM Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 36 7MM Drug-Specific Patient Share of SMA, (2017-2027)
Table 37 United States Market Size of SMA in USD Million, (2017-2027)
Table 38 United States Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 39 United States Drug-Specific Patient Share of SMA, (2017-2027)
Table 40 EU5 Market Size of SMA in USD Million, (2017-2027)
Table 41 EU5 Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 42 EU5 Drug-Specific Patient Share of SMA, (2017-2027)
Table 43 Germany Market Size of SMA in USD Million, (2017-2027)
Table 44 Germany Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 45 Germany Drug-Specific Patient Share of SMA, (2017-2027)
Table 46 France Market Size of SMA in USD Million, (2017-2027)
Table 47 France Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 48 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 49 UK Market Size of SMA in USD Million, (2017-2027)
Table 50 UK Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 51 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 52 Spain Market Size of SMA in USD Million, (2017-2027)
Table 53 Spain Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 54 Spain Drug-Specific Patient Share of SMA, (2017-2027)
Table 55 Italy Market Size of SMA in USD Million, (2017-2027)
Table 56 Italy Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 57 Italy Drug-Specific Patient Share of SMA, (2017-2027)
Table 58 Japan Market Size of SMA in USD Million, (2017-2027)
Table 59 Japan Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 60 Drug-Specific Patient Share of SMA, (2017-2027)

 

Figure 1: Inheritance of SMA in an autosomal recessive pattern
Figure 2: Classification of SMA
Figure 3: Schematic representation of a portion of chromosome 5 that contains two SMN genes
Figure 4: Targets for therapy in SMA
Figure 5: Diagnosis tests in SMA
Figure 6: Diagnostic Evaluation of SMA
Figure 7: Total SMA Cases in 7MM -2017
Figure 8: Total SMA Cases in 7MM - 2027
Figure 9: SMA Incidence and Prevalence Rates
Figure 10: Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Figure 11: Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Figure 12: Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Figure 13: Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Figure 14: Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Figure 15: Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Figure 16: Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Figure 17: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Figure 18: Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Figure 19: Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Figure 20: Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Figure 21: Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Figure 22: Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Figure 23: Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Figure 24: Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Figure 25: Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Figure 26: Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Figure 27: Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Figure 28: Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Figure 29: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Figure 30: Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Figure 31: Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Figure 32: Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Figure 33: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Figure 34: Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Figure 35: Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Figure 36: Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Figure 37: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Figure 38: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 39: 7MM Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 40: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 41: United States Market Size of SMA in USD Million, (2017-2027)
Figure 42: US Estimated revenue of Marketed and Pipeline Drugs in USD Million (2017-2027)
Figure 43: US Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 44: SMA market in EU5 countries in USD Million, (2017-2027)
Figure 45: EU5 Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 46: EU5 Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 47: Germany Market Size of SMA in USD Million, (2017-2027)
Figure 48: Germany Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 49: Germany Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 50: France Market Size of SMA in USD Million, (2017-2027)
Figure 51: France Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 52: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 53: UK Market Size of SMA in USD Million, (2017-2027)
Figure 54: UK Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 55: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 56: Spain Market Size of SMA in USD Million, (2017-2027)
Figure 57: Spain Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 58: Spain Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 59: Italy Market Size of SMA in USD Million, (2017-2027)
Figure 60: Italy Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 61: Italy Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 62: Japan Market Size of SMA in USD Million (2017-2027)
Figure 63: Japan Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 64: Japan Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)

 

Table 1 Types of SMA linked to Chromosome-5
Table 2 Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Table 3 Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Table 4 Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Table 5 Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Table 6 Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Table 7 Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Table 8 Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Table 9 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Table 10 Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Table 11 Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Table 12 Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Table 13 Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Table 14 Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Table 15 Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Table 16 Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Table 17 Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Table 18 Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Table 19 Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Table 20 Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Table 21 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Table 22 Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Table 23 Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Table 24 Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Table 25 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Table 26 Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Table 27 Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Table 28 Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Table 29  Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Table 30 United States Association Current Recommendations for SMA
Table 31 European Association Current Recommendations for SMA
Table 32 Japanese Association Current Recommendations for SMA
Table 33 List of Marketed Drugs for SMA
Table 34 Market Size of SMA in 7MM (USD Million) (2017-2027)
Table 35 7MM Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 36 7MM Drug-Specific Patient Share of SMA, (2017-2027)
Table 37 United States Market Size of SMA in USD Million, (2017-2027)
Table 38 United States Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 39 United States Drug-Specific Patient Share of SMA, (2017-2027)
Table 40 EU5 Market Size of SMA in USD Million, (2017-2027)
Table 41 EU5 Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 42 EU5 Drug-Specific Patient Share of SMA, (2017-2027)
Table 43 Germany Market Size of SMA in USD Million, (2017-2027)
Table 44 Germany Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 45 Germany Drug-Specific Patient Share of SMA, (2017-2027)
Table 46 France Market Size of SMA in USD Million, (2017-2027)
Table 47 France Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 48 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 49 UK Market Size of SMA in USD Million, (2017-2027)
Table 50 UK Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 51 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 52 Spain Market Size of SMA in USD Million, (2017-2027)
Table 53 Spain Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 54 Spain Drug-Specific Patient Share of SMA, (2017-2027)
Table 55 Italy Market Size of SMA in USD Million, (2017-2027)
Table 56 Italy Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 57 Italy Drug-Specific Patient Share of SMA, (2017-2027)
Table 58 Japan Market Size of SMA in USD Million, (2017-2027)
Table 59 Japan Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 60 Drug-Specific Patient Share of SMA, (2017-2027)

 

Figure 1: Inheritance of SMA in an autosomal recessive pattern
Figure 2: Classification of SMA
Figure 3: Schematic representation of a portion of chromosome 5 that contains two SMN genes
Figure 4: Targets for therapy in SMA
Figure 5: Diagnosis tests in SMA
Figure 6: Diagnostic Evaluation of SMA
Figure 7: Total SMA Cases in 7MM -2017
Figure 8: Total SMA Cases in 7MM - 2027
Figure 9: SMA Incidence and Prevalence Rates
Figure 10: Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Figure 11: Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Figure 12: Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Figure 13: Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Figure 14: Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Figure 15: Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Figure 16: Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Figure 17: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Figure 18: Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Figure 19: Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Figure 20: Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Figure 21: Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Figure 22: Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Figure 23: Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Figure 24: Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Figure 25: Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Figure 26: Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Figure 27: Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Figure 28: Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Figure 29: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Figure 30: Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Figure 31: Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Figure 32: Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Figure 33: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Figure 34: Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Figure 35: Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Figure 36: Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Figure 37: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Figure 38: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 39: 7MM Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 40: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 41: United States Market Size of SMA in USD Million, (2017-2027)
Figure 42: US Estimated revenue of Marketed and Pipeline Drugs in USD Million (2017-2027)
Figure 43: US Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 44: SMA market in EU5 countries in USD Million, (2017-2027)
Figure 45: EU5 Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 46: EU5 Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 47: Germany Market Size of SMA in USD Million, (2017-2027)
Figure 48: Germany Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 49: Germany Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 50: France Market Size of SMA in USD Million, (2017-2027)
Figure 51: France Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 52: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 53: UK Market Size of SMA in USD Million, (2017-2027)
Figure 54: UK Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 55: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 56: Spain Market Size of SMA in USD Million, (2017-2027)
Figure 57: Spain Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 58: Spain Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 59: Italy Market Size of SMA in USD Million, (2017-2027)
Figure 60: Italy Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 61: Italy Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 62: Japan Market Size of SMA in USD Million (2017-2027)
Figure 63: Japan Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 64: Japan Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)

 

Table 1 Types of SMA linked to Chromosome-5
Table 2 Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Table 3 Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Table 4 Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Table 5 Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Table 6 Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Table 7 Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Table 8 Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Table 9 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Table 10 Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Table 11 Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Table 12 Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Table 13 Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Table 14 Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Table 15 Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Table 16 Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Table 17 Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Table 18 Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Table 19 Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Table 20 Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Table 21 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Table 22 Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Table 23 Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Table 24 Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Table 25 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Table 26 Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Table 27 Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Table 28 Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Table 29  Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Table 30 United States Association Current Recommendations for SMA
Table 31 European Association Current Recommendations for SMA
Table 32 Japanese Association Current Recommendations for SMA
Table 33 List of Marketed Drugs for SMA
Table 34 Market Size of SMA in 7MM (USD Million) (2017-2027)
Table 35 7MM Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 36 7MM Drug-Specific Patient Share of SMA, (2017-2027)
Table 37 United States Market Size of SMA in USD Million, (2017-2027)
Table 38 United States Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 39 United States Drug-Specific Patient Share of SMA, (2017-2027)
Table 40 EU5 Market Size of SMA in USD Million, (2017-2027)
Table 41 EU5 Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 42 EU5 Drug-Specific Patient Share of SMA, (2017-2027)
Table 43 Germany Market Size of SMA in USD Million, (2017-2027)
Table 44 Germany Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 45 Germany Drug-Specific Patient Share of SMA, (2017-2027)
Table 46 France Market Size of SMA in USD Million, (2017-2027)
Table 47 France Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 48 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 49 UK Market Size of SMA in USD Million, (2017-2027)
Table 50 UK Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 51 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 52 Spain Market Size of SMA in USD Million, (2017-2027)
Table 53 Spain Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 54 Spain Drug-Specific Patient Share of SMA, (2017-2027)
Table 55 Italy Market Size of SMA in USD Million, (2017-2027)
Table 56 Italy Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 57 Italy Drug-Specific Patient Share of SMA, (2017-2027)
Table 58 Japan Market Size of SMA in USD Million, (2017-2027)
Table 59 Japan Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 60 Drug-Specific Patient Share of SMA, (2017-2027)

 

Figure 1: Inheritance of SMA in an autosomal recessive pattern
Figure 2: Classification of SMA
Figure 3: Schematic representation of a portion of chromosome 5 that contains two SMN genes
Figure 4: Targets for therapy in SMA
Figure 5: Diagnosis tests in SMA
Figure 6: Diagnostic Evaluation of SMA
Figure 7: Total SMA Cases in 7MM -2017
Figure 8: Total SMA Cases in 7MM - 2027
Figure 9: SMA Incidence and Prevalence Rates
Figure 10: Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Figure 11: Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Figure 12: Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Figure 13: Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Figure 14: Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Figure 15: Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Figure 16: Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Figure 17: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Figure 18: Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Figure 19: Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Figure 20: Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Figure 21: Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Figure 22: Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Figure 23: Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Figure 24: Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Figure 25: Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Figure 26: Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Figure 27: Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Figure 28: Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Figure 29: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Figure 30: Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Figure 31: Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Figure 32: Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Figure 33: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Figure 34: Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Figure 35: Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Figure 36: Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Figure 37: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Figure 38: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 39: 7MM Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 40: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 41: United States Market Size of SMA in USD Million, (2017-2027)
Figure 42: US Estimated revenue of Marketed and Pipeline Drugs in USD Million (2017-2027)
Figure 43: US Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 44: SMA market in EU5 countries in USD Million, (2017-2027)
Figure 45: EU5 Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 46: EU5 Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 47: Germany Market Size of SMA in USD Million, (2017-2027)
Figure 48: Germany Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 49: Germany Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 50: France Market Size of SMA in USD Million, (2017-2027)
Figure 51: France Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 52: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 53: UK Market Size of SMA in USD Million, (2017-2027)
Figure 54: UK Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 55: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 56: Spain Market Size of SMA in USD Million, (2017-2027)
Figure 57: Spain Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 58: Spain Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 59: Italy Market Size of SMA in USD Million, (2017-2027)
Figure 60: Italy Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 61: Italy Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 62: Japan Market Size of SMA in USD Million (2017-2027)
Figure 63: Japan Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 64: Japan Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)

 

Table 1 Types of SMA linked to Chromosome-5
Table 2 Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Table 3 Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Table 4 Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Table 5 Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Table 6 Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Table 7 Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Table 8 Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Table 9 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Table 10 Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Table 11 Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Table 12 Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Table 13 Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Table 14 Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Table 15 Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Table 16 Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Table 17 Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Table 18 Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Table 19 Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Table 20 Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Table 21 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Table 22 Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Table 23 Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Table 24 Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Table 25 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Table 26 Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Table 27 Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Table 28 Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Table 29  Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Table 30 United States Association Current Recommendations for SMA
Table 31 European Association Current Recommendations for SMA
Table 32 Japanese Association Current Recommendations for SMA
Table 33 List of Marketed Drugs for SMA
Table 34 Market Size of SMA in 7MM (USD Million) (2017-2027)
Table 35 7MM Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 36 7MM Drug-Specific Patient Share of SMA, (2017-2027)
Table 37 United States Market Size of SMA in USD Million, (2017-2027)
Table 38 United States Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 39 United States Drug-Specific Patient Share of SMA, (2017-2027)
Table 40 EU5 Market Size of SMA in USD Million, (2017-2027)
Table 41 EU5 Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 42 EU5 Drug-Specific Patient Share of SMA, (2017-2027)
Table 43 Germany Market Size of SMA in USD Million, (2017-2027)
Table 44 Germany Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 45 Germany Drug-Specific Patient Share of SMA, (2017-2027)
Table 46 France Market Size of SMA in USD Million, (2017-2027)
Table 47 France Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 48 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 49 UK Market Size of SMA in USD Million, (2017-2027)
Table 50 UK Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 51 France Drug-Specific Patient Share of SMA, (2017-2027)
Table 52 Spain Market Size of SMA in USD Million, (2017-2027)
Table 53 Spain Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 54 Spain Drug-Specific Patient Share of SMA, (2017-2027)
Table 55 Italy Market Size of SMA in USD Million, (2017-2027)
Table 56 Italy Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 57 Italy Drug-Specific Patient Share of SMA, (2017-2027)
Table 58 Japan Market Size of SMA in USD Million, (2017-2027)
Table 59 Japan Drug-Specific Market Size of SMA in USD Million, (2017-2027)
Table 60 Drug-Specific Patient Share of SMA, (2017-2027)

 

Figure 1: Inheritance of SMA in an autosomal recessive pattern
Figure 2: Classification of SMA
Figure 3: Schematic representation of a portion of chromosome 5 that contains two SMN genes
Figure 4: Targets for therapy in SMA
Figure 5: Diagnosis tests in SMA
Figure 6: Diagnostic Evaluation of SMA
Figure 7: Total SMA Cases in 7MM -2017
Figure 8: Total SMA Cases in 7MM - 2027
Figure 9: SMA Incidence and Prevalence Rates
Figure 10: Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Figure 11: Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Figure 12: Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Figure 13: Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Figure 14: Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Figure 15: Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Figure 16: Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Figure 17: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Figure 18: Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Figure 19: Diagnosed Prevalent Cases of SMA Type 1 in France, (2017-2027)
Figure 20: Diagnosed Prevalent Cases of SMA Type 2 in France, (2017-2027)
Figure 21: Diagnosed Prevalent Cases of SMA Type 3 & 4 in France (2017-2027)
Figure 22: Diagnosed Prevalent Cases of SMA in UK (2017-2027)
Figure 23: Diagnosed Prevalent Cases of SMA Type 1 in UK (2017-2027)
Figure 24: Diagnosed Prevalent Cases of SMA Type 2 in UK (2017-2027)
Figure 25: Diagnosed Prevalent Cases of SMA Type 3 & 4 in UK (2017-2027)
Figure 26: Diagnosed Prevalent Cases of SMA in Spain (2017-2027)
Figure 27: Diagnosed Prevalent Cases of SMA Type 1 in Spain (2017-2027)
Figure 28: Diagnosed Prevalent Cases of SMA Type 2 in Spain (2017-2027)
Figure 29: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Spain (2017-2027)
Figure 30: Diagnosed Prevalent Cases of SMA in Italy (2017-2027)
Figure 31: Diagnosed Prevalent Cases of SMA Type 1 in Italy (2017-2027)
Figure 32: Diagnosed Prevalent Cases of SMA Type 2 in Italy (2017-2027)
Figure 33: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Italy (2017-2027)
Figure 34: Diagnosed Prevalent Cases of SMA in Japan (2017-2027)
Figure 35: Diagnosed Prevalent Cases of SMA Type 1 in Japan, (2017-2027)
Figure 36: Diagnosed Prevalent Cases of SMA Type 2 in Japan (2017-2027)
Figure 37: Diagnosed Prevalent Cases of SMA Type 3 & 4 in Japan (2017-2027)
Figure 38: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 39: 7MM Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 40: : Total Market Size of SMA for 7 MM in USD Million, (2017-2027)
Figure 41: United States Market Size of SMA in USD Million, (2017-2027)
Figure 42: US Estimated revenue of Marketed and Pipeline Drugs in USD Million (2017-2027)
Figure 43: US Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 44: SMA market in EU5 countries in USD Million, (2017-2027)
Figure 45: EU5 Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 46: EU5 Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 47: Germany Market Size of SMA in USD Million, (2017-2027)
Figure 48: Germany Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 49: Germany Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 50: France Market Size of SMA in USD Million, (2017-2027)
Figure 51: France Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 52: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 53: UK Market Size of SMA in USD Million, (2017-2027)
Figure 54: UK Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 55: France Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 56: Spain Market Size of SMA in USD Million, (2017-2027)
Figure 57: Spain Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 58: Spain Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 59: Italy Market Size of SMA in USD Million, (2017-2027)
Figure 60: Italy Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 61: Italy Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)
Figure 62: Japan Market Size of SMA in USD Million (2017-2027)
Figure 63: Japan Estimated revenue of Marketed and Pipeline Drugs in USD Million, (2017-2027)
Figure 64: Japan Estimated Patient Share of Marketed and Pipeline Drugs, (2017-2027)

 

Table 1 Types of SMA linked to Chromosome-5
Table 2 Diagnosed Prevalent Cases of SMA in United States, (2017-2027)
Table 3 Diagnosed Prevalent Cases of SMA Type 1 in United States, (2017-2027)
Table 4 Diagnosed Prevalent Cases of SMA Type 2 in United States, (2017-2027)
Table 5 Diagnosed Prevalent Cases of SMA Type 3 & 4 in United States, (2017-2027)
Table 6 Diagnosed Prevalent Cases of SMA in Germany, (2017-2027)
Table 7 Diagnosed Prevalent Cases of SMA Type 1 in Germany, (2017-2027)
Table 8 Diagnosed Prevalent Cases of SMA Type 2 in Germany, (2017-2027)
Table 9 Diagnosed Prevalent Cases of SMA Type 3 & 4 in Germany, (2017-2027)
Table 10 Diagnosed Prevalent Cases of SMA in France, (2017-2027)
Table 11 Diagnosed Pr